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Liver metastases.  
The liver is the major site of metastatic spread of primary colorectal cancer, whereas 3% of all 
patients with colorectal cancer will develop resectable liver metastases (1). If a resection with 
curative intent is done, a five year survival rate of 25-30% has been demonstrated in a large 
number of studies (2-7). The natural history of untreated patients with comparable liver 
involvement shows a five year survival rate of 0-3% (8). As noted above, the majority of 
patients with evidence of liver metastases are irresectable, because of extra-hepatic disease or 
excessive liver involvement (2).  
There is no standard treatment for unresectable hepatic metastases confined to the liver, so novel 
treatment modalities have to be developed. In order to achieve a better control of intrahepatic 
disease and to reduce systemic toxicity of the applied therapy, locoregional therapies have 
been developed. These therapies include hepatic arterial embolization (9), intratumoral 
injections of ethanol (10), acetic acid, biological agents (11,12), stereotactic or intra-arterial 
radiotherapy, intralesional laser therapy, cryotherapy, radiofrequency ablation (13) and 
regional infusion or perfusion of chemotherapeutic drugs (14).  
 
Locoregional strategies. 
Although response rates with novel systemic chemotherapeutic agents such as oxaliplatin and 
irinotecan in combination with 5-FU are promising, overall survival remains poor (15-17). In 
order to improve responses and survival loco-regional chemotherapeutic regiments have been 
developed such as hepatic artery infusion (HAI), chemoembolization and isolated hepatic 
perfusion (IHP). For most chemotherapeutic agents a steep dose response curve can be 
demonstrated and exposure of the liver metastases to higher drug concentrations by means of 
loco-regional treatment, might result in improved control of hepatic metastases. HAI exploits 
the first pass effect of the liver, resulting in high local, but low systemic drug exposure. 
Several repeated hepatic artery infusions regimens produced higher response rates, compared 
to systemic chemotherapy, with a 2 –year survival of 50-60% (18-23). 
 
Introduction of TNF in isolated perfusion: the beginning of biochemotherapy. 
The technique of isolated limb perfusion (ILP) was pioneered in the 1950’s by Creech, 
Krementz and coworkers at Tulane University in New Orleans (24). It is a technique of cancer 
treatment which delivers high doses of cytostatic drugs to a tumor-bearing extremity that is 
isolated from the systemic circulation and connected to a heart-lung machine. By ILP regional 
concentrations of chemotherapeutic agents 15-20 times higher than those reached after 
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systemic administration can be achieved without systemic toxicity. The use of tumor necrosis 
factor-α (TNF) in ILP was pioneered by Lejeune et al. in 1992 (25). In patients with in-transit 
melanoma metastases the addition of TNF and interferon-gamma to Melphalan in ILP 
resulted in impressive response rates from 80-90%.  
These promising results have prompted us to investigate possible application of this 
combination of agents in isolated perfusion settings of organs such as liver and kidney (26-
29). Experience with addition of TNF to IHP with Melphalan, however, is limited. Therefore 
we developed an IHP rat model to study the applicability and efficacy of TNF in this setting. 
Hereafter, we investigated if IHP with TNF and Melphalan in rats results in similar 
synergistic anti-tumor effects between these agents as we previously observed in ILP.  
Previous studies led to the hypothesis that the use of TNF in isolated limb perfusion causes 
specific destruction of tumor endothelial cells and thereby induces an increased permeability 
of tumor vasculature. However, whether TNF contributes to the therapeutic efficacy in IHP 
still remains unclear. Based on our findings in the ILP studies, it is indicated to study whether 
TNF can improve tumor response in different tumors after IHP and, if so, to investigate the 
capability of TNF to augment drug accumulation in this perfusion setting. By addressing this 
issue, the usefulness of TNF in IHP might be become clear. Clinical IHP for irresectable 
metastases is still an experimental and non-curative treatment modality. With respect to this 
magnitude, costs and non-repeatability of the procedure are its major drawbacks. We 
developed a less invasive, less costly and potentially repeatable balloon-catheter mediated 
isolated hypoxic hepatic perfusion (IHHP). A phase I-II study in patients is described in this 
thesis. 
 
Gene therapy strategies. 
Gene therapy is the introduction of foreign DNA into a cell. Agents that facilitate the transfer 
of genes to recipient cells are called vectors. Much progress has been made on the use of viral 
vectors for gene transfer. Several viruses can be used for this purpose such as retroviruses, 
adenoviruses and herpes viruses.  In cancer gene therapy the transfer of DNA into the target 
cell is to eliminate or to reduce tumor burden by direct cell killing, immunomodulation or 
correcting genetic alterations. 
Cancer is believed to be associated with multiple genetic alterations especially involving 
normal mechanisms that control growth. Colorectal carcinogenesis is well studied, this 
because most carcinomas arise from adenomas.  Above all ras-oncogene mutations occur in 
an early stage of progression from adenoma to carcinoma. Ras mutations are present in 40 to 
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50% of human colorectal tumors (30). Inhibition of expression of mutated ras has been shown 
to cause tumor growth inhibition and apoptosis in human and murine tumor cell lines (31-35).  
Gene therapy offers possibilities to correct malignant cells by replacement or inhibition of 
mutated genes. In this thesis adenovirus mediated gene therapy is studied in pre-clinical in 
vitro and in vivo models. By locoregional administration of the genetic construct, tumor 
targeting may be improved and consequently result in more favorable transfection efficacy 
responses. Delivery of viral vectors via intratumoral injections is an established method to 
reach transduction but its clinical applicability is limited. A transvascular approach could 
increase the therapeutic window for gene therapy in clinical trials. Previously, we have 
demonstrated successful transduction and anti-tumor activity in a rat sarcoma model with 
isolated limb perfusion (36,37). We hypothesized that the route of delivery might play a 
crucial role in optimizing transduction efficacy and more importantly in anti-tumor activity in 
liver metastases. A transduction efficacy and tumor response study comparing different routes 
of administration of an adenoviral vector carrying the DNA for an intracellular antibody 
against ras. The study explores the pre-requisites for successful liver directed ras-gene 
therapy. Moreover an additional ras-gene therapy study was performed in an ILP model to 
evaluate anti-tumor activity of this particular vector on a different tumor and at a different 
site. 
 
Limb threatening tumors. 
In the management of locally advanced soft tissue sarcoma (STS) limb salvage is a major 
challenge. In contrast to the inefficacy of ILP with Melphalan alone in the management of 
irresectable extremity STS, with response rates between 10 and 35% only (38,39), the 
introduction of tumor necrosis factor-alpha (TNF) in combination with Melphalan in ILP has 
been reported in a European multicenter trial to result in response rates greater than 80% and 
limb salvage rates above 70% in STS (40,41). These results led to the approval of TNF in 
Europe (42). Also in the management of in-transit metastases TNF seems to improve CR rates 
(43). Since the experience with TNF-based ILP is still growing we now are able to analyse 
subgroups of patients from a single-institution database that is among the largest in the world. 
This allows us to report on new and unknown possibilities of the clinical utility of TNF-based 
ILP. 
Recurrent melanoma of the limb has been a challenge for treatment over the years. Some 
patients however, qualify for re-treatment of the limb by ILP as they show to fail only locally 
without signs of systemic metastases. It is for these patients that repeat ILP might provide 
Chapter 1 
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prolonged local control (44-45). The use of TNF in the repeat ILP is thought to improve 
response rates in patients who do not (or insufficiently) respond to Melphalan-only-ILPs, but 
definite prove is still lacking (46).  
As a consequence of epidemiological features we are confronted with a large group of elderly 
patients who might need a limb saving procedure such as ILP. Especially these patients will 
be severely limited in their mobility and loose independence when amputation of a limb has 
to be performed. Because of fear for TNF associated toxicity, ILP with TNF is not offered to 
old patients in some cancer centers. Here we report on a series of older patients with limb 
threatening sarcomas or multiple in-transit melanoma metastases, which demonstrates the safe 
and efficient use of TNF -based ILP.  
 
 
Aims of the Thesis. 
 
As described in the Introduction section several studies were performed in isolated liver and 
limb perfusion models in a pre-clinical and clinical setting. 
In summary the Aims of the studies described in this Thesis are: 
• The development of a pre-clinical IHP model in which the combination of TNF and 
Melphalan could be tested. Feasibility, efficacy and drug uptake studies were performed. 
• To determine the utility of recombinant adenovirus gene therapy in experimental liver 
metastases models. Does loco-regional transvascular delivery offer therapeutic possibilities? 
What are the immunological effects? 
• To study efficacy of recombinant adenovirus gene therapy in tumor-bearing rats by 
administration via ILP. 
• To address new clinical options in the treatment of limb threatening soft tissue sarcoma or 
melanoma metastases in selective patient groups. 
• To evaluate a new less invasive IHP technique using balloon catheters in a prospective 
phase I-II study. 
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Summary 
Isolated hepatic perfusion (IHP) is an attractive approach towards treating irresectable liver 
tumors as the effects of systemic chemotherapy are poor and its application is hampered by 
severe general toxicity. In clinical and experimental settings the efficacy of isolated limb 
perfusion (ILP) with tumor necrosis factor-alpha (TNF) in combination with Melphalan for 
treatment of melanoma in-transit and soft tissue sarcoma has now been well established. In an 
ILP model in rats we previously observed synergistic anti-tumor effects of TNF and 
Melphalan on BN 175 soft tissue sarcoma extremity tumors. The aim of the present study was 
to investigate if similar synergy in anti-tumor effect could be achieved by treating 
experimental BN 175 soft tissue sarcoma liver tumors by IHP with these agents.  
We demonstrated that IHP with TNF and Melphalan results in a dramatic increase in regional 
concentrations of perfused agents with virtually no concomitant systemic leakage. IHP with 
only carrier solution resulted in a significantly diminished growth rate of BN 175 liver tumors 
compared to the growth rate of tumors in non-perfused rats. Perfusing with Melphalan alone 
resulted in minimal anti-tumor effects. Perfusion with only TNF had a slight growth 
stimulatory effect on the BN 175 liver tumors, in any case no negative effect on tumor growth 
was observed. When TNF was added to Melphalan a dramatic anti-tumor effect was 
observed. Thus, like in the rat ILP setting, augmentation of anti-tumor effect is observed 
when adding TNF to IHP with Melphalan for treatment of BN 175 soft tissue sarcoma tumor-
bearing rats. Strikingly, potentiation of tumor response occurred at relatively low 
concentrations of TNF compared to concentrations eliciting synergy with Melphalan in ILP. 
 
Introduction  
 
The clinical success of addition of high dose tumor necrosis factor-alpha (TNF) to isolated limb 
perfusion (ILP) with Melphalan has renewed the interest in this cytokine as an anti-tumor agent. 
Systemic administration of TNF in effective doses is restricted by severe general toxicity (1,2). 
ILP, however, allows addition of high dose TNF in combination with Melphalan for treatment 
of melanoma in-transit-metastases and soft tissue sarcoma and has resulted in tumor responses 
in over 80 % of cases (3,4,5). These promising results have prompted us to investigate possible 
application of this combination of agents in isolated perfusion settings of organs such as liver 
and kidney (6,7,8,9).  
In clinical and experimental settings IHP with high dose Melphalan has resulted in significant 
Chapter 2 
 
 
23 
anti-tumor effects (10,11,12). Clinical experience with addition of TNF to IHP with 
Melphalan, however, is limited (7,13,14,15,16). Although first reports regarding tumor 
responses have been promising, it is clear that, as the liver is a vital organ and much more 
responsive to TNF, more than is the case in ILP, in IHP regional toxicity will dictate if adequate 
dosages of TNF can be administered.  
In order to gain insight into the mechanisms by which TNF elicits its anti-tumor effects and for 
investigating by which agents and manipulations TNF efficacy can be enhanced and it’s toxicity 
reduced, a pre-clinical model IHP is essential. Therefore we developed an IHP rat model using 
the highly vascularized BN 175 soft tissue sarcoma to study the applicability and efficacy of 
TNF in this setting. This tumor was chosen because it previously demonstrated synergistic anti-
tumor effects between TNF and Melphalan in a rat ILP model, closely mimicking clinical 
observations regarding tumor responses and histopathology (17,18,19). 
In this study we first defined the IHP rat model regarding degree of isolation of the hepatic 
vascular compartment during perfusion and characterized the effect of the IHP procedure itself 
on growth of experimental BN 175 liver tumors. Hereafter, we investigated if IHP with TNF 
and Melphalan in rats results in similar synergistic anti-tumor effects between these agents as 
we previously observed in ILP when treating BN 175 soft tissue sarcoma liver tumors.  
 
Materials and Methods 
 
Animals 
Male inbred BN strain rats, weighing 250-300 g obtained from Harlan-CPB (Austerlitz, The 
Netherlands) were used. The rats were fed a standard laboratory diet. All animals were 
housed under standard conditions of light and accommodation. The experimental protocols 
adhered to the rules outlined in the Dutch Animal Experimentation Act 1977 and the 
published Guidelines on the Protection of Experimental Animals by the Council of the 
European Community 1986. The protocol was approved by the committee on animal research 
of the Erasmus University, Rotterdam, the Netherlands.  
 
Tumor model 
BN 175 soft tissue sarcoma (transplantable to BN rats) was used. BN 175 is a rapidly growing 
and metastasizing tumor and is highly vascularized. The tumor is non-immunogenic and can 
be maintained in tissue culture. From culture new tumors were produced by subcutaneous 
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inoculation in the flank of rats. Tumors were subsequentially passaged serially. 
Small viable tumor fragments of 1-2 mm were implanted under the liver capsule in the left 
liver lobe with a 19 G Luer lock needle in a standardized manner. IHP was performed 6 days 
after implantation of BN 175 soft tissue sarcoma at which time the tumors had reached a 
diameter of approximately 6 mm. During follow-up tumor diameters were assessed through a 
small midline incission by calliper measurement. Tumor volume was calculated by using the 
equation 0.4 (A2xB) where B is the largest tumor diameter measured and A the diameter 
perpendicular to A. Animals were sacrificed when tumor diameter exceeded 20 mm or when 
abdominal adhesions made further assessment of tumor size impossible.  
 
Drugs 
Melphalan (Alkeran, 50 mg per vial, Wellcome, Beckenham, UK) was diluted in 10 ml 
diluent solvent. Further dilutions were made in 0.9% NaCl to give a concentration of 0.2  
mg/ml and stored at -20 °C for further use.  
Recombinant human TNF was provided by Boehringer (Ingelheim, Germany) with a specific 
activity of 5.8x107 U/mg as determined in the murine L-M cell assay (20). Endotoxin levels 
were <1.25 EU/mg protein. 
 
Perfusion system 
The perfusion circuit consisted of arterial and portal inflow limbs, a venous outflow limb and 
a collection reservoir/oxygenator. The circuit was primed with 30 ml Haemaccel (Behring 
Pharma, Amsterdam, Netherlands) containing 50 IU of Heparine. The perfusate was 
oxygenized in the reservoir with a mixture of O2/CO2  (95%:5%) and kept at 38-39 °C by 
means of a heat exchanger connected to a warm water bath. A temperature probe was 
positioned in the lumen of the portal catheter 5 cm from the catheter tip. Arterial and portal 
flow was maintained with two low-flow roller pumps (Watson Marlow type 505 U, Falmouth, 
UK) and kept at 2.5 ml/min and 10 ml/min respectively. Rats were perfused for 10 minutes 
with Haemaccel and dissolved agents, whereafter, a wash out of agents was performed with 
oxygenized Haemaccel for 2 minutes. 
 
Surgical Procedure 
The procedure was a modification of the IHP technique described by de Brauw et al (21). 
Anesthesia was induced and maintained with ether. During the surgical procedure, which on 
average took 60-80 minutes, rats were kept at constant temperature with a warmed mattress. 
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A mid-line laparotomy was performed and the hepatic ligament exposed. The pyloric side 
branch of the portal vein and the gastroduodenal side branch of the common hepatic artery 
were cannulated positioning the tips of the silastic cannulas (0.025 inch outer diameter (OD), 
0.012 inch inner diameter (ID) (Dow Corning, Michigan, USA)) in the hepatic artery and 
portal vein. Through an inguinal incission the femoral vein was exposed. To collect hepatic 
venous outflow a silicon cannule (0.025 inch ID and 0.047 OD (Dow Corning, Michigan, 
USA)) was femorally introduced and retrogradely inserted in the caval vein with the tip 
positioned at the level of the hepatic veins.  
Isolation of the hepatic vascular bed was obtained by clamping the hepatic artery and the 
portal vein. The venous outflow limb was isolated by clamping the supra hepatic caval vein 
and by applying a temporary ligature around the infra-hepatic caval vein containing the 
canule, cranial to the right adrenal vein. During isolation the mesenteric artery was clamped 
to reduce splanchnic bloodpressure and the risk for translocation of intestinal bacteria.  
After the IHP procedure clamps on caval vein, portal vein, hepatic artery and mesenteric 
artery were released. Gastroduodenal artery, pyloric vein and femoral vein were ligated and 
gastroduodenal and pyloric canules removed.  
 
Assessment of TNF concentrations in perfusate and systemic blood compartment during 
IHP 
In order to validate the leakage free quality of the IHP model, TNF concentrations in regional 
and systemic blood compartments throughout and after perfusion were determined. Hereto 
three BN-strain rats underwent IHP with 20 µg TNF and 200 µg Melphalan added to the 
perfusate. Samples were obtained from the perfusate at 0, 5 and 10 minutes after start of 
perfusion and drawn from the iliac artery at 0, 5, 10, 12.5, and 15 minutes after start of 
perfusion.  Samples were centrifuged at 2600 r.p.m. for 6 minutes whereafter the obtained 
plasma/carrier solution was stored at -70 °C until analysis. Plasma and perfusate TNF 
concentrations were determined using ELISA for rhTNF as described by Engelberts et al (22). 
The detection limit for human TNF was 20 pg/ml.  
 
Treatment schedule 
BN strain rats underwent IHP six days after implantation of the tumor providing tumor 
diameter was approximately 6 mm. Five rats served as untreated controls. Rats were perfused 
in random order with 200 µg Melphalan (n=7), 20 µg TNF (n=8), a combination of 20 µg 
TNF and 200 µg Melphalan (n=8), or underwent a sham perfusion with Haemaccel (n=5). 
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The administered Melphalan dose was extrapolated from effective dosages in ILP with TNF 
and Melphalan. The administered TNF dose was the maximum tolerated dose TNF for IHP in 
BN rats.  
 
Statistics 
Differences in mean tumor volumes of treatment groups at day 10 after IHP were evaluated 
for statistical significance with the Mann-Whitney U-test using SPSS® for Windows™ 
software. P-values < 0,05 were considered as significant. 
 
Results 
 
Over 85 % of IHP’s were technically succesfull. All succesfully perfused animals survived 
after the IHP procedures until they had to be sacrificed due to tumor size or abdominal 
adhesions. IHP with carrier solution was well taken by perfused rats and had no apparent 
effect on their weights. Perfusing with either Melphalan or TNF alone or with a combination 
of both agents in some cases resulted in transient weight reduction or stagnation. However, 
weight reduction was never more than 10% (data not shown).  
 
Distribution of TNF during IHP over hepatic and systemic blood compartments 
In order to assess the leakage quality of this IHP rat model TNF plasma concentrations in the 
regional and systemic compartment during IHP were determined. Figure 1 shows the mean 
regional and systemic TNF concentrations during and after IHP of three rats. Throughout 
isolation TNF concentrations in the perfusate remained stable at approximately 550 ng/ml. 
Virtually no concomitant leakage of TNF to the systemic compartment was observed. The 
efficacy of the washout procedure was apparent from the fact that after isolation was 
terminated only a minor transient elevation of systemic TNF levels was observed (max 60 
ng/ml). 
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Fig.1 TNF plasma and perfusate concentrations in regional (●) and systemic (○) blood compartments during 
and after IHP with 20 µg TNF and 200 µg Melphalan in rats. Rats were perfused for 10 minutes whereafter 
during two minutes agents were washed out with carrier solution. Mean values are given +/- SEM (n = 3). 
 
Tumor response after IHP 
In figure 2 the growth curve of BN 175 soft tissue sarcoma in non perfused animals is 
compared with the growth curve of tumors in animals having undergone a sham perfusion 
with carrier solution. Strikingly, IHP with only carrier solution resulted in a significantly 
diminished growth rate of tumors compared to tumors in non-perfused animals.   
Figure 2 also demonstrates the effect of IHP with various agents on tumor volume. IHP with 
200 µg Melphalan (n=7) significantly reduced tumor growth rates compared to sham treated 
animals (n=5) (p<0.02), but failed to induce a reduction of mean tumor volume as all rats 
demonstrated progressive tumor growth. Perfusing with 20 µg/ml TNF alone (n=8) resulted in 
a slight growth stimulatory effect on BN 175 liver tumors, as compared to tumors in sham 
treated rats (p<0.01). No negative effect on tumor growth was observed in any animal. When 
IHP was performed with a combination of 20 µg TNF and 200 µg Melphalan (n=8) a 
dramatically enhanced tumor response was observed in all animals, resulting in a significant 
reduction of mean tumor volume compared to mean tumor volumes in rats perfused with 
either TNF or Melphalan alone (p<0.005 and p<0.01 respectively). At day 10 after IHP mean 
tumor volume was reduced by more than 50 % of its value before IHP. No animals 
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demonstrated tumor progression, while 4/8 animals demonstrated a reduction in tumor 
volume of more than 90 %. At day 14 3/8 animals demonstrated progression of tumor growth, 
while other animals showed a decline in tumor volume. Five of eight animals treated with 
TNF and Melphalan were sacrificed due to multiple abdominal adhesions. The remaining 
animals all demonstrated regrowth of tumors when followed up for a longer period of time 
(data not shown). 
 
Fig.3 Mean tumor volumes of BN 175 soft tissue sarcoma liver tumors in rats after isolated hepatic perfusion 
with TNF and/or Melphalan and in non-perfused control rats (■, n = 5). Rats were perfused with 20 µg TNF (□, 
n = 8), 200 µg Melphalan (○, n=7), or a combination of 20 µg TNF and 200 µg Melphalan (▼, n = 8) or they 
underwent a sham perfusion (●, n = 5).  Mean tumor volumes are given +/- SEM. 
 
Discussion 
 
In the present study we demonstrated a leakage free IHP rat model. We observed that IHP 
without addition of anti-tumor agents had an anti tumor growth effect in BN 175 soft tissue 
sarcoma bearing rats. When performing IHP with either TNF or Melphalan alone no tumor 
responses were observed. However, perfusing with a combination of TNF and Melphalan 
resulted in dramatically enhanced anti-tumor effects. Strikingly, this potentiation by TNF was 
observed at lower TNF concentrations than those that are necessary to elicit synergistic anti-
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tumor effects between these agents in ILP when treating BN 175 soft tissue sarcoma 
extremity tumors.  
Regional chemotherapy of liver tumors yields higher response rates than systemic therapy 
(23,24,25). Following the success of addition of TNF to ILP with Melphalan for the treatment 
of soft tissue sarcoma of the extremities (3,4), we set ourselves to investigate application of 
this cytokine in regional chemotherapy settings of the liver.  
Hepatic artery infusion (HAI) exploits the high tissue extraction ratios that many 
chemotherapeutic agents demonstrate, leading to higher tumor concentrations and less 
systemic side effects (26,27). However, for an agent like TNF, which at high concentrations 
demonstrates relatively little hepatic uptake (8), subsequent systemic exposure is potentially 
fatal. In addition to HAI, IHP has been developed as a treatment modality that not only 
maximizes drug concentrations in the target organ, but at the same time also shields the 
organism from systemic toxicity (28,29,30). While TNF can be used in very high doses in the 
clinical ILP setting, theoretically similar doses could be used in IHP, as in both cases a 
complete wash out of agents can be achieved, thus limiting systemic exposure. Furthermore, 
temporary isolation of the hepatic vascular bed during IHP allows for the modulation of 
perfusate parameters like temperature, oxygenation and pH, thus creating optimal conditions 
for the anti-tumor agents to have an effect (19). Previously, it was demonstrated that IHP in 
rats leads to significantly higher tumor concentrations of Melphalan compared to HAI (12). In 
this study we perfused over both arterial and portal hepatic inflow limbs. Although hepatic 
metastases mainly derive their blood supply from the hepatic artery, connections with the 
portal circulation do exist at the periphery of the tumor (31). It seems rational therefore to 
perfuse both hepatic circulations if one aims its therapy at the viable, vascularized rim of the 
tumor. Additionally, in the clinical situation non-vascularized ‘micro-metastases’ can be 
expected to totally depend on the portal circulation.  
TNF in vivo has the ability to induce tumor necrosis with acute softening of the tumor, 
believed to be brought about by a selective destruction of the tumor micro-vasculature, 
causing acute hemorrhagic necrosis of the tumor (3,18,32,33). This effect seems to be dose 
dependent as low dose TNF has been reported to have an angioproliferative effect, whereas 
higher concentrations cause destruction of newly formed vessels (34). Similar to clinical 
results, ILP in rats with high dose Melphalan and TNF yields tumor responses of BN 175 soft 
tissue sarcoma extremity tumors in over 80% of animals treated (17,19). These are believed to 
be predominantly indirect effects as previously, in in vitro studies, no direct cytotoxic effect 
and no synergistic potentiation by TNF of Melphalan were found using the BN 175 tumor 
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cells (17).  
High concentrations TNF are necessary only for a short period as in clinical ILP an immediate 
increase in vascular permeability was observed resulting in an increased accumulation of the 
drugs (35). Likewise, experimental ILP in rats with TNF in combination with Melphalan or 
Doxorubicin clearly resulted in an enhanced accumulation of these agents in BN 175 soft 
tissue sarcoma extremity tumors, corresponding with observed augmented tumor responses 
(36,37). Having observed similar augmentation of anti-tumor effect on BN 175 soft tissue 
sarcoma after addition of TNF to Melphalan in IHP as in ILP one could postulate that 
endothelium mediated TNF effects are responsible in both settings. 
A recent report by Alexander et al (38), however, questions the role of TNF in enhancing 
capillary endothelial permeability in tumor associated vasculature in hyperthermic IHP, as 
addition of TNF did not effect melphalan concentrations in liver tumors. Apart from the 
possibility that the hyperthermia related capillary leakage may have ‘masked’ a TNF effect, 
these contradicting observations may reflect the importance of tumor characteristics, like for 
instance the degree of tumor vascularization, in determining if TNF mediated effects can 
come about. Kuppen et al (39) demonstrated that although IHP in patients resulted in 
relatively high levels of TNF in liver tissue compared to systemic administration, TNF did not 
accumulate preferentially in the tissue of colorectal metastases. Interestingly, in a recent 
clinical IHP study using TNF and Melphalan markedly better results were observed in tumors 
of mesenchymal origin compared to colorectal metastases (16).  
It is clear that isolated perfusion of organs is accompanied by a higher risk of regional toxic 
side effects than ILP. In IHP liver toxicity rather than systemic toxicity is dose-limiting 
(12,21). This has been shown to be particularly the case when perfusing with TNF (7,13,14). 
In an isolated kidney perfusion model in the rat we previously found that the maximum 
tolerated dose of TNF  (0.2 µg/ml) was ineffective, which clearly demonstrated the restriction 
of TNF dose in perfusion settings due to local toxicity (9). The current IHP model, however, 
seems to allow above threshold levels of TNF regionally to elicit augmentation of anti-tumor 
effects.  
In our experiments effective treatment of BN 175 liver tumors with IHP was achieved at TNF 
concentrations (550 ng/ml) approximately four times lower than the minimal required dose 
for treating this tumor in ILP (2 µg/ml) (19). Possibly, the IHP procedure itself, also 
contributes to the anti-tumor effects observed. This could not only explain the observed 
reduction in tumor growth in sham treated rats, but may also be in accordance with reports of 
tumor responses after IHP despite low tumor concentrations of perfused agents (11,39). 
Chapter 2 
 
 
31 
Explanations could be the secondary release of cytokines by the liver which is associated with 
IHP (40,41,42) or the mild hyperthermia of the perfusate as hyperthermic IHP by itself has 
been shown to have a tumoricidal effect (43). Other mechanisms could be (temporary) 
relative ischaemia during the procedure or transient changes in local hemodynamics as a 
result of IHP. 
With the dawning of minimally invasive IHP techniques (8,44), the reduction in procedure 
associated risks enhances the clinical application potential of TNF in this setting. An efficient 
pre-clinical IHP model is extremely useful to further investigate by what means the agents- 
associated risks can be reduced and their efficacy improved. Next to investigating the 
possibility of dose reduction, it may be of use in investigating the application potential of 
TNF-mutants, which have shown to be less toxic than wild type TNF, but at the same time 
have retained their anti-tumor effects (45). An IHP model may also be of use in addressing 
questions concerning the concomitant systemic administration of agents during IHP that 
reduce the toxic side effects of TNF (46,47 ). 
In this study we have shown that, like in ILP, addition of TNF to IHP with Melphalan for 
treatment of hepatic soft tissue sarcoma results in augmentation of anti tumor effects. Thus, as 
is the case for the ILP setting, we have a pre-clinical model rat model to study pre-requisites 
for optimal IHP with TNF and Melphalan.  
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Summary 
 
Isolated hepatic perfusion (IHP) with Melphalan with or without TNF is currently performed 
in clinical trials in patients with hepatic metastases. Previous studies led to the hypothesis that 
the use of TNF in isolated limb perfusion causes specific destruction of tumor endothelial 
cells and thereby induces an increased permeability of tumor vasculature. However, whether 
TNF contributes to the therapeutic efficacy in IHP still remains unclear. In an in vivo rat liver 
metastases model we studied three different tumors: colon carcinoma CC531, ROS-1 
osteosarcoma and BN-175 soft tissue sarcoma which exhibit different degrees of 
vascularization. IHP was performed with Melphalan with or without addition of TNF. IHP 
with Melphalan alone resulted in all tumor types in a decreased growth rate. However in the 
BN-175 tumor addition of TNF resulted in a strong synergistic effect. In the majority of the 
BN-175 tumor bearing rats a complete response was achieved. In vitro cytoxicity studies 
showed no sensitivity (CC531 and BN-175) or only minor sensitivity (ROS-1) to TNF, ruling 
out a direct interaction of TNF with tumor cells. The response rate in BN-175 tumor bearing 
rats when TNF was co-administrated with Melphalan, was strongly correlated with drug 
accumulation in tumor tissue, as only in these rats a 5-fold increased Melphalan concentration 
was observed. Secondly, immunohistochemical analysis of microvascular density (MVD) of 
the tumor showed a significantly higher MVD for BN-175 tumor compared to CC531 and 
ROS-1. These results indicate a direct relationship between vascularity of the tumor and TNF-
mediated effects. Assessment of the tumor vasculature of liver metastases would be a way of 
establishing an indication for the utility of TNF in this setting. 
 
 
Introduction 
 
Tumor necrosis factor alpha (TNF) is a cytokine with an interesting potential in the treatment 
of cancer (1).  When administered systemically it is accompanied with severe toxicity, 
however especially when TNF in combination with chemotherapy  is used locoregionally 
without systemic exposure it has very potent antitumor effects. Clinical trials of isolated limb 
perfusion (ILP) with recombinant human tumor necrosis factor alpha (TNF) and Melphalan 
resulted in high complete response rates of 75-90 % in patients with in transit melanoma and 
unresectable sarcoma of the extremities (2-5). This is in contrast to ILP with Melphalan alone 
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which is relatively effective against small in transit melanoma metastases (6) but achieves 
very poor results against large tumors such as soft tissue sarcomas  (7-9).  
In order to elucidate the mechanism of TNF several studies have been performed. In our pre-
clinical ILP model we observed drastic alterations in tumor microvasculature integrity (10). 
Rüegg et al. demonstrated elegantly that TNF in combination with IFN-γ induced functional 
down regulation of αvβ3, resulting in detachment of the endothelial cells of the tumor 
vasculature (11). Moreover, angiographic studies performed in patients pre and post TNF 
perfusion showed selective destruction of tumor associated vasculature and histologic studies 
demonstrated hemorrhagic necrosis of the tumor (12). Recently we demonstrated, what we 
consider a key explanation for the potent synergy between TNF and chemotherapy, an up to 
six-fold increased intratumoral Melphalan or doxorubicin concentration in rat sarcomas after 
ILP when high dose TNF was co-administrated (13,14). These findings led to the hypothesis 
that TNF causes specific destruction of tumor endothelial cells and thereby induces an 
increased permeability of tumor vasculature.  
As a result of the favourable experience with the ILP system, other isolated perfusion settings 
have been developed (15,16).  Especially the liver offers superb opportunities for isolated 
perfusion. Irresectable liver metastases are a significant clinical problem. Isolated hepatic 
perfusion (IHP) with Melphalan with or without TNF is technically feasible and is currently 
performed in clinical trials in patients with hepatic metastases (17,18). Whether TNF 
contributes to the therapeutic efficacy in IHP still remains unclear. 
Based on our findings in the ILP studies, it is indicated to study whether TNF can improve 
tumor response in different tumors after IHP and, if so, to investigate the capability of TNF to 
augment drug accumulation in this perfusion setting. By addressing this issue, the usefulness 
of TNF in IHP might be become clear. Since the tumor associated vasculature is the target of 
TNF, we expect that tumor microvessel density (MVD) is a predictor of the potentiating 
effect of TNF during isolated perfusions. Here we present data that indicate that the anti-
tumor effect of TNF is correlated with the tumor microvessel density. 
 
 
Materials and Methods 
 
Rat Liver Metastases Model 
We used male inbred WAG/RIJ or Brown-Norway (BN) strain rats, weighing 250-300 g, 
obtained from Harlan-CPB (Austerlitz, The Netherlands). The rats were fed a standard 
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laboratory diet. All animals were housed under standard conditions of light and 
accommodation. The protocol was approved by the committee for animal research of the 
Erasmus University, Rotterdam, the Netherlands.The experimental protocols adhered to the 
rules outlined in the Dutch Animal Experimentation Act of 1977 and the published Guidelines 
of the UKCCCR for the Welfare of Animals in Experimental Neoplasia (UKCCCR, 1998).  
Three different tumors were used in this study. The weakly immunogenic colon carcinoma 
CC531 is an 1,2-dimethylhydrazine-induced, moderately differentiated adenocarcinoma 
transplantable in syngeneic WAG/RIJ rats. The estimated doubling in vivo is about 6-8 days. 
The spontaneously originated nonimmunogenic osteosarcoma ROS-1 is also transplantable in 
the WAG-RIJ rat and in the liver metastases model it has a mean doubling time of about 4-5 
days. The spontaneously originated nonimmunogenic soft tissue sarcoma BN-175 is the 
fastest growing tumor of the tumors tested, with an estimated doubling time in vivo of about 
2-3 days and is transplantable in syngeneic BN rats. Following a standardized protocol, small 
viable tumor fragments of CC531, ROS-1 or BN-175 tumor fragments of 1 by 2 mm were 
implanted under the liver capsule, one in the left and one in the right side of the left liver lobe, 
using a 19 G Luerlock needle. Experiments started at a fixed tumor diameter between 5 and 6 
mm. When tumors reached a size of 20 mm in diameter or animals showed obvious signs of 
discomfort the animals were sacrificed. 
 
Drugs 
Recombinant human TNF-alpha (TNF, 4.9-5.8 x 107 units/mg) was provided as a kind gift by 
Boehringer Ingelheim GmbH, Ingelheim/Rhein, Germany. Melphalan (L-pam, Alkeran, 
Wellcome Ltd., London, United Kingdom) was obtained as a sterile powder (100 mg) that 
was dissolved aseptically using solvent and diluent provided by Burroughs Wellcome 
(London, United Kingdom).  
 
Isolated Hepatic Perfusion  
This rat isolated liver perfusion model has been described in detail earlier by van IJken et al 
(15). A schematic representation is shown in Figure 1. Anaesthesia was induced and 
maintained with ether (Merck, Darmstadt, Germany). During the surgical procedure, with an 
average duration of 60-75 minutes, rats were kept at a constant temperature using a warmed 
mattress. A mid-line laparotomy was performed and the hepatic ligament exposed. The 
gastroduodenal side branch of the common hepatic artery was cannulated, positioning the tips 
of the cannula (0.025 outer diameter (OD), 0.012 inch inner diameter (ID), (Dow Corning, 
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Michigan, USA)) in the proper hepatic artery. Through a small inguinal incision the femoral 
vein was exposed. To collect hepatic venous outflow a silicon cannula (0.047 OD, 0.025 inch 
ID), (Dow Corning, Michigan, USA) was introduced in the femoral vein and moved up into 
the caval vein positioning the tip of the cannula at the level of the hepatic veins.  
Isolation of the hepatic vascular bed was obtained by temporarily ligating the common 
hepatic artery and the portal vein. The venous outflow limb was isolated by temporarily 
clamping the supra hepatic caval vein and by applying a temporary ligature around the infra-
hepatic caval vein containing the cannule, cranial to the right adrenal vein. The mesenteric 
artery was temporarily clamped in order to reduce splanchnic blood pressure. The circuit was 
primed with 10 ml Haemaccel (Behring Pharma, Amsterdam, Netherlands). Arterial flow of 5 
ml/min was maintained with a low-flow roller pump (Watson Marlow type 505 U, Falmouth, 
UK). Rats were perfused for ten minutes with oxygenated Haemaccel in which Melphalan 
and/or TNF was dissolved. Afterwards a washout was performed by perfusing with 10 ml of 
oxygenated Haemaccel. 50 IU of Heparin (Heparine Leo, The Netherlands) was added to the 
perfusate. The perfusate was oxygenated in a reservoir with a mixture of O2/CO2  (95%:5%) 
and was kept at 38-39 °C by means of a heat exchanger and a warm water bath. A 
temperature probe was positioned in the lumen of the arterial catheter, 5 cm from the catheter 
tip. Following the washout-procedure, the clamps on caval vein, portal vein, hepatic artery 
and mesenteric artery were released. The gastroduodenal artery and femoral vein were ligated 
and the gastroduodenal and femoral cannulas were removed. 
 
 
Fig. 1 Schematic representation of an Isolated Hepatic Perfusion 
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In Vivo Anti-tumor Efficacy Study 
Treatment started at a fixed tumor size of 5-6 mm in diameter. Rats were perfused in random 
order. In a pilot dose finding study performed for each tumor type the Melphalan dose 
inflicting a partial tumor response was chosen for this study. So in case of additive or 
synergistic effect of TNF on Melphalan this could still be demonstrated in the growth curves 
of the tumors. All animals were underwent IHP only once. CC531 bearing rats were treated 
with 50 µg  Melphalan (n=6), 20 µg TNF (n=6), or a combination of  50 µg Melphalan and 20 
µg TNF (n=6). ROS-1 bearing rats were perfused with 50 µg  Melphalan (n=6), 20 µg TNF 
(n=8), or a combination of  50 µg Melphalan and 20 µg TNF (n=6). In the BN-175 bearing 
rats perfusions were carried out with 200 µg  Melphalan (n=6), 20 µg TNF (n=6), or a 
combination of  200 µg Melphalan and 20 µg TNF (n=6).  After IHP tumor size was 
measured via a small midline laparotomy every fourth day. Tumor volume was calculated by 
using the following formula: tumor volume = A2 x B x 0.4. In which B is the largest diameter 
and A the diameter perpendicular to B, measured with a standardized calliper. In every 
treatment group, sham perfused rats (n=6) and untreated control rats (n=5) were included.  
 
In Vitro Cytotoxicity Assay 
CC531 and BN-175 cells were grown in RPMI 1640 and ROS-1 cells in modified Eagle’s 
medium (Gibco BRL, Paisley, UK) supplemented with 10% fetal calf serum (Harlan/Sera-
Lab, UK), 1% penicillin (5000 IU/ml), 1% streptomycin (5000 IU/ml) and 1% L-glutamine 
(200mM) (all Gibco BRL) in a humidified incubator at 37 °C and 5% CO2. Before usage, the 
cells were trypsinised (1 min, 37 °C), centrifuged (5 min, 700 g), resuspended and the 
viability measured by trypan blue exclusion. For in vitro testing of proliferation inhibition, 1.0 
x 104 viable cells were seeded in flat bottomed 96-well microtiter plates (Costar, USA). After 
24 hours the cells were incubated with different concentrations of TNF for 72 hours ranging 
from 0 to 10 µg/ml . Afterwards, cells were washed with PBS and fixed for 1 hour with 10% 
trichloro-acetic acid at 4 °C. Growth of tumor cells was measured using the sulpharhodamine-
B assay according to the method of Skehan et al (19). Tumor cell proliferation was measured 
using the formula: tumor growth = (test well/control) x 100%. Five independent tests were 
performed for each point on the line. 
 
Measurement of Melphalan in Tissue 
Five minutes after the restoration of the circulation the perfused tumor and part of the liver 
were excised. The tissues were immediately frozen in liquid nitrogen to stop metabolism of 
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Melphalan and stored at –80°C. Tumor and liver tissues were homogenized in 2 ml 
acetonitrile (Pro 200 homogenizer, Pro scientific, CT, USA) and centrifuged at 2500g. 
Melphalan was measured in the supernatant by gas chromatography-mass spectrometry (GC-
MS). P-[Bis(2-chloroethyl)amino]-phenylacetic acid methyl ester was used as an internal 
standard. Samples were extracted over trifunctional C18 silica columns. After elution with 
methanol and evaporation, the compounds were derivatized with trifluoroacetic anhydride and 
diazomethane in ether. The stable derivates were separated on a methyl phenyl siloxane GC 
capillary column and measured selectively by single ion monitoring GC-MS in the positive EI 
mode described earlier by Tjaden et al (20). 
 
Assessment of Tumor Microvessel Density by Immunohistochemistry 
Cryosections of tumors were fixed for 15 minutes with 4% formaldehyde. After rinsing with 
PBS, sections were incubated for 1 hour with 1:10 PBS diluted,  mouse-anti-rat-endothelial 
cell antibody (RECA-1, Instruchemie, Hilversum, The Netherlands). For the negative control 
an aspecific mouse IgG was used  (SantaCruz Biotechnology, Santa Cruz, California, USA). 
Thereafter sections were rinsed with PBS and incubated for 1 hour with 1:100 diluted, in 5% 
normal rat serum in PBS, goat-anti-mouse peroxidase labeled antibody (DAKO, Carpinteria, 
CA, USA). After rinsing with PBS, positive cells were revealed by immunoperoxidase 
reaction with DAB solution (DAB-kit, DAKO) and counterstained with hematoxylin. For 
microvessel quantification two independent persons performed a blinded analysis. Positive 
cells were counted in 3 different high power fields (magnification 160x) in each slide 
according to the method of Bosari et al (21). In total 3 slides per tumor and 3 tumors per 
tumor type were evaluated.  
 
Statistical Analysis 
In vitro bioassays and in vivo tumor response results were evaluated for statistical 
significance with the Mann-Whitney-U tests with SPSS8.0 for Windows 98. Mann Whitney U 
test was used to compare Melphalan concentrations in different groups and Kruskal-Wallis 
test to compare number of positive cells in different tumors. A significance level of p<0.05 
was used in all analyses. 
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Results 
 
Tumor Response after Isolated Hepatic Perfusion 
The anti-tumor efficacy of IHP with Melphalan with or without TNF was evaluated for the 
CC531, ROS-1 and BN-175 tumor starting at an equal size of 5-6 mm in diameter. In all 
groups sham IHP’s with only perfusion medium were performed. The graphs in Figure 2 
show the growth curves of CC531 tumor (A) , ROS-1 (B) and BN-175 (C) after IHP with 
Melphalan, TNF, both, or after sham perfused rats. Perfusion with Melphalan alone 
significantly reduced tumor growth rates compared with sham perfused animals in all tumor 
types. When IHP was performed in BN-175 bearing rats with the combination of Melphalan 
and TNF a dramatically enhanced tumor response was observed in all animals. This is a 
significant reduction of mean tumor volume compared with rats perfused with either TNF 
only or Melphalan alone (p<0.005 and p<0.01 respectively). In the CC531 or ROS-1 tumors 
this effect was not observed.  
 
In Vitro Cytotoxicity Assay 
The effect of TNF on the growth of tumor cells in vitro was determined to evaluate whether 
the synergistic effect of TNF could be related to direct tumor cell toxicity. The calculated 
concentration of TNF in the perfusate during IHP in vivo is about 1.5 µg/ml. So in vitro tumor 
cells were exposed to a range of TNF concentrations varying from 0 to 10 µg/ml. The growth 
curves are shown in Figure 3. It is demonstrated that the BN-175 and the CC531 tumor cell 
line did not show significant sensitivity to TNF. Only the ROS-1 tumor cells were moderately 
sensitive to TNF, a growth inhibition of up to 30% at 10 µg/ml was observed.  
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Fig. 2 Growth curves of in vivo tumors after IHP. Each group contains at least 6 animals. Mean values (±SEM) 
are shown.  
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Fig. 3 In vitro growth curves of tumor cells upon exposure to TNF; CC531 (•), ROS-1 (♦), BN-175(■). Six 
independent assays were performed in duplicate for each point on the line. Mean values (± SEM) are shown. 
 
Melphalan Concentration in Tumor and Liver Tissue 
In this perfusion setting, in which the dose of TNF is 20% of the dose used in ILP, an 
enhanced drug accumulation in tumor tissue might take place as well, as observed after TNF 
based ILP. In order to investigate this mechanism, Melphalan concentrations were measured 
in tumor and liver tissues after IHP with Melphalan with and without TNF. In the CC531 and 
ROS-1 tumors Melphalan concentration did not increase significantly after IHP with 
Melphalan and TNF (Figure 4A en 4B). After IHP with Melphalan alone in the BN175 tumor 
bearing rats the Melphalan concentration in tumor and liver tissue was equal (Figure 4C). 
After IHP with TNF however a more than 5-fold increase of Melphalan in tumor tissue is 
measured compared to tumor tissue after IHP without TNF; (p<0.05).  So an augmented drug 
accumulation can also be achieved in the IHP setting when TNF is co-administered.  
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Fig. 4 Melphalan concentrations in liver and tumor tissue after IHP with Melphalan with or without TNF. Six 
IHPs were performed per tumor type. Mean values (±SD) are shown. 
 *=P<0.05 BN-175 tumor after IHP with Melphalan + TNF vs. Melphalan alone. 
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Assessment of Tumor Microvessel Density 
We already hypothesized that TNF by increasing leakage of tumor vessels enhances 
intratumoral concentrations of chemotherapeutics. The increased uptake of Melphalan might 
therefore be correlated with the microvessel density (MVD) of the tumor. Quantification of 
the MVD was performed by immunohistochemical staining of endothelial cells. The 
microvessel count of the colon carcinoma CC531 and the osteosarcoma ROS-1 were equal 
(Figure 5). The soft tissue sarcoma BN-175 however showed a significantly higher MVD than 
CC531 en ROS-1. These results indicate a relationship between vascularity of the tumor and 
TNF-mediated effects. 
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Fig. 5 Microvessel count of CC531, ROS-1 and BN-175 tumors. Mean values (SEM) are shown. *=P<0.001 
BN-175 vs. ROS-1 and vs. CC531. 
 
 
Discussion 
 
In the present study we demonstrated that addition of TNF in IHP results in strongly 
improved response rates of rat liver sarcoma. In vitro no or only minor sensitivity of tumor 
cells to TNF was found. Even in ROS-1 tumors, which are moderately sensitive to TNF in 
vitro, IHP with TNF alone showed no tumor response. These data indicate strongly that in 
vivo indirect mechanisms mediated by TNF in combination with Melphalan determine anti-
tumor effects in IHP. Our data support the notion that this indirect mechanism is the 
selectively destructive effect of TNF on the tumor associated vessels and thereby increasing 
vascular permeability (10,11). To investigate this hypothesis the Melphalan uptake in liver 
and tumor tissue was measured after IHP with or without TNF. Tumor Melphalan 
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concentrations were increased in all tumors but  varied significantly in a tumor type 
dependent way. Moreover enhanced uptake of Melphalan by healthy liver was not observed. 
With TNF alone no tumor response was found in any of the tumor types. Only the 
combination of TNF and Melphalan resulted in a complete tumor response in the BN175 
tumor.  To elucidate this tumor type dependent response, the MVD of the tumors was 
determined. We expected a higher tumor vascularity in this tumor. Indeed a significantly 
higher MVD compared to the CC531 and ROS-1 tumors could be demonstrated. This 
indicates that TNF has specific tumor vascular mediating capacity in this perfusion model, 
which results in enhanced tumor responses in highly vascularized tumors. As a result of our 
findings in ILP and now also in IHP we know that TNF is able to augment the accumulation 
of Melphalan. The presence of lack of TNF mediated synergy appeared to be independent of 
tumor size as also in smaller (diameter 3-4 mm ) or bigger (7-8 mm) tumors comparable  
tumor responses were observed  (data not shown). We are of the opinion that this observation 
is essential in understanding and explaining the impressive responses demonstrated.  
Changes in vascular permeability in patients which underwent IHP with TNF was studied by 
Alexander and coworkers (22). Vascular permeability was measured by diffusion of 
radiolabeled I131 albumin in liver and tumor tissue. A significant increase of the I131 albumin 
post-perfusion could be demonstrated compared to levels I131 albumin measured before 
perfusion. However, this rise was equal in tumors perfused with or without TNF. A TNF 
independent mechanism of the increased endothelial permeability was suggested by the 
authors. However in the present study we demonstrated that TNF is effective in increasing 
vascular permeability for Melphalan selectively in tumor tissue. A more important finding 
however, is that this effect could only be found in the highly vascularized BN-175 tumor. The 
results of Alexander et al. reported on intra-tumoral I131 albumin concentrations were mainly 
based on colorectal carcinoma liver metastases. In hypovascular rat colon carcinoma we also 
could not find an increase of Melphalan intratumorly.  We therefore hypothesize that the 
usual hypovascularity of colorectal metastases in patients explains the lack of TNF-benefit in 
the experience as described by Alexander in patients, which correlates closely to our 
observations in our hypovascular colon cancer liver metastases model in rats. 
IHP with Melphalan and TNF performed in patients with metastases of ocular melanoma or 
leiomyosarcoma showed overall response rates of 50-52% (23,24). Both tumor types are 
highly vascularized. A prolonged duration of response was found in melanoma patients: 14 
months after IHP with TNF versus 6 months after IHP without TNF (23).  After IHP with 
Melphalan with or without TNF in patients with colorectal liver metastases the mean duration 
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of response was in both groups 8-10 months (17,25). The data we now present and the first 
reports of IHP in melanoma and sarcoma liver metastases strongly indicate that in these 
patients TNF has therapeutic potential in IHP. In patients with colorectal liver metastases 
however, IHP with Melphalan alone may well be just as effective as combined with TNF. 
Assessment of the degree of tumor vasculature of liver metastases would be a way of 
establishing an indication for the utility of TNF in this setting. 
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Summary 
 
Ras mutations are present in 40 to 50% of colorectal cancers. Inactivating this oncogene may 
therefore reduce proliferation capacity. In order to target ras we studied the transduction 
efficacy and anti tumor activity of an adenoviral vector expressing a intracellular, neutralizing 
single chain antibody to p21-ras (Y28). In in vitro studies transfection levels of the K-ras 
mutated rat coloncarcinoma cell line CC531 were studied using the LacZ marker gene. In our 
in vivo liver metastases model different routes of administration were evaluated to determine 
which regimen resulted in the best transfection levels and tumor responses: intravenous 
injection (IV), intratumoral injection (IT), isolated liver perfusion (IHP), or hepatic artery 
infusion (HAI). 
CC531 cells are readily transfected in vitro, resulting in significant inhibition of tumor cell 
proliferation by the Y28 construct. Intravenous injection did not result in any measurable 
transfection. Intratumoral injection resulted only in the transfection of tumor cells along the 
needle track. IHP as well as single HAI achieved low transfection levels of tumor tissue. 
Expression of Y28 was demonstrated in tumors after IT injection, HAI and IHP. Whereas, 
repeated HAI’s clearly achieved expression in and around tumor associated vessels. Only five 
times repeated HAI’s with Y28 resulted in a tumor response: in all animals tumor growth was 
inhibited, and in 3 rats out of 8 a complete regression of the liver tumors was observed. 
 
 
Introduction 
 
After resection of the primary tumor recurrent colorectal carcinoma occurs in about 50% of 
patients. In these patients the liver is the major site of metastatic disease (1). Patients with 
resectable liver metastases may have a partial hepatectomy with a five year survival rate of 
25-30% (2-4). On the other hand the natural history of patients with untreated liver metastases 
shows a five-year survival rate of 0-3 % (5).  
Colorectal carcinogenesis is associated with multiple genetic alterations. Ras mutations occur 
in an early stage of progression from adenoma to carcinoma. Ras mutations are present in 40 
to 50% of human colorectal tumors (6). Physiologically, the ras gene leads to the production 
of p21–ras, a protein that catalyses the hydrolysis of guanosine triphosphate to guanosine 
diphosphate, and in this way controls cell proliferation by regulating signal transduction 
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pathways (7). Inhibition of expression of mutated ras has been shown to cause tumor growth 
inhibition and apoptosis in human and murine tumor cell lines (8-12).  
In the development of gene therapy protocols it has been often shown that data from in vitro 
experiments do not always predict anti-tumor effects in vivo. The main reason for this may be 
insufficient tumor targeting. By locoregional administration of the genetic construct, tumor 
targeting may be improved and consequently result in more favorable responses. Previously, 
we have demonstrated successful transfection and anti-tumor activity in a rat sarcoma model 
with isolated limb perfusion (13,14) 
Isolated liver perfusion and hepatic artery infusion are used in surgical oncology trials for the 
administration of chemotherapeutics and cytokines in patients with liver tumors (15-20). High 
local drug concentrations can be achieved at the tumor site by means of isolated hepatic 
perfusion (IHP), a technique with minimal systemic exposure. Effective administration of 
adenoviral vectors via IHP has already been demonstrated by de Roos an coworkers (21-23).  
Repetitive locoregional administration of drugs can be achieved by regional infusions via the 
hepatic artery (17, 24, 25). Thus repeated delivery of adenoviral vectors via the hepatic artery 
may further increase the efficacy of transfection.  
We anticipated that the route of delivery plays a crucial role in optimizing transduction 
efficacy and more importantly in anti-tumor activity. We report here on a transduction 
efficacy study of an adenoviral vector encoding the LacZ marker gene, administrated to the 
liver via systemic and different locoregional routes of administration, and subsequently on the 
antitumor activity of an adenoviral vector expressing a single chain antibody to p21-ras (Y28) 
in vitro and in vivo using the rat colon carcinoma CC531. 
 
 
Materials and methods 
 
Recombinant adenovirus constructs 
AV1.0CMV.Y28 is a recombinant replication-deficient adenovirus vector expressing the Y28 
gene. It encodes the hypervariable regions of an anti-p21-ras single chain antibody driven by 
the human cytomegalovirus (CMV) promoter. It is derived from the rat Y13-259 monoclonal 
antibody to p21-ras (11, 26, 27). The Y28 expression unit, which also contains the bovine 
Growth Hormone polyadenylation signal (bGH polyA), replaces the E1 adenovirus region. 
The AV1.0CMV.Y28 backbone is an E1/E3 deleted human adenovirus serotype 5. This 
construct was subjected to multiple plaque purification and produced in the 293 cell line 
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(human transformed primary embryonal kidney cell line) trans-complementing for E1 gene 
products. Adenovirus was recovered from cell culture supernatant and purified by two rounds 
of cesium chloride ultracentrifugation. Purified virus was then gel-filtered on a PD10 column 
with a PBS buffer containing 0.5 mM MgCl2, 0.5 mM CaCl2 and 10% glycerol. Virus stock 
was aliquoted and stored at -80°C until used. The batch used, met the preclinical grade 
specifications (Quality Control analyses), in regard to sterility, endotoxins, mycoplasma, viral 
particles and plaque forming unit titers. AV1.0CMV.LacZ and AV1.0CMV are also 
recombinant replication-deficient adenovirus vectors constructed on the same basis of an E1 
and E3 deleted human adenovirus type 5 backbone and produced in 293 packaging cell line. 
The former expresses the E. coli derived ß-galactosidase protein that can be detected by 
histochemistry in order to access the transduction efficacy of the vector. The latter contains 
only the CMV promoter and SV40 signal without any transgene inserted. This "empty" 
construct has been used as the control vector in all experiments.  
 
Tumor 
The colon carcinoma cell line CC531, a 1,2-dimethylhydrazine-induced, moderately 
differentiated adenocarcinoma was used (28). The cell line is transplantable in syngeneic 
WAG/RIJ rats.  It exhibits a mutated K-ras gene in codon 12 (GGT to GAT), changing 
glycine to aspartic acid (unpublished data, laboratory of Dr. R. Koesters, DKFZ-Heidelberg, 
Germany). The tumor is weakly immunogenic, as determined by the immunisation method of 
Prehn and Main (29). The tumor can also be maintained in tissue culture. New tumor was 
produced from this culture by subcapsularly implantation in the liver. It is a relatively slowly 
progressing and poorly vascularized tumor. In vivo tumors were subsequently passaged 
serially. 
 
In vitro bioassay 
CC531 cells were grown in RPMI 1640 (Gibco BRL, Paisley, UK) supplemented with 10% 
fetal calf serum (Harlan/Sera-Lab, UK), 1% penicillin (5000 IU/ml), 1% streptomycin (5000 
IU/ml) and 1% L-glutamin (200mM) (all Gibco BRL) in a humidified incubator at 37 °C and 
5% CO2. Before usage, the cells were trypsinized (1 min, 37 °C), centrifuged (5 min, 700 g), 
resuspended and the viability measured by trypan blue exclusion. Viability always exceeded 
85%. For in vitro testing of proliferation inhibition, 1.0 x 104 cells were seeded in flat-
bottomed 96-wells microtiter plates (Costar, USA). After 24 hours the cells were incubated 
with different concentrations of the Y28 or empty construct for 48 hours ranging from a 
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multiplicity of infection (MOI) of 1 to 2.0 x 105. Afterwards, cells were washed with PBS and 
fixed for 30 minutes with 10% trichloro-acetic acid at 4 °C . Growth of tumor cells was 
measured using the sulpharhodamine-B assay according to the method of Shekan et al (30). 
Tumor cell proliferation was measured using the formula: tumor growth = (test well/control) 
x 100%. Five independent tests were performed for each point on the line. 
 
Animals 
We used male inbred WAG/RIJ rats, weighing 250-300 g, obtained from Harlan-CPB 
(Austerlitz, The Netherlands). The rats were fed a standard laboratory diet. All animals were 
housed under standard conditions of light and accommodation. The experimental protocols 
adhered to the rules outlined in the Dutch Animal Experimentation Act of 1977 and the 
published Guidelines on the Protection of Experimental Animals by the Council of the 
European Community. The protocol was approved by the committee for animal research of 
the Erasmus University, Rotterdam, the Netherlands. 
 
In vivo colorectal liver metastases model 
Following a standardized protocol, small viable CC531 tumor fragments of 1 by 2 mm were 
implanted under the liver capsule, one in the left and one in the right side of the left liver lobe, 
using a 19 G Luerlock needle. Experiments started at a tumor diameter of 5-6 mm, which was 
reached about 14 days after implantation of the tumor. 
 
Isolated hepatic perfusion 
This rat isolated liver perfusion model has been described in detail earlier by van IJken et al 
(31). Briefly, the perfusion circuit consisted of an arterial inflow limb, a venous outflow limb 
and a collection reservoir/oxygenator. The circuit was primed with 10 ml Haemaccel (Behring 
Pharma, Amsterdam, Netherlands). Arterial flow of 5 ml/min was maintained with a low-flow 
roller pump (Watson Marlow type 505 U, Falmouth, UK). Rats were perfused for ten minutes 
with oxygenated Haemaccel and 1.0 x 1011 virus particles (vp), which was determined as the 
Maximum Tolerated Dose (MTD), in a pilot study performed previously. 50 IU of Heparin 
(Heparine Leo, The Netherlands) was added to the perfusate. The perfusate was oxygenated in 
the reservoir with a mixture of O2/CO2  (95%:5%) and was kept at 38-39 °C by means of a 
heat exchanger and a warm water bath. A temperature probe was positioned in the lumen of 
the arterial catheter, 5 cm away from the catheter tip. Afterwards, a wash out to remove all 
left viruses was performed by perfusing with 10 ml of oxygenated Haemaccel. 
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Surgical procedure of the isolated hepatic perfusion. 
Anesthesia was induced and maintained with ether (Merck, Darmstadt, Germany). During the 
surgical procedure, with an average duration of 60-75 minutes, rats were kept at a constant 
temperature using a warmed mattress. A mid-line laparotomy was performed and the hepatic 
ligament exposed. The gastroduodenal side branch of the common hepatic artery was 
cannulated, positioning the tips of the cannula (0.025 inch outer diameter (OD), 0.012 inner 
diameter (ID), (Dow Corning, Michigan, USA)) in the proper hepatic artery. Through a small 
inguinal incision the femoral vein was exposed. To collect hepatic venous outflow a silicon 
cannula (0.047 inch OD, 0.025 ID), (Dow Corning, Michigan, USA) was introduced in the 
femoral vein and moved up into the caval vein positioning the tip of the cannula at the level of 
the hepatic veins.  
Isolation of the hepatic vascular bed was obtained by temporarily ligating the common 
hepatic artery and the portal vein. The venous outflow limb was isolated by temporarily 
clamping the supra hepatic caval vein and by applying a temporary ligature around the infra-
hepatic caval vein containing the cannule, cranial to the right adrenal vein. The mesenteric 
artery was temporarily clamped in order to reduce splanchnic blood pressure.  
Following the procedure, the clamps on caval vein, portal vein, hepatic artery and mesenteric 
artery were released. The gastroduodenal artery and femoral vein were ligated and the 
gastroduodenal and femoral cannulas were removed. 
 
Single time and repeated hepatic artery infusion 
Single time hepatic artery infusion. 
Anesthesia was carried out with Hypnorm (Janssen Animal Health, Beerse, Belgium) and 
Ketamine (Apharmo B.V., Arnhem, The Netherlands). During the total procedure, which took 
on average 2 hours and 20 minutes, rats were kept at a constant temperature with a warmed 
mattress and a heat producing lightbulb. A mid-line laparotomy was performed and the 
hepatic ligament exposed. The gastroduodenal side branch of the common hepatic artery was 
then cannulated, positioning the tips of the cannula in the proper hepatic artery.  The cannula 
was connected to the infusion pump (B.Braun, Melsungen AG, Germany). 2.5 x 1011 vp 
(MTD) were dissolved in 1.5 ml of 0.9% NaCl/fractionated heparin solution (Fragmin, 
Pharmacia & Upjohn, Woerden, The Netherlands) (2500IU Fragmin per 100 ml 0.9% NaCl). 
The virusses were infused in one hour. Afterwards the cannula was flushed with 0.9% NaCl 
in order to infuse the remaining viruses in the cannula. During the infusion the arterial hepatic 
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blood supply was maintained. At the end of the procedure the gastroduodenal artery was 
ligated and the cannula removed.  
Repeated hepatic artery infusion. 
After positioning of the canula in the gastroduodenal side branch of the hepatic artery as 
describred above, the cannula was led through a flexible tube and connected via a bubbletrap 
to a continuous 0.9% NaCl/Fragmin solution infusion pump which was set at a continuous 
infusion rate of 0.5 ml/hr. Treatment with 2.5 x 1011 vp (MTD) started at the day of operation 
and was repeated with 2.5 x 1011 vp every other day. The animals stayed in an adjusted 
filtertop cage during the treatment schedule.  
 
Intravenous injection 
Anesthesia was induced and maintained with ether. A volume of 200 µl of PBS containing 2.5 
x 1011 vp (MTD) was slowly injected into the penile vein using a syringe with a 25 G needle. 
 
Intratumoral injection 
Anesthesia was induced and maintained with ether. A mid-line laparotomy was performed 
and the tumors were exposed.  Using a syringe with a 28 G needle, 5.0 x 1010 vp  (MTD) in 50 
µl sterile PBS were injected centrally in each tumor. 
 
In vivo transduction efficacy study 
Experiments started at a diameter between 5 and 6 mm. In order to determine the transduction 
efficacy, tumor-bearing rats were treated with the AV1.0CMV.LacZ construct intravenously, 
by intratumoral injection, via a single time hepatic artery infusion, isolated hepatic perfusion 
and hepatic artery infusion repeated five times. PBS solution was used as a control. 24 hours 
after treatment the animals were sacrificed. Tumors, liver and spleen were taken out, 
snapfrozen in liquid nitrogen and stored at –80 °C  until further usage. 
 
X-Gal staining on cultured cells and cryosections 
Staining of cultured cells. 
1.0 x 104 CC531 cells were seeded in flat-bottomed 96-wells microtiter plates. After 24 hours 
the cells were incubated for 48 hours with various concentrations of the LacZ construct 
ranging from a MOI of 1 up to  2.0 x 105. Then, cells were washed with PBS and fixed for 30 
minutes with 4% paraformaldehyde at 4°C . The cells were washed three times with PBS and 
stained with X-gal staining solution overnight at 37°C. This solution is a mixture of solution 
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A: K4Fe(CN)6.3H20 5 mM, K3Fe(CN)6 5mM in wash buffer (MgCl2 2mM, deoxychlate 
0.01%, NP-40 0.02% in 0.1 M sodium phosphate buffer pH 7.8) and solution B: 5-bromo, 4-
chloro, 3-indolyl β-d-galactopyranoside 50 mg/ml in dimethyl formamide) at ratio of 50 : 1. 
The cells were then washed once with PBS and stored at 4°C. 
Staining of cryosections. 
Cryosections of snapfrozen tissue samples were fixed in 4% paraformaldehyde for 30 minutes 
at 4°C. After three washes with phosphate buffered saline (PBS) pH 7.4, the sections were 
incubated overnight with X-gal staining solution at 37°C. Then, the sections were washed 
twice in PBS, counter-stained with hematoxylin, dehydrated with ethanol and xylene and 
coverslipped with entalan. 
 
Endothelial immunohistochemistry 
In order to investigate transfected cells in relationship to the tumor vasculature cryosections 
were first  stained by the X-gal method (see above) and secondly counter stained using a 
mouse-anti-rat antibody against rat endothelial cell antigen (RECA-1, Instruchemie, 
Hilversum, The Netherlands). After overnight X-gal staining sections were thoroughly rinsed 
with PBS. RECA-1 was diluted 1:10 in PBS and cryosections were incubated for 1 hour. 
Thereafter sections were rinsed with PBS and incubated for 1 hour with 1:100 diluted, in 5% 
normal rat serum in PBS, goat-anti-mouse peroxidase labeled antibody (DAKO, Carpenteria, 
CA, USA). After rinsing with PBS, positive cells were revealed by immunoperoxidase 
reaction with DAB-solution (DAB-kit, DAKO) and counter stained with hematoxylin. 
 
In vivo anti-tumor efficacy study 
The various treatment modalities were started at a tumor size of 5-6 mm in diameter about 14 
days after implantation of the tumor. After start of treatment tumor size was measured via a 
small midline laparotomy every fourth day. Tumor volume was calculated by using the 
following formula: tumor volume = A2 x B x 0.4. In which B is the largest diameter and A the 
diameter perpendicular to B, measured with a standardized calliper. In every treatment group, 
control rats were included. The AV1.0CMV construct was used as negative control in the 
efficacy study.  In each treatment group, except for the 5xHAI treated rats, 2 animals were 
sacrificed 24 hours after start of treatment in order to collect tumor and liver tissue. Tissue 
were snapfrozen in liquid nitrogen and stored at –80 °C  until usage for 
immunohistochemistry. 
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Y28 immunohistochemistry 
Cryosections of snapfrozen tissue samples were fixed in aceton for a few seconds. After three 
washes with PBS/Tween for 15 minutes the sections were incubated for 60 minutes with the 
1:2000 diluted polyclonal rabbit anti-Y28 antibody (kindly provided by M. Janicot, Institut 
Curie, Paris, France) at room temperature. After incubation the sections were washed twice in 
PBS/0.5% BSA, and incubated for 60 minutes with 1:20 diluted FITC-conjugated F(ab’)2 
fragment of swine anti-rabbit immunoglobuline. (Dako, Glostrup, Denmark). The sections 
were again washed with PBS/0.5% BSA. Afterwards slides were coverslipped with 90% 
PBS/glycerol and immediately analysed and photographed with a Leica DM-RXA 
fluoresence microscope equiped with a Sony DXC950 digital camera. 
 
Toxicity study 
In order to determine possible toxicity of the virus, rats were weighed every four days after 
start of treatment. Four days after treatment blood samples were taken via the tail vein. Serum 
was collected after centrifugation (14,000 rpm) and stored at -80°C until further analysis. 
Liver functions (alkaline phosphatase, alaline aminotransferase, aspartate aminotransferase, 
total bilirubin and γ-glutamyl transpeptidase) and renal functions (creatinin and urea) were 
measured by spectophotometric analysis (ELAN-analyzer; Eppendorf-Merck, Hamburg, 
Germany). Thrombocyte, leukocyte, and erythrocyte numerations were also determined in 
these samples (Sysmex; Kyoto, Japan). 
 
Statistical analysis 
In vitro and in vivo results were evaluated for statistical significance with the Kruskal-Wallis 
and Mann-Whitney-U tests with SPSS8.0 for Windows 98. A significance level of p<0.05 
was used. 
 
 
Results 
 
In vitro transfection efficacy and cytotoxicity study 
Cells were incubated with different concentrations of the AV.1.0CMV.LacZ construct. After 
X-gal staining the percentage of transfected cells was calculated by scoring upon light 
microscopy. The concentration of virus required to achieve a 50% transfection rate was 
determined as TD 50 (Transfection Dose). Our estimated TD 50 in this experiment was 
Adenoviral liver directed gene therapy. 
 64 
determined at a MOI of 10,000. The maximum percentage of transfected cells was 64% at a 
MOI of 20,000. Above this concentration incubation of CC531 cells with LacZ virus resulted 
in cell death. 
Inhibition of proliferation of CC531 cellls was observed with both constructs at a MOI higher 
than 2000. However, the Y28 construct showed a much stronger inhibition (Figure 1). The 
MOI resulting in 50% growth inhibition (ID 50) was 15,000 for the Y28 construct and 89,000 
for the empty construct.  Therefore next to a direct cytotoxic effect of the adenovirus, an 
additive inhibitory effect of Y28 on CC531 cells in vitro was demonstrated.  
Fig. 1 Growth of CC531 colon carcinoma cells in vitro after exposure to increasing concentrations of 
AV.1.0CMV.Y28 (Y28) or AV1.0CMV (empty). Five independent assays were performed in duplicate for each 
point on the line. Mean values (+/- SEM) are shown. (MOI: multiplicity of infection). 
 
 
In vivo transduction efficacy study 
X-gal staining of cryosections and the Y28 immunohistochemistry studies revealed a needle 
track transfection pattern of tumor cells after intratumoral injection, with an estimated 
percentage of positive cells 5% (Figure 2, panel A). After IHP scattered foci of positive tumor 
cells per frozen section could be observed, 2-3 % positive cells (Figure 2, panel B). Almost no 
transfected tumor cells could be detected after single time intravenous or repeated (5 times) 
intravenous or a single time hepatic artery infusion. After repeated HAI (5xHAI) however 
clear foci of transfection of tumor vasculature and peri-tumor vasculature transfection were 
observed, estimated 2-3% positive cells (Figure 2,  panel C and Figure 3). Very low 
transfection levels were observed in liver tissue in all groups. 
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Fig. 2 Y28 fluorescence immunohistochemistry on cryosections of tumours collected 24 hours after treatment in 
vivo with AV.1.0CMV.Y28 (Y28). A: tumour after IT, transfection around the needle track. B: foci of Y28 
expression in tumour after IHP. C: expression in tumour after HAI.  
Original magnification: A, B and C: 16 x, insert 40 x. No staining was found in case of treatment with 
AV1.0CMV. 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Two examples of X-gal stained and RECA stained cryosections of tumours of different animals after HAI 
treatment with AV.1.0CMV.LacZ  (left and right). Tumour vessel (brown) and perivascular orientation of 
transfected cells (dark blue) are clearly visible. Original magnification: 40 x.  No staining was found in case of 
treatment with AV1.0CMV. 
 
In vivo anti-tumor efficacy study 
In correspondence with the findings of the transduction efficacy study intratumoral injection, 
intravenous injection, single time hepatic artery infusion and isolated hepatic perfusion with 
the Y28 construct did not result in any tumor response. All of the treated rats demonstrated 
progressive disease (Table 1). Only the tumors injected IT with Y28 showed a slight, but non 
significant decrease in growth rate compared to empty construct. Strikingly, five times 
repeated hepatic artery infusion showed a complete response in 3 out of 8 rats, a partial 
response in 1 rat and a growth inhibition in the other 4 tumors, resulting in an overall response 
rate of 50% (p<0.02 on day 12 and p<0.05 on day 16, compared to controls). All rats treated 
by 5xHAI with the empty construct demonstrated progressive disease (Figure 4, Table 1). As 
a consequence of these results we performed additional five times repeated intravenous 
injections with Y28 as an additive control group. This repeated treatment resulted in 
progressive disease in all animals (Table 1). 
A CB
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Fig. 4 Tumour response of CC531 tumours in vivo after 5xHAI with AV.1.0CMV.Y28 (n=8) or AV1.0CMV 
(n=4) treated rats. On day 0, 2, 4, 6, and 8 rats were infused (treatment schedule indicated by: ↑ ). Mean values 
(+/- SEM) are shown (p<0.02 on day 12 and p<0.05 on day 16). At day 12-24 animals with progressive disease 
had to be sacrificed because of bulky tumour growth (indicated by: ), so only the partial and complete 
responders are depicted after that time point. 
 
Table 1: Responses of CC531 tumors in vivo on day 20 after start of treatment with 
AV1.0.CMV.Y28 (Y28) or AV1.0CMV (empty) 
  
        
    Responses*   
Treatment        
model§ rats (n) PD SD PR CR RR† (%)  
IT Y28 4 4 - - - 0  
IT empty 4 4 - - - 0  
IHP Y28 4 4 - - - 0  
IHP empty 4 4 - - - 0  
1xHAI Y28 4 4 - - - 0  
1xHAI empty 4 4 - - - 0  
5xHAI Y28 8 4 - 1 3 50  
5xHAI empty 4 4 - - - 0  
IV Y28 4 4 - - - 0  
IV empty 4 4 - - - 0  
        
        
*Response were scored by measurement of tumor size as described in the Materials and methods section; PD: 
progressive disease growth= >25%, SD: stable disease= growth <25% increase or <25% decrease of tumor size, 
PR: partial response= >50% growth reduction, CR: complete response= disappearance of all detectable disease. 
§IT= intratumoral injection, IHP= isolated hepatic perfusion, 1xHAI= single time hepatic artery infusion, 
5xHAI= five times repeated hepatic artery infusion, IV= intravenous injection. 
†RR= response rate: percentage of rats with PR or CR. 
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Toxicity study 
No severe hepatic, renal or hematological toxicity could be detected in any group after 
treatment with the Y28 construct. Sera from rats treated by repeated hepatic artery infusion 
were collected at day 8 after start of treatment. Levels of toxicity parameters measured in sera 
varied in an range of + and – 25% of the control values. The only abnormality observed was a 
doubling of γ-glutamyl transpeptidase (γGT) levels, which was detected in all groups and was 
equal after AV.1.0CMV.Y28 and AV.1.0CMV administration. Most changes in toxicity 
parameters seemed to be due to the surgical procedure or the viral constructs rather than the 
encoded gene. Hematological parameters showed a normal leucocyte count after IHP with 
Y28, but in all other groups there was a rise in leukocytes. Only in rats who underwent IT this 
leucocytosis was not statistically significant. The course of animal weights showed a decrease 
of at maximum 5 %, except for IHP and 5xHAI treated rats, where a transient weight loss of 
about 10% was observed in most of the animals. 
 
 
Discussion 
 
For successful cancer gene therapy, tumor targeting is essential. This can be achieved by 
adjusting the vector, but also by adjusting vector delivery (32). In the present study, we 
describe several loco-regional delivery routes for treatment of tumors confined to the liver. 
The aim was to target a poorly vascularized colorectal tumor located in liver tissue and to 
study anti-tumor efficacy by targeting p21-ras. Delivery via intratumoral injection is an 
established method to achieve transfection but its clinical applicability is limited. We consider 
a transvascular approach a prerequisite for testing the real therapeutic window of gene 
therapy. IHP and HAI are transvascular administration modalities, which give rise to high 
local concentrations of the drug through out the liver. De Wilt et al. successfully performed 
isolated limb perfusion in sarcoma-bearing rats for the transfer of the IL-3β-gene (14). The 
IL-3β cytokine was excreted upon transfection of the cells and thereby induced a major 
bystander effect in this tumor model, which resulted in excelent tumor responses. The BN-
175 tumor used in the IL-3β study is a high grade, rapidly growing tumor with an extensive 
vascularization. These characteristics offer superior possibilities for transfection. Fast 
growing tumors are more susceptible for genes driven by a CMV promotor (33). In contrast to 
the BN175 tumor, CC531 tumors have a slow growth rate and are poorly vascularized. Apart 
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from that, the immunologic activity of the liver, in comparison with a limb, is enormous. In 
vitro transfection studies demonstrated that transfection of CC531 cells is possible. The in 
vitro cytotoxicity assay of AV.1.0CMV.Y28 construct showed effective tumor growth 
inhibition and cytotoxicity on CC531 cells. The TD 50 in the transfection efficacy study is 
about equal to the ID 50 of AV.1.0CMV.Y28 in the cytotoxicity assay. This suggests that 
transfection of a CC531 cell with Y28 anti-ras antibody results in proliferation inhibition. 
Next to this we performed in vitro bioassays on human umbilical vein derived endothelial 
cells (HUVECs) which do not harbor a ras mutation. On HUVECs AV.1.0CMV.Y28 hardly 
results in growth inhibition compared with the CC531 cell line (data not shown).  
In order to study transfection efficacy in vivo we targeted the tumor by various locoregional 
delivery routes. We initiated treatment when the tumor size was about 5-6 mm in diameter. In 
patients, a liver tumor of 5 mm diameter is the minimal size of metastases detectable with the 
current imaging techniques. Therefore, in our model we used clinically relevant tumors that 
are locally established and have their own blood supply. Obviously, the tumor-associated 
vasculature is essential for the delivery of vectors. 
In vivo IT injection shows significant transfection of tumor cells on X-gal stained 
cryosections and immunohistochemistry. Strikingly, a single administration of 
AV.1.0CMV.Y28 intratumorally did not result in a significant tumor response. Only minimal 
growth inhibition was seen, which corelates with previous observations (16).  This might be 
explained by the fact that IT injection results in transfection only around the needle track. A 
trans-endothelial route causes a more homogeneous distribution of transfection of the tumor. 
We have shown this previously in a highly vascularized rat sarcoma model and particular in 
the viable rim of the tumor (34). 
The internalization of adenoviral vectors into a cell is receptor mediated. This occurs pre-
dominantly via the Coxsackievirus-adenovirus receptor (CAR) and via αvβ3-integrin (35-41). 
αvβ3 is upregulated in response to vascular damage, during angiogenesis and in certain types 
of malignancy (42).  Isolated perfusion of a limb or an organ causes minor vascular damage. 
As a consequence of this, an increase of αvβ3 may occur, which could improve 
internalization of adenoviruses into cells in the perfused region.  CC531 however, is a poorly 
vascularized tumor and we speculate that upregulation of αvβ3 may not effectively influence 
the transfection, which may contribute to the low transfection efficacy we found after IHP.  
Bilbao et al. found that a blood-tumor barrier in hepato-cellular carcinoma in rats limits the 
gene transfer in tumors greater than 5 mm in diameter (43). Moreover, they also concluded 
that tumors beween 2 and 5 mm could only be transfected by hepatic artery infusion. As 
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already mentioned we started treatment at a tumor diameter of about 5 mm, so a blood-tumor 
barrier may well play a role in the limited transvascular transfection we observed. After 
multiple HAI, the transfection rate of tumor tissue still remains low, however in the 
AV1.0CMV.LacZ and Y28 immunohisochemistry experiments more transfection could be 
clearly detected around tumor vessels.  
It is known that down regulation of p21-ras causes a decrease of vascular endothelial growth 
factor (VEGF) production (44, 45). A bystander effect caused by down regulation of VEGF 
after p53-gene therapy in vivo has already been described (46). Transfection of the tumor 
associated endothelial cells by the Y28 construct may cause an anti-angiogenic effect by this 
VEGF-pathway. A higher transfection of tumor endothelial cells and, as a consequence of 
this, a reduction of VEGF levels around tumor vessels upon 5xHAI could explain the 50% 
tumor response observed in this treatment group.  
Moreover, a direct cytotoxic effect of Y28 on endothelial cells and peri vascular tumor cells 
could contribute to the anti-tumor effect as well. Regions of the tumor supplied by affected 
vessels could have a deficiency of oxygen and nutrients and as a result will become necrotic. 
Our experiments indicate that indirect immunological anti-tumor effect by repeated 
adenovirus administration can be ruled out, because not only five times repeated HAI with the 
empty control vector, but also five times repeated systemic treatment with AV1.0.CMV.Y28 
did not result in any anti-tumor efficacy. Both of these treatment modalities resulted in a 
leucocytosis at least as high as 5xHAI with Y28 (data not shown). It seems to be a 
prerequisite to deliver this vector loco-regionally and in a repetitive way. 
Targeted gene therapy is a major issue in the development of gene therapy towards clinical 
trials. Furthermore, gene therapy has to be safe. In this study we report on a successful 
repeated administration of adenoviral vectors without significant toxicity. We demonstrated 
that loco-regional gene therapy of slowly progressing, poorly vascularized colon carcinoma 
liver metastases is feasible and that repeated treatment might offer possibilities for future gene 
therapy trials. 
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Summary 
 
Isolated hepatic perfusion (IHP) is a methodology that offers possibilities to deliver high 
concentrations of viral vectors locally without systemic exposure and washout possibilities for 
non-bound viruses. By means of IHP a very high transduction efficacy is achieved in vivo 
without significant toxicity using an E1-deficient adenoviral vector in fully immunocompetent 
rats. Moreover a remarkable decreased immune response to the adenoviral vector after IHP 
was observed. Significantly impaired neutralizing antibody formation and decreased 
leukocytes proliferation was demonstrated.  These findings are a strong argument for further 
development of gene therapy in pre-clinical isolated perfusion settings. 
 
Introduction 
 
Adenoviruses are widely used in gene therapy protocols as they proved among the most active 
in transfecting cells and gene expression. However promising in vitro results are often not 
predictive for good in vivo activity. The main reason for this is insufficient transduction 
efficacy in vivo. A method, which improves in vivo efficacy, is locoregional administration of 
the genetic construct. By augmenting local vector concentration while abrogating systemic 
spread targeting is improved and results in more favorable transduction efficacy.  
Previously, we and others demonstrated successful transduction and subsequent tumor 
response in rat gene therapy studies after isolated limb perfusion (ILP) and isolated hepatic 
perfusion (IHP) (1-4). These studies indicate that IHP could be an attractive modality for 
hepatic disorders and malignancies.  
However adenoviral mediated gene transfer results in transient the gene expression and is 
accompanied by an immune response towards the vector. The loss of the therapeutic gene 
requires readministration to achieve prolonged gene expression. After systemic treatment 
however, neutralizing antibodies formation towards viral antigens preclude secondary gene 
transfer (5,6). Upon a non-systemic route of administration like IHP it is unknown to which 
extend neutralizing antibodies are produced by the host. Since IHP is a technique with 
minimal systemic exposure and washout possibilities after the perfusion immune response 
after adenoviral treatment may be impaired. We performed IHP in rats with a recombinant 
adenoviral vector and investigated the production of neutralizing antibodies and leukocytes 
compared to systemic intravenous (IV) treatment. 
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Materials and methods 
Animals 
Male inbred immunocompetent WAG/RIJ rats, weighing 250-300 g (Harlan-CPB, Austerlitz, 
The Netherlands) were used. The rats were fed a standard laboratory diet and were housed 
under standard conditions of light and accommodation. The protocol was approved by the 
committee for animal research of the Erasmus University Medical Center, Rotterdam, the 
Netherlands. The experimental protocols adhered to the rules outlined in the Dutch Animal 
Experimentation Act of 1977 and the published Guidelines on the Protection of Experimental 
Animals by the Council of the European Community 1986.  
 
Recombinant adenovirus construct 
The viral constructs were provided by Aventis-Pharma (Vitry-sur-Seine, France) and are 
described previously by us in detail (4). AV1.0CMV is a recombinant replication-deficient 
adenovirus vector constructed on the basis of an E1 and E3 deleted human adenovirus type 5 
backbone. It contains the human cytomegalovirus (CMV) promoter and SV40 signal without 
a transgene inserted. AV1.0CMV.LacZ expresses the E. coli derived ß-galactosidase protein 
that can be detected by histochemistry in order to access the transduction efficacy of the 
vector.  
 
Routes of administration 
Isolated hepatic perfusion. 
We have described the rat isolated liver perfusion model in detail earlier (7). Briefly, the 
perfusion circuit consisted of an arterial inflow limb in the hepatic artery, a venous outflow 
limb in the caval vein and a collection reservoir/oxygenator. Isolation of the hepatic vascular 
bed was obtained by temporarily ligating the common hepatic artery and the portal vein. The 
venous outflow limb was isolated by temporarily clamping the supra-hepatic caval vein and 
by applying a temporary ligature around the infra-hepatic caval vein containing the cannula, 
cranial to the right adrenal vein. The mesenteric artery was temporarily clamped in order to 
reduce splanchnic blood pressure. The circuit was primed with 10 ml colloid fluid 
(Haemaccel, Behring Pharma, Amsterdam, Netherlands). Arterial flow of 5 ml/min was 
maintained with a low-flow roller pump. Rats were perfused for ten minutes with oxygenated 
and heated (38-39 °C) Haemaccel with 1.0 x 1011 virus particles (vp). This dose was 
determined as the Maximum Tolerated Dose (MTD), in a previously performed pilot study. 
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50 IU of heparin was added to the perfusate. Afterwards, a washout procedure was performed 
to remove all non-bound viruses by perfusing with 10 ml Haemaccel.  
Intravenous injection. 
A volume of 200 µl of PBS containing 2.5 x 1011 vp (MTD) was slowly injected into the 
penile vein using a syringe with a 25 G needle. 
 
Blood sampling 
In order to determine toxicity and neutralizing antibody production blood samples were taken 
via the tail vein at day 0, 3, 6, 9,16, 23, and 30 after treatment. Serum was collected after 
centrifugation (14,000 rpm) and stored at -80°C until further analysis. Moreover rats were 
weighed every four days after start of treatment.  
 
Tissue sampling and X-Gal staining 
In order to determine the transduction efficacy rats were treated with the AV1.0CMV.LacZ 
construct IV or IHP. PBS solution was used as a control. 24 hours after treatment the animals 
were sacrificed. Liver was taken out, snap frozen in liquid nitrogen.  
Cryosections of snap frozen tissue samples were stained according to the X-gal staining 
protocol we previously described (4). 
 
Measurement of neutralizing antibodies 
Adenovirus type 5 specific neutralizing antibodies were measured by the virus neutralization 
(VN) test as previously described (8). The VN test was conducted with Hep-2 cells growing 
in 96-well microtiter plates. Serum samples were inactivated for 30 min at 56 °C (9). 50 µl of 
serial serum dilutions were incubated with equal amounts of adenovirus with a concentration 
of 100 TCID50 (tissue culture infective dose when 50% of cells are infected with a virus titer 
of 102). After 60 min at 37 °C 100 µl Hep-2 cells were added with a concentration of  
2x105/ml. After 5 days the presence of cytopathic effects caused by the virus were scored 
under the microscope. Neutralizing antibody titers were expressed as the highest serum 
dilution showing no cytopathological effects. 
 
Measurement of leukocyte count 
Leukocyte numerations were determined with a microcell counter (Sysmex; Kyoto, Japan). 
Liver functions (alkaline phosphatase, alaline aminotransferase, aspartate aminotransferase, 
total bilirubin and γ-glutamyl transpeptidase) and renal functions (creatinin and urea) were 
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measured by spectophotometric analysis (ELAN-analyzer; Eppendorf-Merck, Hamburg, 
Germany). 
 
Statistical analysis 
Results were evaluated for statistical significance with the Kruskal-Wallis and Mann-
Whitney-U tests with SPSSv10.0 for Windows 2000. A significance level of p<0.05 was 
used. 
 
Results 
 
Firstly we tested whether we could repeat previously reported results and show augmented 
transfection of cells after an isolated perfusion compared to systemic therapy. IHP resulted in 
a high transduction efficacy of near 80-90 % (Figure 1-A). After IV injection low 
transduction efficacy (±5%) of hepatocytes after IV injection was observed (Figure 1-B). All 
animals survived the surgical procedures.  
 
   
 Fig. 1 
X-gal staining of liver tissue after treatment with AV1.0CMV.LacZ.  
A After IHP, estimated transduction of 80-90 % B After IV injection, estimated transduction of about 5 %. 
A 
B 
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Secondly we studied the production of neutralizing antibodies towards adenovirus after IHP 
compared to systemic injection. Antibody titers after IHP were significantly lower compared 
to IV from day 3 up to day 23 (Figure 2). On day 6 after treatment a mean peak titer could be 
measured: 352 after IV injection versus 27 after IHP (p= 0.03). During follow-up, performed 
up to 30 days after treatment the levels decreased and were equalized approximately as from 
day 23.  
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Fig. 2 Neutralizing antibody titer after IVor IHP with AV1.0CMV determined as described in materials and 
methods section. Antibody titers after IHP were significantly lower compared to IV from day 3 up to day 23 (p< 
0.05). On day 6 after treatment a mean peak titer could be measured: 352 after IV injection versus 27 after IHP 
(p= 0.03). Mean values of 5 animals ± SD are shown. 
 
 
Leukocyte count was determined at day 6 after treatment (Figure 3). Numerations of 
leukocytes were significantly higher after IV compared to IHP or the untreated control group 
whereas leukocyte count after IHP was not increased compared to control values. The 
increased leukocyte count following IV administration correlates directly with the rise of 
titers measured after IV treatment.  
No severe hepatic or renal toxicity could be detected in the IV or IHP group after treatment. 
Levels of toxicity parameters measured in sera varied in a range of + and – 25% of the control 
values (data not shown). After IV injection no weight loss was observed. Following IHP a 
maximum transient weight loss of 10% was observed, which could not be related to the viral 
vector as similar weight loss was observed upon sham IHP.  
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Fig. 3 Leukocyte count after IHP and IV with AV1.0CMV measured on day 6 after treatment. Controls are 
untreated rats. Numerations of leukocytes were significantly higher after IV than after IHP  (IV vs. IHP: p< 0.05) 
and also compared to the untreated control group and (IV vs. control: p< 0.05). Leukocyte level after IHP is not 
increased compared to control values. Mean values of 3 animals ± SD are shown. 
 
 
Discussion 
 
Isolated hepatic perfusion is an effective and safe method to deliver adenoviral vectors 
towards liver parenchyma and liver tumors in experimental rodent models (1,4). A 
transduction efficacy up to 45% of hepatocytes by means of IHP with Ad.RSV.βgal combined 
with a chelating agent has been described by de Roos et al.(1). We here demonstrate that this 
highly selective delivery method can result in even higher transduction rates and importantly, 
is accompanied by an impaired neutralizing antibody formation and leukocyte proliferation. 
Several studies have been conducted to influence immune response upon adenoviral gene 
therapy, including incorporation of immunosuppressive genes into the vector or manipulation 
of the immune system during administration (10-12). To our knowledge this is the first report 
demonstrating an impaired immune response using isolated perfusion methodology with a 
“regular” adenoviral vector in an immunocompetent animal model.  
The liver is known for its ability to induce immune tolerance. Already since the beginning of 
liver transplantation the liver is a fascinating organ for immunologists (13). There are several 
reports of patients that received a graft liver with long-term survival without the need for 
immunosuppression (14). This host-to-graft tolerance was also commonly observed in 
experiments with pigs and rats (15). The liver locally controls the immune response when 
antigens from the systemic circulation enter the liver. Limmer et al. investigated the role of 
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the liver sinusoidal endothelial cells (LSECs), which clear the antigen from the blood and can 
function as an antigen presenting cell (16). The naïve T cells, which are activated by the 
LSECs, do not differentiate into effector T-cells thereby inducing antigen specific T cell 
tolerance (17). This mechanism might play a role in the lesser immune response we observed.   
At the end of the IHP we perform a thorough washout until the effluent is completely clear. 
Exposure to viral vectors is strongly diminished to a short period with high local 
concentrations of the virus. It is known that the height of neutralizing antibodies titers is 
correlated with the dose of virus administrated (18). Since most circulating viruses are washed 
away at the end the perfusion, only a relative low viral load is left behind in the liver. In this 
respect acute innate immune mechanisms may contribute in the low titers we observed. 
Worgall et al. demonstrated this innate immune component dominates elimination of 
adenoviral vectors in vivo (19). They reported that 90 % of circulating viruses are cleared 
within 24 hours due to this mechanism and the remnant viruses are eliminated by the normal 
immune response. So if hardly any circulating viruses are left after the IHP and the majority is 
cleared rapidly, only an extremely low amount of viruses can induce the humoral immune 
response and thereby results in impaired neutralizing antibody production.  
Peeters et al. performed biliary infusion of adenoviruses in mice that resulted in increased 
hepatic restricted gene transfer, and was also combined with lower neutralizing antibody titers 
(20).  Another report showed that the route of administration strongly determines the humoral 
immunity to the transgene in experiments with adeno-associated virus vectors in mice. Loco-
regional delivery via the hepatic artery resulted in higher transgene expression and an absent 
immune response to the transgene product (21). These results and our current findings suggest 
that loco-regional liver directed gene therapy offers advantages at gene transfer efficacy level 
as well as at immune response level. 
In conclusion this remarkable finding of impaired neutralizing antibody formation after IHP 
with an adenoviral vector is a strong argument for further research on delivery of viral vectors 
in isolated perfusion settings and could widen the therapeutic index for adenovirus based gene 
therapy. 
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Summary 
 
Inhibition of ras oncogene is a promising new strategy. Gene therapy against ras proved 
successful in human and murine tumor cell lines. Previously we demonstrated effective 
targeted transfection of tumor in a rat model by using an isolated limb perfusion (ILP) for the 
delivery of adenoviral vectors.  
This study explores the anti tumor activity of an adenoviral construct encoding an intracellular 
single-chain antibody (scFv) against p21ras (Y28). In order to determine the influence of the 
ras status on the efficacy of the scFv we used a wild type rat rhabdomyosarcoma and its ras–
oncogene transfectant, for in vitro studies. In vivo we used the ILP delivery method to study 
anti-tumor activity on established limb tumors.  
In vitro studies demonstrated an inhibition of growth caused by the Y28 construct. No 
significant difference between transfected and wild type cell lines could be demonstrated. 
Upon ILP homogeneous transduction in the tumor with on estimate 5 % transduction of tumor 
cells was observed. Perfusion with the Y28 construct however, did not result in any additional 
anti-tumor activity compared to controls.  
Despite in vitro activity and in vivo transfection no significant tumor response could be 
detected using anti-p21ras gene therapy in this ILP-tumor model. 
 
 
Introduction 
 
The wildtype ras gene leads to the production of p21–ras, a protein that catalysis the 
hydrolysis of guanosine diphosphate to guanosine triphosphate. Through this pathway cell 
proliferation is controlled by interfering with signal transduction (1). Inhibition of ras 
oncogene expression is a promising new strategy in anti-tumor therapy. Gene therapy against 
ras using ribozymes, anti-sense RNA or single chain antibodies (scFv) proved successful in 
causing growth inhibition and apoptosis in human and murine tumor cell lines (2-13).  
However, data obtained in in vitro gene therapy experiments often do not correlate with in 
vivo results. In vivo transfection of established tumors remains a major problem and as a 
consequence limits the possibilities of clinical cancer gene therapy. Isolated limb perfusion 
(ILP) proved to be a successful method for the administration of chemotherapeutics and 
cytokines in patients with locally advanced soft tissue sarcomas and in-transit melanoma 
metastases (14-17). We were able to replicate this way of administration in our rat ILP model 
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(18-21). High concentrations of anti tumor agents can be reached at the tumor site with 
negligible systemic exposure. Recently others and we demonstrated effective targeted 
transfection of tumor in a rat model by using an ILP for the delivery of adenoviral vector (22, 
23).  
We now report on a study that explores the anti tumor activity of an adenoviral construct 
encoding an intracellular scFv against p21-ras. Delivery of viral vectors via intratumoral 
injections is an established method to reach transfection but its clinical applicability is limited. 
A transvascular approach could increase the therapeutic window for gene therapy in clinical 
trials. Considering this advantage we used the ILP delivery method to study anti-tumor 
activity of an anti-ras construct on established tumors in the hind limb of a rat.  
In order to study the influence of the ras status on the efficacy of the scFv we used a wild type 
rat rhabdomyosarcoma and its ras–oncogene transfectant, expressing six copies of the ras 
gene, during in vitro studies. In experiments performed in vivo we only used the ras oncogene 
transfected rhabdomyosarcoma.  
 
Materials and methods 
 
Recombinant adenovirus constructs 
AV1.0CMV.Y28 is a recombinant, replication-deficient adenoviral vector expressing the Y28 
gene. It encodes for the hypervariable regions of an anti-p21-ras single chain antibody driven 
by the human cytomegalovirus (CMV) promoter. It is derived from the rat Y13-259 
monoclonal antibody to p21-ras (3, 24, 25). The Y28 expression unit, which contains also the 
bovine Growth Hormone polyadenylation signal (bGH polyA), replaces the E1 adenovirus 
region. The AV1.0CMV.Y28 backbone is an E1 deleted and E3 partially deleted human 
adenovirus serotype 5. This construct was subjected to multiple plaque purification and 
produced in the 293 cell line (human transformed primary embryonal kidney cell line) trans-
complementing for E1 gene products.  
AV1.0CMV.LacZ and AV1.0CMV are also recombinant replication-deficient adenovirus 
vectors constructed on the same basis of an E1 and partially E3 deleted human adenovirus 
type 5 backbone and produced in 293 packaging cell line. The former express the E. coli 
derived ß-galactosidase protein that can be detected by histochemistry in order to access the 
transduction efficacy of the vector. The latter contains only the CMV promoter and bGH 
polyA signal without any transgene inserted. This "empty" construct has been used as the 
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control vector in all experiments. A pilot study revealed a Maximum Tolerated Dose (M.T.D.) 
of 2,5 x 1011 vp for systemic treatment in vivo for each of the constructs. 
 
Tumor 
The rat rhabdomyosarcoma cell line R2 and the transfectants R2T24 and R2-neo, which can 
be maintained in tissue culture, have been described previously (26, 27). The in vivo tumor 
was produced by subcutaneous implantation of cells. The tumor is transplantable in syngeneic 
WAG/RIJ rats and was subsequently passaged serially. The R2T24 cell line was cotransfected 
with the plasmid pT24 carrying the c-H-ras oncogene (28) and the plasmid carrying the neo 
gene (29). The R2-neo cell line was transfected by the neo gene only. The R2T24 contains six 
copies of the 6.6 kb BamHI fragment of the pT24 plasmid revealed by Southern blot analysis 
and exhibits constitutive expression of the c-H-ras oncogene determined by Northern blot 
assay (26). In the parental R2 cell line no H-ras oncogene could be detected (26). 
 
In vitro transfection efficacy study and anti tumor activity study 
R2T24, R2 and R2-neo cells were grown in Dulbecco’s modified culture medium (Gibco 
BRL, Paisley, GB) supplemented with 10% fetal calf serum (Harlan/Sera-Lab, GB), 1% 
penicillin (5000 IU/ml), 1% streptomycin (5000 IU/ml) and 1% L-glutamin (200mM) (all 
Gibco BRL) in a humidified incubator at 37 °C and 5 % CO2. Before usage, the cells were 
trypsinized (1 min, 37 °C), centrifuged (5 min, 700 g), resuspended and viability was 
measured by trypan blue exclusion. Viability always exceeded 85%. For in vitro tests, cells 
were seeded in flat-bottomed 96-wells microtiter plates (Costar, USA), in a final volume of 
200 µl and 1.0 x 104 cells per well. After 24 hours the cells were incubated with different 
concentrations of adenovirus for 48 hours ranging from 1.0 x 104 virus particles (vp) /ml to 
2.0 x 1010 vp/ml in a final volume of 200 µl per well (corresponding with a multiplicity of 
infection (M.O.I.) of 5 to 100,000).  
Transfection efficacy study.  
After 48 h incubation with the LacZ construct cells were washed with PBS and fixed for 30 
minutes with 4% paraformaldehyde at 4 °C. Then cells were washed three times with PBS 
and stained with X-gal staining solution overnight at 37 °C. This solution is a mixture of 
solution A: K4Fe(CN)6.3H20 5 mM, K3Fe(CN)6 5mM in wash buffer (MgCl2 2mM, 
deoxychlate 0.01%, NP-40 0.02% in 0.1 M sodium phosphate buffer pH 7.8) and solution B: 
5-bromo, 4-chloro, 3-indolyl β-d-galactopyranoside 50 mg/ml in dimethyl formamide) in a 
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ratio of 50 : 1. The cells were then washed once with PBS and stored at 4 °C until further 
analysis. 
Anti-tumor activity study. 
After incubation with Y28 or empty construct, cells were washed with PBS and fixed for 30 
minutes with 10% trichloro-acetic acid at 4 °C. Growth of tumor cells was measured using the 
sulpharhodamine-B assay according to the method of Shekan et al (30). Tumor cell 
proliferation was measured using the formula: tumor growth= (test well/control well) x 100%. 
At least five independent tests were performed for each time point. 
 
Animals 
Male inbred WAG/RIJ strain rats, weighing 250-300 g, obtained from Harlan-CPB 
(Austerlitz, The Netherlands) were used. The rats were fed a standard laboratory diet. All 
animals were housed under standard conditions of light and accommodation. The 
experimental protocols adhered to the rules outlined in the Dutch Animal Experimentation 
Act 1977 and the published Guidelines on the Protection of Experimental Animals by the 
Council of the European Community 1986. The protocol was approved by the committee on 
animal research of the Erasmus University Medical Centre, Rotterdam, the Netherlands. 
 
 
Isolated Limb Perfusion (ILP) model 
The perfusion technique was performed as described previously (18, 19) and a schematic 
representation is shown in Figure 1. Briefly, small fragments (3-5 mm) of the 
rhabdomyosarcoma were implanted subcutaneously into the right hind limb. Perfusion was 
performed at a tumor diameter between 12 and 15 diameter. Time between implantation and 
perfusion was about 14-16 days. Animals were anaesthetized with Hypnorm (Janssen 
Pharmaceutica, Tilburg, the Netherlands) and Ketamine (Apharmo B.V., Arnhem, The 
Netherlands). Heparin (50 IU) was injected intravenously to prevent coagulation. To keep the 
rat's hind limb at a constant temperature, a warm water mattress was applied. Temperature 
was measured with a temperature probe on the skin covering the tumor and was maintained 
between 38.0 and 39.0 ºC. The femoral artery and vein were cannulated with silastic tubing 
(0.012 inch ID, 0.025 inch OD; 0.025 inch ID, 0.047 inch OD respectively, Dow Corning, 
Michigan, USA). Collaterals were occluded by a groin tourniquet and isolation time started 
when the tourniquet was tightened. An oxygenation reservoir and a roller pump were included 
into the circuit. The perfusion solution consisted of 5 ml Haemaccel (Behring Pharma, 
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Amsterdam, the Netherlands) and the adenoviruses were added as boluses to the oxygenation 
reservoir. A roller pump (Watson Marlow, Falmouth, UK; type 505 U) recirculated the 
perfusate at a flow rate of 2.4 ml/ min. A washout with 5 ml oxygenated Haemaccel was 
performed at the end of the perfusion. After the perfusion, the cannulas were removed and the 
femoral vesels of the perfused limb were ligated. The extensive collateral circulation restored 
the blood supply of the perfused leg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Schematic representation of an Isolated Limb Perfusion setting in the rat. 
 
 
In vivo transfection efficacy study 
In order to determine transfection efficacy, tumor-bearing rats (n=3) were treated with 2,5 x 
1011 vp AV1.0CMV.LacZ construct by ILP. Animals were sacrificed 24 hours after treatment. 
Tumor, quadriceps muscle of the perfused limb, quadriceps muscle of the other hind limb, 
liver and spleen were taken out, snapfrozen in liquid nitrogen and stored at –80 °C until 
further analysis. Before X-gal staining cryosections were fixed in 4% paraformaldehyde for 
30 minutes at 4 °C. After three times washing with phosphate buffered saline (PBS) pH 7.4, 
sections were incubated in with X-gal staining solution overnight at 37 °C. Thereafter sections 
were washed twice in PBS, counter-stained with haematoxylin, dehydrated with ethanol and 
xylene and coverslipped with entalan. 
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In vivo anti-tumor efficacy study 
Four rats were left untreated to determine the normal growth pattern of the R2T24 tumor in 
vivo. Another four rats were sham perfused with Haemaccel only. ILP with 2,5 x 1011 vp of 
AV1.0CMV.Y28 (n=6) or the control vector AV1.0CMV (n=5) were performed. Tumor size 
was determined daily by calliper measurement in a standardised way. Tumor volume was 
calculated by using the formula: tumor volume = A2 x B x 0.4. In which A is the smallest 
diameter and B the diameter perpendicular to A.  
 
 
Statistical analysis 
In vitro and in vivo results were evaluated for statistical significance with the Kruskal-Wallis 
test and Mann-Whitney test with SPSS v10.0 for Windows 2000. A significance level of 
p=0.05 was used. 
 
 
Results 
 
In vitro transfection efficacy is dose dependent 
After X-gal staining the percentage of transfected cells was calculated by means of light 
microscopic scoring. Positive cells were counted in four different fields with magnification of 
100 X. The results for the different cell lines are shown in Table 1. The wild type R2 is more 
sensitive to transfection by the LacZ construct then the transfected R2T24 and R2-neo cell 
line at concentrations from 2.0 x 105 to 2.0 x 107 vp/ml (p<0.05). There are no significant 
differences between R2T24 and R2neo. A clear dose-transfection relation is present in all cell 
lines (p<0.05). 
 
 
Dose 
(vp/ml) 
R2  
% pos (±SD) 
R2T24  
% pos (±SD)  
R2-neo  
% pos (±SD) 
2x108 100 (28) 100 (19) 86 (36) 
1x108 100 (33) 100 (21) 75 (26) 
2x107 93 (19) 72 (39) 65 (30) 
1x107 82 (27) 66 (29) 59 (38) 
2x106 59 (17) 29 (11) 33 (16) 
1x106 45 (30) 24 (18) 20 (7) 
2x105 18 (7) 7 (12) 8 (9) 
 
Table 1 In vitro transfection rate by means of X-gal staining on R2, R2T24 and R2-neo cells after 48-hour 
incubation with increasing concentrations of AV1.0CMV.LacZ. Wild type R2 is more sensitive to transfection in 
vitro by the LacZ construct then the transfected R2T24 and R2-neo cell line at concentrations from 2.0 x 105 to 
2.0 x 107 vp/ml (p<0.05). A clear dose-transfection relation is present in all cell lines (p<0.05). 
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In vitro anti-tumor activity induced by the Y28 construct 
The bioassay of R2, R2T24 and R2-neo incubated with the viral constructs demonstrated an 
inhibition of growth caused by the Y28 construct (Figure 2, panel A-C). Inhibition of growth 
occurred at a concentration of 1.0 x 108 vp/ml and higher for all cell lines. The dose causing 
50% growth inhibition (ID 50) was 3.9 x 108 vp/ml in the wild type R2 cell line, 1.5 x 109 
vp/ml in the R2T24 cell line, and 8,9 x 109 vp/ml in the R2-neo cell line. Statistical analysis 
showed no significant difference between the three cell lines (p=0.17). 
 
Homogeneous in vivo transduction by ILP 
X-gal staining of cryosections of tumors and organs (3 slides per tumor or organ) treated with 
AV.1.0CMV.LacZ were scored by light microscopy. Upon ILP tumors showed on estimate 5 
% transduction of tumor cells (Figure 3). There was a homogeneous distribution of 
transduction in the tumor (3-A,B). Moreover around tumor-associated vessels transduced cells 
could often be detected (3-C). Muscle tissue of the perfused limb showed almost no 
transduced cells. In liver tissue a few positive cells could be detected, which can be caused by 
adenoviruses left in the limb after the ILP or by some leakage during the ILP (Figure 3-D). 
No transduced cells could be detected in spleen, kidney, heart, lung or intestine. 
 
Lack of in vivo anti-tumor efficacy 
All rats survived the surgical procedure and no systemic toxic side effects were observed as 
measured by weight changes. However, in each of the virus treated group one rat suffered 
impaired limb function and oedema. So this local toxicity determined the dosage of 2,5 x 1011 
vp as the M.T.D.  Sham ILP resulted in a temporary growth inhibition of R2T24 tumors 
compared to untreated tumors (Figure 4). We previously observed similar perfusion related 
growth inhibitory effect after sham ILP in the ROS-1 osteosarcoma that also grows in WAG-
RIJ rats [31]. We hypothesize this may be a rat strain dependent effect, rather then a tumor 
dependent effect. Perfusion with the Y28 anti-ras construct however, did not result in any 
additional anti-tumor activity. The control vectors showed comparable results (Figure 4). In 
all groups rats demonstrated progressive disease 7 days after ILP. 
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Fig. 2 In vitro bioassay of A: wild type R2 cells, B: R2T24 cells transfected with six copies of H-ras, C: R2-neo 
cells transfected with the neo gene only. Cells were incubated for 48 hours with increasing concentrations of 
AV.1.0CMV.Y28 (Q) or AV1.0CMV (empty) (V). Four independent bioassays were performed in duplicate for 
each point of the line. Mean values ± SEM are shown. MOI: multiplicity of infection. 
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Fig. 3 Light microscopy of X-gal stained cryosections of tumor and liver 24 hours after in vivo treatment by ILP 
with 2.5 x 1011 vp AV1.0.CMV.LacZ. Showing: A R2T24 tumor, viable rim area B R2T24 tumor, central area, 
C: R2T24 tumor, detail: perivascular transduction , D: liver. Original magnification: A, B and C: 160 x, D: 400x. 
 
 
 
Fig. 4 Growth curve of R2T24 tumor in vivo: control (without treatment) (X, n=4), after sham ILP with 
perfusion medium only (W, n=4) after ILP with 2.5 x 1011 vp  AV1.0CMV(empty) (V, n=6) or 2.5 x 1011 vp  
AV.1.0CMV.Y28 (Q, n=6). Mean values ± SEM are shown. 
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Discussion 
 
 
In the present study we explored in vitro and in vivo anti tumor activity of an anti-ras 
adenovirus construct. Significant growth inhibition of the Y28 scFv could be demonstrated in 
vitro, but was only noted when high concentrations were used indicating only modest activity 
at best. The empty control virus did not have any anti-tumor activity.  Administration of an 
adenoviral LacZ construct in the ILP model resulted in homogeneous transfection of the 
tumor without significant systemic transfection or systemic toxicity. Despite these in vitro and 
in vivo results, the Y28 construct lacks anti tumor efficacy using ILP in this tumor model.  
The in vitro results suggests that the status of the ras gene has no influence on the response of 
tumor cells after AV1.0CMV.Y28 transfection. The R2T24 cell line expressing six copies of 
H-ras did not show an increased or reduced sensitivity to the anti-p21ras scFv. Russell et al. 
found Y28 mediated enhancement of radiosensitivity in various tumor cell lines with N-ras, 
K-ras and wild type ras in vitro (31), confirming that the mechanism of Y28 is independent of 
the status of the ras-gene. The Y28 scFv has been derived from the neutralizing antibody 
Y13-259. This antibody recognizes the H-, N-, and K-ras proteins (24, 25). It seems that this 
aspecific inhibition of ras expression in tumor cells influences the cell function in a broad 
spectrum from enhancement of radiosensitivity to induction of apoptosis (4, 31).  
In soft-tissue sarcoma, osteosarcoma and colon carcinoma rat tumor models we already 
demonstrated transfection efficacy of adenoviral vectors by ILP and isolated hepatic perfusion 
(IHP)(13, 22). Moreover, ILP for adenovirus mediated IL-3ß gene therapy resulted in a 
significant tumor respons in the soft tissue sarcoma (BN-175) as well as the osteosarcoma 
(ROS-1)(32). We currently performed ILP with an adenoviral vector harbouring the LacZ 
gene in order to determine the transduction efficacy in R2 rhabdomyosarcoma. Remarkable 
perivascular transduction was observed in the tumor with on estimate 5% transduction of 
tumor cells. On the basis of these results we wanted to study the in vivo anti-tumor activity 
study of the Y28 construct. In vivo we currently only investigated the R2T24 tumor because it 
has the fasted growth in vivo compared to the R2 and R2neo (26). This is of special 
importance because vectors driven by a CMV promoter are preferably active in dividing cells, 
since the promoter is activated by factors in the nucleus (33). Nevertheless, AV1.0CMV.Y28 
could not induce a significant anti-tumor effect in this tumor by using the ILP.  In spite of the 
fact that the R2T24 is fastest growing tumor among these it took about 2 weeks after 
implantation in the limb to obtain a tumor with the an adequate size for ILP. The above-
mentioned BN-175 and ROS-1 tumors grow twice as fast. We previously demonstrated that 
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fast growing tumors are well vascularized (34). We speculate R2T24 is less vascularized in 
which individual tumor cells are difficult to reach by a transvascular delivery method.  
Cochet et al. described significant growth inhibition of HCT116 human colon carcinoma cell 
line after intratumoral injection of AV1.0CMV.Y28 (4). They reported similar transduction 
efficacy after intratumoral injection. As a consequence some bystander effect of Y28 
transduction in vivo in the HCT116 cell line was suggested. However, upon Y28 based ILP 
no additional anti tumor activity was present, indicating that Y28 transduction lacks a 
bystander effect in this tumor. We hypothesize that a higher transduction level is needed to 
achieve anti-tumor efficacy in this tumor model. Higher transduction rates can be obtained by 
using a higher virus dose or repeated administration. As previously demonstrated in our liver 
metastases model in which we achieved tumor response only upon five times repeated hepatic 
artery infusion (13). Since there is minimal systemic exposure in ILP of the vector we 
anticipated a dose escalation. However in this tumor model we were confronted with local 
toxicity of the limb in 2 out of the 11 perfusions. This result prohibited usage of higher 
dosages of the vector.  
Furthermore internalisation of adenoviral vectors is receptor mediated. Pre-dominantly this 
occurs via the Coxsackie- and adenovirus receptor (CAR) (35). Absence of CAR on the 
surface of R2, R2-neo and R2T24 cells might be responsible for the relatively high M.O.I. 
necessary for inducing proliferation inhibition in vitro as well as growth inhibition in vivo.  
For successful cancer gene therapy tumor targeting is essential. Adjusting vector delivery 
methods has a major influence on transduction efficacy (36). ILP proved to be a effective in 
reaching the tumor, however next to vector delivery, also tumor type, extent of tumor 
vascularisation, presence of receptors and type of gene to deliver are factors crucial in the 
process of achieving a tumor response in vivo. 
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Summary 
 
Locoregional administration of a genetic construct by means of isolated perfusion (IP) of a 
target organ or extremity is a method that may increase in vivo efficacy. Vascular isolation 
and perfusion minimizes systemic exposure and thereby reduces unwanted side effects. 
Isolated hepatic perfusion (IHP) is the most extensively studied IP model, especially in gene 
therapy protocols for inborn errors of metabolism. To achieve stable transduction most 
frequently retroviruses are used in IHP. IHP is combined with hepatectomy or vascular 
ligation of liver lobes to induce liver regeneration increasing transduction efficacy. When 
adenoviruses are used in IHP high transduction percentages of hepatocytes can be achieved 
without significant toxicity. In tumor models adenoviral IHP has been performed, but has not 
been very successful up till now. 
Isolated limb perfusion (ILP) is a promising treatment modality in pre-clinical cancer gene 
therapy studies. After ILP a homogeneous distribution of transduced cells was demonstrated 
especially at the viable rim of the tumor and around tumor associated vessels. Moreover 
complete tumor responses have been observed. Isolated pulmonary perfusion (IPP) results in 
selective expression in the perfused lung and the duration of expression is longer than after 
systemic administration. In rats a significant decrease of tumor nodules upon IPP can be 
achieved. Furthermore other less studied perfusion models are discussed: isolated kidney 
perfusion (IKP), isolated spleen perfusion (ISP) and isolated cardiac perfusion (ICP).  
IP is a methodology that delivers vectors highly selectively, with a long exposure time and 
high concentrations at the target side. This results in higher transduction rates and thereby 
may improve therapeutic effects. 
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Introduction 
 
A method for safe and efficient introduction of foreign DNA into a target cell would allow 
further development of gene therapy protocols in the treatment of inborn errors of metabolism 
and cancer. Promising in vitro results are often faced by poor in vivo activity. The main 
reason for this is insufficient transduction efficacy in vivo. A method, which may improve in 
vivo efficacy, is locoregional administration of the genetic construct by means of isolated 
perfusion of the target organ or extremity. Isolated perfusion is a technique that uses the in 
vivo, in situ vasculature of the target organ or extremity for highly selective, mostly arterial, 
delivery and has controlled venous outflow of the perfusate. Vascular isolation of the target 
minimizes systemic exposure and connection to closed circuit with roller pumps offers the 
option to recirculate the perfusate to further increase the delivery of drugs or vectors. By 
augmenting local vector concentration while abrogating systemic spread, targeting is 
improved and may result in more favorable transduction efficacy. Isolated perfusion models 
administering cytostatic agents are already successfully used in clinical oncology trials. By 
isolated perfusion regional concentrations of chemotherapeutic agents 15-20 times higher than 
those reached after systemic administration can be achieved without systemic toxicity. 
Isolated limb perfusion (ILP) with Melphalan in combination with tumor necrosis factor- 
alpha (TNF) performed in patients with limb threatening soft tissue sarcoma or in-transit 
melanoma metastases results in impressive tumor responses and high limb salvage rates (1-3). 
Isolated hepatic perfusion (IHP) with a cytostatic agent is a treatment option for patients with 
unresectable primary or metastatic tumors confined to the liver and can mediate clinical 
regression of advanced liver metastases (4-8). This methodology of regional administration is 
also conducted in several pre-clinical gene therapy studies in various models and by using 
different type of viral and non-viral vectors. This review outlines the results of administration 
of vectors in vivo isolated perfusion models in a wide field of research on inborn genetic 
defects and cancer gene therapy.  
 
Isolated hepatic perfusion (IHP) 
 
The liver is an important target organ for gene therapy already for many years.  As a 
consequence IHP is the most extensively studied isolated perfusion model in gene therapy 
protocols.  All studies reported in literature are performed with viral vectors (Table 1).  
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IHP perfusion techniques and circumstances vary greatly in the studies published. With 
respect to the inflow site of the perfusion the portal vein is most commonly used. Only de 
Roos et al performed double infusion via the arterial as well as the portal vascularisation of 
the liver (9). Our group currently performs IHP via the hepatic artery only (10,11).  Especially 
in liver metastases models the inflow site is of specific interest since the metastatic tumors are 
mainly vascularized by the hepatic artery (12,13).  
Hepatocyte-targeted Gene Therapy for Inborn Errors of Metabolism. 
The majority of reported IHP studies aim to transduce hepatocytes in order to develop 
treatment options for inborn errors of metabolism. Retroviral transfection ensures genomic 
integration and results in stable expression of the foreign gene (14-17). However, cell division 
is required to achieve retroviral transfection and most hepatocytes are quiescent cells in vivo. 
So as a consequence transduction efficacy will be low. Following partial liver resection many 
hepatocytes start dividing to regain complete liver volume (18,19). A peak in DNA synthesis 
occurs 20-24 hours after hepatectomy (20). This phenomenon of organ regeneration offers 
possibilities to increase retrovirus transfection efficacy. All hepatocyte-directed studies listed 
in Table 1 combine IHP with hepatectomy or vascular ligation of liver lobes. Already in 1991 
Ferry et al. described a rat model in which they performed a partial hepatectomy followed by 
a retrovirus mediated gene transfer by IHP 24-48 hours later(21). This study showed that the 
time interval between perfusion and hepatectomy is an important factor. Significantly higher 
numbers of LacZ positive cells were counted in rats perfused 24 hours after hepatectomy 
compared to a time interval of 48 hours (2-5% vs. 0.05%). One year later Rozga et al. 
confirmed these findings with retroviral hygromycine-B delivery into hepatocytes (22). IHP 
performed 20 hours after anterior lobe portal vein ligation resulted in expression of 
hygromycine-B in 16% of harvested hepatocytes vs. 2.8 % in the negative controls in which 
IHP was performed without artificial DNA synthesis stimulation. When IHP was carried out 
during the same surgical procedure as the portal vein ligation 9% positive cells were found.  
De Godoy et al. perfused rat livers with retrovirus 24 hours after partial hepatectomy for 60 
minutes followed by a 30-minute washout and high transduction rates were obtained. In up to 
34 % of hepatocytes transgene expression could be detected. The very long exposure to the 
vector might be the explanation for this very high transduction efficacy in this study. 
Adenoviruses are able to introduce genes in non-dividing cells and have a high affinity for 
liver cells when administrated intravenously. When adenoviruses are used in IHP it has been 
demonstrated that high transduction percentages can be achieved (9,10,23,24). Regarding 
toxicity following IHP a maximum transient weight loss of 10% was observed, which could 
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not be related to the viral vector as similar weight loss was observed upon sham IHP (10). 
Drazan et al. studied the influence of adenovirus mediate gene transfer on hepatic function in 
further detail by means histological, biochemical and functional studies (23). They 
demonstrated that even with high transduction rates the rat liver was not compromised 
regarding hepatic cell metabolism and integrity. In liver directed gene therapy for inborn 
errors of metabolism these vectors seem suitable, however, the major disadvantage is the 
transient expression of the foreign gene since it is not integrated in the genome of the target 
cell. Expression is typically detectable for a few weeks only. Moreover a strong immune 
response is induced against viral proteins and the transgene product precluding secondary 
gene transfer (25-27) In anti-cancer protocols adenoviruses are widely used because of their 
high transfection efficacy. Moreover stable integration is not needed in cancer directed gene 
therapy.  
Comparability Problems. 
It is hard to compare the results of transduction efficacy between the different studies, because 
of many interstudy variations. In this respect several factors are of importance: (1) type and 
doses of viral vector, (2) type of animal or rat strains, (3) specific perfusion conditions and (4) 
methods to determine the number of transduced cells. These detection techniques vary from 
histochemistry of cryosections of liver samples, to ex vivo harvesting of hepatocytes or 
luciferase activity of tissue samples. Regarding the technical aspects of the isolated perfusion 
many different techniques and conditions are used. The inflow site is already mentioned 
above. Also the flow rate can influence the transduction efficacy. Higher flow rates might, as 
an example, induces an increased perfusion pressure and as a consequence virus particles pass 
trough the fenestrae of the sinusoidal endothelial lining more easily and higher transduction 
rates might be reached. Hydrodynamic studies with increased injection pressure are already 
reported for plasmid based gene therapy in mice(28). After IHP in pigs Borel Rinkes et al. 
have reported mild transient sinusoidal dilatation as well as septal edema, without necrosis or 
severe hepatic dysfunction suggesting that the perfusion pressure is higher than the 
physiologic blood pressure in the hepatic circulation (29). Only in three IHP models 
recirculation of the perfusate is carried out. Recirculation is a technically more demanding 
procedure but has the advantage that after the first passage all non-bound viruses can be 
administered repeatedly making the whole procedure more efficient. Washout of the target 
organ is also an option in isolated perfusion methodology, however is not often used in IHP 
gene therapy protocols. Washout by rinsing the liver with clean perfusate directly after 
perfusion might decrease toxicity of non-bound viruses and increases the selectivity of the 
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transfection to the perfused organ only. De Godoy et al. performed a 30 minutes washout 
procedure and measured the viral load in the venous effluent (30). During the rinsing 
procedure a dramatic decrease in retrovirus concentration was measured. Oxygenation of the 
perfusate is also not frequently used. The liver is very tolerant to ischaemic conditions. From 
clinical experience it is known that the normothermic in situ liver can accept an anoxic period 
up to one hour. Godoy et al. perfused rat livers during 90 minutes but with oxygenation and 
heating of the perfusate, toxicity however was not determined (30). In hepatocyte directed 
gene therapy for inborn errors of metabolism stable transfection is warranted, however high 
transfection levels are not often indicated. Tada et al. demonstrated that only 1-5 % of 
hepatocytes have to be transduced to induce a decrease in bilirubin in Gunn rats (31). 
Following IHP with recombinant retrovirus encoding bilirubin uridine diphosphoglucoronate- 
glucoronosyl transferase (UGT) in 3 weeks time bilirubin levels decreased 20 to 25%. These 
levels remained during the study period (18 months), indicating a stable transfection.  
Gene Therapy for Cancer. 
In cancer directed gene therapy often higher transduction rates have to be reached. We 
previously reported adenoviral IHP transferring a single chain antibody to p21 ras in to colon 
carcinoma cells (10), but with only 1-3 % transduced tumor cells a tumor response could not 
be induced. In this tumor model there was no bystander effect, and probably higher 
transduction rates were necessary. Some viral constructs are known for their bystander effect 
inducing capacity, (32-36), but have not been described in isolated liver perfusion model up 
till now. Another option is combination therapy like Alves et al. showed by performing 
retroviral gene therapy with herpes simplex virus-thymidine kinase (HSV-TK) and 
interleukin-2 (IL-2) followed by ganciclovir administration (37). Monotherapy with these 
vectors failed to induce tumor regression, but combination therapy demonstrated a partial 
tumor response.  
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Author Year Animal Virus A/P Time 
(min) 
Flow 
(ml/min) 
Re- 
circ. 
W.O. O2 Tox. Transd. 
(% + cells) 
Resp 
Ferry 1991 rat RV P1 10 5 - - - - 2-5 NA 
Rozga 1992 rat RV P 15 3 + - - - 9-162  NA 
Moscioni 1993 rat RV P 15 3 - - - - 21-263 NA 
Cardoso 1993 dog RV P4 20 20-80 - + - - 0.15-0.6 NA 
Fong 1995 rat HSV P5 20 0 - - - - 1-3 NA 
Drazan 1995 rat AV p 10 2.5 - - - - 30 NA 
de Roos 1997 rat AV P+A 25 20+5 + + + ND 456 NA 
Tada 1998 rat RV P7 10 5 - - - - 1-5% Bili↓ 
Futagawa 2000 rat AV P 15 0.5 - - - - Variable8 NA 
DeGodoy 2000 rat  RV P1 60 2 + + + ND 34 NA 
Brooks 2001 rat HSV P5 20 0 - - - - 1-3 TNF↑9 
van Etten 2002 rat AV A 10 5 + + + - Tumor10 1-3 PD 
Alves 2003 rat RV P11 5 0 - - - - Tumor + PR12 
van Etten subm rat AV A 10 5 + + + - 80-90 NA 
 
Tabel 1 Gene therapy by Isolated Hepatic Perfusion (IHP). 
 
Abbreviations:  
RV, retrovirus; HSV, herpes simplex virus; AV, adenovirus; P, portal inflow site; A, arterial inflow site; Recirc., 
recirculation; W.O., washout; O2, oxygenation of perfusate; Tox, toxicity; Transd. Transduction; NA, not 
applicable; ND, not determined; bili, bilirubine; TNF, Tumor Necrosis Factor; PD, progressive disease; PR, 
partial response.  
 
Notes: 
1. IHP performed 24-48 hours after 66% partial hepatectomy. 
2. Transduction efficacy determined ex vivo in isolated hepatocytes. IHP which was performed with portal 
branch ligation of the anterior liver lobes. 
3. IHP combined with 70% partial hepatectomy. Transduction efficacy:see note 2.  In situ β-galactosidase 
histochemistry showed 0.5% positive hepatocytes. 
4. IHP performed 72-96 hours after 44-72% partial hepatectomy. 
5. Portal vein infusion with total vascular outflow occlusion, followed by a 20 minutes stopflow period. 
6. Determined after ex vivo IHP with chelating agent. In vivo IHP only with AV.Luc: after IHP 5 times more 
luciferase activity compared to portal vein infusion. 
7. See note 1. Performed in hyperbilirubemea Gunn rats. 
8. Variable transduction of liver different liver lobes. 
9. IHP with HSV transduced cells expressed TNF. Elevated levels of TNF in liver tissue.  
10. Transduced CC531 coloncarcinoma cells, transduction of hepatocytes not determined. 
11. See note 5. Stopflow period 5 minutes.  
12. All tumors showed transduction, quantification not reported. Partial response achieved after combination 
gene therapy with IL-2. 
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Isolated limb perfusion (ILP) 
 
Isolated perfusion of an extremity is a treatment modality used successfully in pre-clinical and 
clinical studies (38). Several studies have already explored the possibilities for gene transfer 
by viral vectors in ILP models (Table 2). All of these studies were performed in tumor 
bearing rats. Since only two different groups worldwide performed the studies perfusion 
conditions and surgical aspects were almost equal. Perfusions were carried at out during 15 
minutes with a flow a 2.5 ml/min. The perfusate consisted of saline or colloid solution and 
was heated and oxygenated. Milas et al. demonstrated efficient gene delivery in tumor tissue 
via ILP using an adenovirus (39). Leakage to the systemic circulation was measured by 
radioactive labeled red blood cells. We performed ILP studies in which we quantified the 
local and systemic transduction rate compared to other routes of administration by LacZ and 
luciferase methods (40). Upon ILP tumor tissue showed 10-30 times more luciferase activity 
compared to all others tissue including muscle tissue of the perfused limb. So highly selective 
tumor transduction is possible by adenovirus based ILP. Moreover, the histochemistry 
showed remarkable differences in transduction pattern in tumor tissue. After intratumoral 
injection (IT) a needle track was clearly visible but after ILP a more homogeneous 
distribution of transduced cells was demonstrated especially at the viable rim of the tumor and 
around tumor associated vessels. Two studies have been performed to investigate anti-tumor 
activity of adenovirus mediated gene transfer. We previously performed ILP with an 
adenoviral IL3β construct driven by a CMV promotor and observed strong tumor growth 
inhibition (41). In 50% of the animals complete remission was achieved. Tumor response was 
not observed after intratumoral injection or by viral constructs with a weaker promotor. Due 
to expression of IL3β transient leucocytosis and fever was observed. We also studied an 
adenovirus construct carrying the Y28 gene that encodes a single chain antibody, which 
intracellularly blocks p21-ras oncogene activity (42). Efficient in vivo transduction was again 
demonstrated, however, in this rhabdomyosarcoma tumor model we were confronted with 
dose limiting limb edema. Dose escalation to higher doses then used intravenously was not 
possible and tumor response could not be demonstrated. Favorable transduction efficacy 
remains an important prerequisite in cancer gene therapy, but the anti-tumor response can still 
not be predicted and depends also on tumor and vector specific factors. 
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Author Year Animal Tumor Vector Toxicity Transduction 
of Tumor 
Response 
Milas 1997 rat FS AV.LacZ Limb function1 +2 NA 
de Roos 2000 rat STS+OS AV.LacZ/Luc - +3 NA 
de Wilt 2000 rat STS+OS AV.IL3β Leukocytosis4 ND PR & CR 
van Etten subm rat RMS AV.Y285 Limb edema6 + SD & PD 
 
Table 2  Gene therapy by Isolated Limb Perfusion (ILP) in tumor-bearing animals .  
 
Abbreviations: FS, fibrosarcoma; STS, soft tissue sarcoma; OS, osteosarcoma; RMS, rhabdomyosarcoma; AV, 
adenovirus serotype 5; NA, not applicable; ND, not determined; PR, partial response; CR, complete tumor 
response; SD, stable disease; PD, progressive disease.  
 
Notes: 
1. Local toxicity of the perfused limb. Oedema and impaired limb function, resolved within 72 hours. 
2. Transduction of tumors in 66-75% of animals. No quantification applicable. 
3. β-galactosidase histochemistry showed homogeneous transfection of tumors after ILP, preferentially at the 
viable rim. Lucifase activity after ILP significantly higher compared to systemic treatment, and similar to 
intratumoral injection. 
4. Transient dose-dependent leukocytosis accompanied with fever and elevated serum histamine levels after ILP.  
5. Y28 is a single chain intracellular antibody to p21-ras. 
6. Limb edema after ILP during 24 hours, no impaired limb function. 
 
 
Other isolated perfusion models 
 
Isolated Pulmonary Perfusion (IPP). 
Only a few other isolated perfusion studies are reported up till now (Table 3). Isolated 
pulmonary perfusions with chemotherapeutic agents have already demonstrated promising 
results in pre-clinical models in experimental treatment of primary lung tumors or pulmonary 
metastases (43-47). Lee et al. demonstrated IPP liposome mediated gene transfer (48). The 
IPP was performed in rats and was in fact a 2-step procedure. First 10 minutes infusion of 5 
ml saline solution carrying the liposomes via the pulmonary artery, followed by a stopflow 
period of 30 minutes for incubation with the same solution. The effluent was collected via the 
pulmonary vein. No heating of oxygenation was applied. After 48 hours selective expression 
in lung tissue of the perfused lung was observed. Moreover the duration of expression was 
longer than after systemic administration. Expression lasted for at least 21 days (end of 
experiment), while in the systemic group no expression could be detected at this time point. 
Brooks et al. investigated two IPP methods in a tumor bearing rodent model with herpes 
simplex virus (HSV) vectors (49). In a rat sarcoma lung metastases model IPP was performed 
with rapid arterial infusion of 0.5 ml perfusate followed by an indwelling, stopflow period of 
20 minutes with venous outflow occlusion. The second method was a low, continuous flow of 
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100 µl/min during 10 minutes without venous outflow occlusion. This study demonstrated 
that higher transduction rates could be achieved by continuous flow: 5% transduced 
pneumocytes and macrophages versus 20%. But in the stopflow group the HSV-LacZ 
perfusion resulted in a significant tumor response, which was also observed in the saline only 
and the HSV-TNF group. Prolonged ischemia probably induced tumor growth inhibition in 
this tumor model. In the continuous IPP saline perfusion showed the same growth rate as the 
untreated control tumors.  However, there was no difference in tumor response between HSV-
LacZ and HSV-TNF. Both resulted in a significant decrease of tumor nodules. Studies in 
large animals have been carried out by the group of Parpala et al.: several models have been 
explored in pigs: IPP, isolated kidney perfusion (IKP) and isolated splenic perfusion (ISP) 
(50-52). Regarding the IPP they perfused a single lobe of the right lung for 60 minutes with a 
adenovirus vector and observed transgene expression in different cell types trough out the 
perfused lobe (52). 
 
Isolated Kidney Perfusion (IKP). 
The kidney is another organ that lends itself quite easily for isolated perfusion from an 
anatomical point of view. In cancer research studies isolated kidney perfusion (IKP) has been 
performed mainly with anti-tumor agents (53-55), but also for genetic disorders or other renal 
diseases IKP has been studied. Heikkila et al. performed AV-LacZ mediated IKP with 
recirculation in pigs during 120 minutes with a heated and oxygenated Krebs-Ringer solution 
(50). Gene tranfer into glomeruli (estimated 75% positive glomeruli) was demonstrated 
without significant toxicity. Whereas this and previous reports on single injection of this 
vector only results in scattered transduction pattern of endothelial cells in the renal medulla 
(56). These findings again demonstrate the importance of long and continuous exposure the 
viral vector. Stephan et al have also investigated IKP with an adenovirus construct (57). After 
a 15-minute IKP with venous outflow occlusion in rats they observed a dose dependent 
predominantly endothelial cell transduction in peritubular capillaries and arterioles. Upon IKP 
with the highest virus concentration focal tubular necrosis was observed.  
 
Isolated Cardiac Perfusion (ICP).  
Isolated cardiac perfusion is technically a demanding isolated organ perfusion and for 
complete isolation a heart-lung machine is essential. Cardiac adenovirus mediated gene 
therapy is mostly delivered via the coronary arteries by means of balloon catheter techniques 
(58). Up till now there is only one study in the literature describing the technique of an in vivo 
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ICP for gene transfer (59). This study was performed in pigs, which underwent sternotomy 
and cardiopulmonary bypass. During hyperkalemic cardioplegia adenoviruses encoding the 
human β-adrenergic receptor (AV-AR) or the LacZ gene (AV-LacZ) were injected in the 
aortic root and dwelled into the coronary arteries during 30 minutes. ICP with AV-AR with 
resulted in a 4 times higher expression in the myocardial of the left ventricle tissue compared 
to AV-LacZ. A systemic control group was not included in this study. No inflammatory 
response could be demonstrated in histological studies of the myocard at 1 week after ICP. It 
is known that the β-adrenergic receptor enhances cardiac performance, however since the ICP 
was carried out on healthy young pigs no data were available on myocardial function after 
treatment. 
 
Isolated Splenic Perfusion (ISP) 
Isolated splenic perfusion for gene transfer has been reported in literature only once as well 
(51).  In this study infusion of adenovirus expressing β-gal in the splenic artery is described. 
No gene expression was detected after this infusion, but after ISP significant expression was 
mainly observed in macrophages, which located around capillaries and in the red pulp. 
Several regional treatment methodologies have also been studied in other organs. Selective 
intra-arterial delivery of virus vectors has been investigated for brain neoplasma, lung tumors 
or liver metastases. Vesical instillations with adenoviruses for patients with bladder cancer are 
already reported as well. Since these routes of administration are not true isolated perfusions 
they are are not within the scope of this review and will not be discussed in further detail. 
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Author  
 
Year Organ Animal Vector Perfusion 
Time(min) 
Recircu-
lation 
Washout Toxicity Transduction/ 
Outcome 
Davidson 2001 Heart pig AV 301 - + - Myocard 
Heikkila 1996 Kidney pig AV 120 + - - Glomeruli 
Stephan 1997 Kidney rat AV 152 - - +3 Endothelium 
Lee 1998 Lung rat Liposome 40 - + - Perfused Lung 
Brooks 2001 Lung4 rat HSV 10-20 - - - Tumorresponse 
Parpala 2001 Lung pig AV 60 + - - Perfused Lung5 
Parpala 2001 Spleen pig AV 60 + - - Macrophages 
 
Tabel 3 Gene therapy in other organ perfusion models. 
 
Abbreviations: AV, adenovirus; HSV, herpes simplex virus.  
 
Notes: 
1. Infusion in coronary arteries during cardioplegia and cardiopulmonary bypass. 
2. Infusion with vein outflow occlusion, follow by a stopflow period. 
3. Focal necrosis at highest dose. 
4. Fibrosarcoma lung metastases model perfused with HSV-TNF inducing a partial tumor response. 
5. Transgene expression in alveolar epithelial cells, capillary endothelial cells, airway epithelial cells and 
alveolar macrophages of the perfused lung 7 days after perfusion. 
 
 
Conclusions and future directions 
 
Locoregional gene therapy by means of isolated perfusion (IP) of the target organ with 
vectors is a new, but promising strategy in gene therapy studies. It offers possibilities to 
selectively transduce cells in vivo with higher efficiency than systemic administration. 
Moreover, unwanted side effects by transduction of tissues in the rest of the body are 
minimized. As reported IP can be used in gene therapy protocols for inborn errors of 
metabolism but also in cancer directed gene therapy. Most studies discussed above stress the 
importance of high local concentration of the viral vectors at the target side during a time 
period that is long enough to effectively reach and transduce the cells. The IP methodology 
offers both conditions and thereby achieves encouraging transduction rates. Next to high 
transduction efficacy successful gene therapy depends on many factors.  IP not only increases 
the number of transduced cells in vivo, but also delivers the transgene in a more homogeneous 
way.  As shown by de Wilt et al. IT results in equal percentage of transduced tumor cells as 
compared to ILP, nevertheless a tumor response upon IT was absent where ILP showed 
impressive tumor shrinkage. Besides transduction rates, gene delivery at the accurate site is a 
prerequisite in gene therapy. With respect to future developments IP is a treatment strategy in 
gene therapy protocols, which needs further study especially in optimizing the vector type that 
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has to be delivered as well as the various transgenes. Lans et al. recently reported ex vivo 
Endothelial Monocyte Activating Polypeptide-II (EMAP-II) gene therapy followed by ILP 
with TNF in tumor bearing rats (60). Ongoing studies are performed at this moment to 
explore in vivo delivery of the EMAP gene into the tumor cells and tumor associated 
vasculature thereby inducing a more TNF sensitive tumor. Combination treatment of gene 
therapy with cytokines or chemotherapeutic agents may lead to a more targeted therapy.  
Regarding liver directed gene therapy it is unlikely that in case of retroviral gene delivery 
partial hepatectomy will be performed in patients. Non- or less- invasive techniques have to 
be developed as an alternative to surgically induced liver regeneration. Portal vein ligation 
can be effective as demonstrated by Rozga et al. (22). In humans this can be performed by 
percutaneous catheter techniques with selective embolisation of portal branches. Patijn et al. 
demonstrated an alternative method by means of adenovirus pre-treatment of the liver (61).  
By expressing a modified form of urokinase type plasminogen activator, which is toxic to 
hepatocytes, hepatocellular proliferation was induced during an eight-day period. Within this 
period continuous infusion of retroviruses was performed achieving a hepatocyte transduction 
rate of 33%. Liver proliferation can also be stimulated by growth factors like keratinocyte 
growth factor or hepatocyte growth factor (62,63). When these growth factors are used in 
combination with retrovirus gene therapy an increase of transduced hepatocytes can be 
achieved as well.  
In adenovirus based gene therapy we are investigating the immune response upon IHP. 
Recently an impaired neutralizing antibody production was observed after IHP in rats (24). 
Manipulation of adenoviruses to reduce antigenicity is now performed on a wide scale and 
this may in combination with local delivery be a future option for repeated delivery (64-67).  
These encouraging results in the field of gene delivery by IP are a strong argument for further 
research in the development of in vivo vector delivery.  
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Summary 
 
Isolated limb perfusion (ILP) is an effective treatment modality for multiple in-transit 
melanoma metastases confined to the limb.  Recurrences after ILP however, occur in 
approximately 50% of patients and are a challenge for further treatment. The efficacy of 
repeat ILPs to prolong local control in this patient category is evaluated in this report. 
A prospective database in tertiary referral center is analyzed. Out of 100 TNF-based ILPs 
with TNF and Melphalan (TM-ILPs) in melanoma patients between March 1991 and July 
2003, 25 repeat ILP procedures were performed in 21 patients who failed prior ILP treatment. 
All patients had bulky and/or numerous lesions and were treated with a mild hyperthermic 
TM-ILP using 2-4 mg TNF and 10-13 mg/L limb volume for the leg and arm respectively. 
Complete response (CR) rate was 76%, Partial Response (PR) occurred in 20% and No 
Change (NC) was recorded in 4%. There was no difference in CR rate or local toxicity 
between first and repeat perfusions. Local recurrence occurred in 72%; median time to local 
progression was 14 months. Five-years survival rate was 47%, which compares favorably 
with known survival rates of stage III A/AB patients. 
Patients who fail after previous ILP treatment respond very well to repeat perfusion and 
prolonged local control can thus be obtained, especially in stage IIIA patients with a long 
recurrence-free interval and in patients failing Melphalan ILPs. The subgroup of patients 
qualifying for repeat ILP represents a relatively favorable biological behavior of the 
melanoma.   
 
 
Introduction 
 
Recurrent melanoma of the limb remains a treatment challenge. Many options, varying from 
simple surgical excision, to intralesional injections with cytokines, to isolated limb perfusion 
(ILP), have been proposed. Depending on the size and the number of the lesions, each 
modality is more or less suitable 1. ILP for melanoma has demonstrated to be very effective in 
patients with multiple metastases where surgical excision is impossible. Melphalan-based ILP 
is associated with CR rates of 40-50% and overall response rates of 75-80%. When Tumor 
Necrosis Factor-α (TNF) was introduced in the isolated limb perfusion model by Lejeune and 
Lienard in 1988 2, CR rates of 80-90% were reported. The first report on the European 
multicenter experience with TNF-based ILP in melanoma patients revealed that a significant 
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increase in CR rates was observed in the 4 participating centers of 91% with TNF and 
Melphalan (TM)-ILPs compared to 52% CR rate for Melphalan-only-ILPs 3. By this 
treatment, disease control in the limb can be obtained in patient categories with a poor 
prognosis quod vitam 4. However, local progression in the limb after ILP with Melphalan has 
been reported to develop in 46-54% of patients, and is 55% in our own experience in 100 TM-
ILPs with predominantly high numbers of metastases and/or bulky disease (Grünhagen D.J. et 
al.: unpublished data). For this patient category, treatment options are limited. Some patients 
however, qualify for re-treatment of the limb when they fail only locally without evidence of 
systemic metastases. Particularly for these patients repeat ILP might provide prolonged local 
control 5-7. The use of TNF in the repeat ILP is hypothesized to improve response rates in 
patients who do not, or insufficiently, respond to Melphalan-only-ILPs, but definitive prove is 
still lacking 6.  
In this study, we report on 25 TM-ILPs for locally recurrent melanoma in patients who have 
failed previous ILP treatment, both with and without TNF. Special attention is given to local 
and systemic progression after repeat ILP and on the locoregional toxicity of the repeat 
procedure. 
 
 
Patients and Methods 
 
Patients. 
Out of 100 TNF-based ILPs in 87 patients performed in our institution between 1991 and July 
2003, 25 ILPs in 21 patients were repeat ILPs because of failure of previous ILP treatment for 
extensive in transit melanoma metastases. Of these 25 ILPs, 12 were performed after failure 
of Melphalan-based ILPs performed in referring hospitals, one after a TM-ILP elsewhere, and 
12 ILPs were second (N=10) or third (N=2) TNF-based perfusions performed in our own 
institution. Tumor stage was assessed according to the MD Anderson staging system: 7 stage 
IIIA patients (IIIA: only in-transit metastases, no lymph node metastases or distant 
metastases), 15 IIIAB patients (IIIAB: both in-transit metastases and lymph node metastases, 
but no distant metastases) and 3 stage IV patients (IV: in-transit metastases and distant 
metastases). At the time of a second perfusion in our institution, progression of tumor stage 
had occurred in 6 patients. Local control of the in-transit recurrences by surgery was 
impossible due to numerous lesions (>10 lesions in 21 ILPs) and/or size of the lesions (>40 
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mm in 12 ILPs). Patient and tumor characteristics of the 25 repeat ILPs in 21 patients are 
summarized in Table 1. 
 
 
Patient and tumor characteristics of 21 patients undergoing 25 repeat TM-ILPs 
Sex Female 15  
 Male 6  
Age (years), mean+range  60 (25-83) 
Stage IIIA 7  
 IIIAB 15  
 IV 3  
Stage shift IIIA Æ IIIAB 4  
 IIIAB Æ IV 1  
 IIIA Æ IV 1  
No. of tumors <10 4  
 10-50 9  
 >50 12  
Size of largest lesion (mm) <40 mm 13  
 >40 mm 12  
Prior treatment None 20  
(apart from ILP) XRT 1  
 CT 2  
 Immuno 1  
 XRT + CT 1  
 
Table 1 Patient and tumor characteristics of 25 repeat ILPs in 21 patients. 
 
Abbreviations: 
ILP=Isolated Limb Perfusion, XRT=Radiotherapy, CT=Systemic chemotherapy, Immuno=Immunotherapy 
 
Treatment. 
All patients underwent an ILP of the lower extremity, either by iliac (N=15), femoral (N=6) 
or popliteal (N=4) approach. The method of ILP has been described by us in detail previously 
8,9. In short: isolation of the limb is achieved by clamping and canulation of the major artery 
and vein, connection to an oxygenated extracorporeal circuit, ligation of collateral vessels and 
application of a tourniquet proximal to the site of perfusion. Once tissue temperature has 
reached 38 ºC, recombinant TNF (Boehringer Ingelheim GmbH, Ingelheim/Rhein, Germany) 
is administered via the arterial line in a dose of 2-4 mg (mean 3.6 mg). Tissue temperatures 
are stabilized between 38-39.5 ºC and leakage monitoring is performed by using a precordial 
scintillation probe to detect leakage of radiolabelled albumen injected to the perfusion circuit 
10. After 30 minutes, Melphalan (L-PAM, Alkeran, Wellcome Ltd., London, UK) is added to 
the perfusate in a dose of 10 mg/L for leg- and 13 mg/L for arm perfusions. In 6 ILPs, 
performed between 1991 and 1994, interferon γ (IFN) was added to the schedule according to 
trial prescriptions consisting of the subcutaneous injection of 0,2 mg IFN on days –2 and –1 
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prior to the ILP and the injection of 0.2 mg IFN during the ILP procedure into the arterial line 
prior to the administration of TNF. Median dose of Melphalan was 100 mg (mean 92.6, range 
40-140), and all 6 IFN-ILPs were performed with 0.2 mg IFN. At the end of the perfusion 
period, a washout procedure using 2-4 liters of a dextrane and/or electrolyte solution is 
performed. In patients undergoing an iliac perfusion routinely an iliac lymph node dissection 
is performed; an axillary lymph node dissection is performed in patients undergoing an 
axillary ILP. In patients with palpable nodal disease in the groin an ilio-inguinal lymph node 
dissection is performed in the same operative session as the ILP, the iliac lymph node 
dissection prior to the ILP and the inguinal lymph node dissection immediately after the ILP. 
 
Evaluation of response and toxicity. 
Acute local toxicity of the ILP procedure was classified according to Wieberdink et al. 11: (I) 
no reaction, (II) slight erythema or edema, (III) considerable erythema or edema with some 
blistering, slightly disturbed motility permissible, (IV) extensive epidermolysis or obvious 
damage to the deep tissues, causing definite functional disturbance, and threatening or 
manifest compartmental syndrome, and (V) reaction that may necessitate amputation. 
Response evaluation was performed 4, 8, 12 weeks after ILP by clinical examination, 
hereafter at 3 months regular intervals for the first 2 years and subsequently at longer 
intervals. Response rates were reported according to WHO criteria 12, in which complete 
response (CR) is the complete disappearance of all lesions and no new areas of disease 
appearing within the field of ILP. Partial response (PR) is defined as a reduction of 50-99% of 
the total tumor size; no change (NC) is recorded if <50% of the total tumor size responds. 
Recurrence of tumor within the extremity after a CR, or progression of the lesions and the 
appearance of new lesions after a PR or after NC, is reported as local progression.  
 
Statistical evaluation. 
Estimates of survival and local/systemic progression were made using the Kaplan and Meier 
method and differences were evaluated using the logrank test. P-values <0.05 were considered 
to be significant. 
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Results 
 
Of the 25 repeat ILPs performed in our institution, 19 (76%) resulted in a complete response. 
With an additional 5 ILPs with a PR, total response rate was 96%. One patient (pt no. 12) 
showed regression of the lesions of 20-25%, which is recorded as NC. There was no 
difference in CR rate between repeat ILPs after prior treatment elsewhere (83%) and repeat 
TM-ILPs in our institution (69%, p=0.36). In the 12 patients receiving multiple TM-ILPs in 
our institution, no difference in response rate was detected between first (70%) and second or 
third ILP (75%, p=0.58). Response rates for the different patient categories analyzed are 
reported in Table 2. Median time between first and repeat ILP was 25 months (range 3-76).  
The median leakage of the repeat ILPs was 0% (range 0-13%), leading to absence of severe 
(grade IV) systemic toxicity (Table 3). Local toxicity was mild to moderate in all cases with 
Wieberdink grade I in 12%, grade II in 60% and grade III in 28% of the ILPs, and not a singe 
case of grade IV toxicity. No increase in local toxicity was observed in the patients receiving 
multiple TM-ILPs (Table 4).  
Compared to our total database of TM-ILP for melanoma, consisting of 100 ILPs, CR rate of 
repeat perfusions did not differ from the CR rate of patients undergoing only one ILP (76% 
vs. 68%, p=0.61). Local progression occurred after 18 repeat ILPs (72%). The median time to 
local progression (TTLP) was 14 months for repeat perfusions vs. 16 months for the overall 
population and 18 months for single ILPs (p=0.40, Figure 1). Sixteen patients developed 
systemic metastases during the course of follow up; 3 of whom were already stage IV at time 
of repeat ILP. Time to systemic progression (TTSP) did not differ between patients receiving 
single (12 months) and multiple ILPs (15 months, p=0.27). In 3 patients (no. 1,2,5), repeat 
ILP (+ resection of a local recurrence on the lateral side of the proximal thigh in patient no. 1) 
contributed to sustained local control of disease in the leg. No systemic progression was 
observed in these patients during follow-up of 91, 129 and 72 months, respectively. The 21 
patients who received multiple ILPs had a 5-years survival of 47% vs. 28% for patients 
receiving single treatment  (p=0.05, Figure 2). 
Chapter 8 
 123 
 
Response Rates   
 Overall Repeat Prior M-ILP TM-ILP repeats 
 N=100 N=25 N=13 N=12 
CR 69/100=69% 19/25=76% 10/12=83% 9/13=69% 
PR 26/100=26% 5/25=20% 2/12=17% 3/13=23% 
NC 5/100=5% 1/25=4%  1/13=8% 
Overall 94% 96% 100% 92% 
 
Table 2 Response rates for the different patient categories.  
Abbreviations: 
M-ILP=Melphalan-only Isolated Limb Perfusion, TM-ILP=Isolated Limb Perfusion with TNF and Melphalan, 
CR=Complete Response, PR=Partial Response, NC=No Change 
 
 
 
 
Local toxicity 
Wieberdink Grade I Grade II Grade III Grade IV Grade V 
 12% 60% 28%   
Systemic toxicity 
 Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Neurologic* 96% 4%    
Liver* 100% 0%    
Renal* 100% 0%    
Haematologic* 96% 4%    
 <38ºC 38-39ºC 39-40ºC >40ºC, <24 hrs >40ºC, >24 hrs 
Temp 36% 24% 32% 8%  
 Absent Present    
Shock& 100% 0%    
 
Table 3 Local and systemic toxicity after TM-ILP. 
Abbreviations: 
Hrs=hours, Temp= temperature. 
Notes: 
*= WHO criteria  
&= support of vasopressors needed 
 
Repeat ILP for melanoma. 
 124 
 
Pt no 
Prior 
else-
where interval 1st TM-ILP interval 2nd TM-ILP interval 3rdTM-ILP 
   months level resp tox months level resp tox months level resp tox 
1 yes 14 Fem CR 2 25 Iliac PR 2       
2 yes* 29 Poplit CR 2             
3 no   Iliac CR 3 11 Iliac CR 2 26 Iliac CR 2 
4 no   Poplit PR 2 19 Iliac CR 3       
5 yes* 42 Fem CR 2 18 Poplit CR 2 42 Fem CR 2 
6 yes& 76 Fem CR 3             
7 no   Iliac CR 4 9 Fem CR 3       
8 no   Iliac CR 2 58 Poplit PR 2       
9 yes 47 Iliac CR 3             
10 yes 40 Iliac CR 1             
11 no   Iliac CR 1 9 Iliac CR 2       
12 yes$ 28 Iliac NC 2             
13 yes 4 Poplit CR 2             
14 yes# 28 Iliac CR 1             
15 no   Iliac CR 2 30 Iliac CR 2       
16 no   Fem PR 2 13 Iliac PR 2       
17 yes 36 Iliac CR 3             
18 yes 17 Iliac PR 3             
19 no   Iliac PR 3 15 Iliac CR 3       
20 yes 5 Fem CR 2             
21 yes! 3 Iliac PR 1                 
 
Table 4 Patient characteristics, responses and toxicity after repeat ILP in 21 patients. 
 
Abbreviations:  
TM-ILP=Isolated Limb Perfusion with TNF and Melphalan, Fem=Femoral, Poplit=Popliteal, Iliac=Iliacal, 
CR=Complete Response, PR=Partial Response, NC=No Change, resp=response, tox=toxicity. 
 
Notes: 
*= previous ILP: M-ILP double schedule 
&= adjuvant ILP 
$= prior TM-ILP  
#= 2 previous ILPs: 1st adjuvant, 2nd cisplatin 
!= 3 previous ILPs 
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Time to local progression(TTLP) by previous perfusions 
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Figure 1 Time to local progression (TTLP), repeat (=Yes) vs. single (=No) ILPs 
X-axis: time (months) 
Y-axis: cumulative percentage 
 
 
 
Overall survival by previous perfusions 
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Figure 2 Overall survival (OS), repeat (= Yes) vs. single (=No)  ILPs 
X-axis: time (months) 
Y-axis: cumulative percentage 
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Discussion 
 
These results show that in a selected patient population of patients with local progression after 
previous ILP treatment, repeat TM-ILP is associated with excellent response rates (96%).  
The complete response rate after TM-ILP was 76%, which compares favorably with the CR 
rate of single ILPs in our institution. This is in line with the scarce literature on the efficacy of 
repeat ILPs 5-7 and indicative of the fact that a rather favorable group of patients, mostly 
patients with stage IIIA disease only and with a good response to the first ILP, are considered 
for repeat ILPs when they recur with in-transit metastases. The 5-years survival rate of 47% 
reported in this study compares favorably with recently published survival rates of patients 
with locally advanced melanoma (23-47% 4) and is again an indication of relatively mild 
biologic behavior of the melanoma in this patient population. 
The mechanism of recurrence after previous ILP treatment remains speculative. It is a 
common finding that in patients after a CR to the first perfusion, the new recurrent in-transit 
metastases arise at different locations than the original lesions that went into a CR after the 
initial ILP. Hypothetically this indicates that larger, well-vascularized lesions are completely 
eradicated but that dormant, (relatively) non-vascularized lesions are not eradicated by an 
ILP, because of inadequate drug exposure 13. 
Patient selection for repeat ILP treatment is determined by the time to local progression after 
initial ILP and the absence of systemic metastases, unless the bulkiness of the disease is 
directly limb-threatening. Rapid disease progression after ILP is an indicator for aggressive 
disease and is therefore a relative contraindication for repeat ILP treatment, as the expected 
response rates are low 14. The median interval between initial ILP treatment and repeat TM-
ILP of 25 months, as indicated in table 4, is markedly longer than the median time to local 
progression both in this study after repeat ILP (14 months) and in our total database of 100 
ILPs (16 months). In three patients (pt no. 13, 20, 21) repeat TM-ILP was performed 3-5 
months after failure of ILP with other chemotherapeutics in order to obtain sufficient 
response, which resulted in 1 PR and 2 CRs. This shows that failure to respond to a M-ILP 
can be overcome by adding TNF, which in tumor models has been shown to enhance the 
uptake of Melphalan by the tumor 15, 16. This is in line with the observation that Melphalan-
only ILPs in STS patients is very poor, whereas TM-ILPs are associated with high response 
rates 3. For our melanoma population we can conclude that, apart from these three patients 
with rapid failures after a M-ILP, the melanoma of patients qualifying for repeat treatment is 
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relatively indolent. This observation is sustained by the significant difference in overall 
survival between repeat- and single ILPs.  
Whether to consider a patient for repeat ILP should be influenced by the stage of disease at 
first ILP. We found in our experience with 100 TM-ILPs that curves of TTLP and TTSP are 
virtually overlapping in stage IIIAB disease, whereas in stage IIIA patients, median TTSP 
was 55 months at a median TTLP of 18 months. This difference makes IIIA patients with 
local progression much better candidates for repeat ILP than IIIAB patients (Grünhagen D.J. 
et al.: unpublished data). 
We found toxicity after repeat TM-ILPs to be mild to moderate in all performed procedures. 
Compared to the first ILP, repeat TM-ILP did not increase local toxicity, in contrast to a 
previous report using Melphalan alone 5.  In this report however more intensive schedules 
were used for the repeat ILP (higher tissue temperatures, ILPs at short intervals 5. Other, 
smaller studies, do not report on increased local or systemic toxicity 6, 7. On the basis of these 
data, we state that the use of mild hyperthermic TM-ILP for repeat perfusion is a safe 
procedure. Median leakage to the systemic compartment was zero percent in these 25 repeat 
ILPs, just like in our overall experience with TM-ILP in over 350 patients. TM-ILP is a safe 
procedure, provided adequate leakage monitoring is assured, and postoperative fluid 
management is generous to deal adequately with the TNF-mediated transient drop in the 
peripheral vascular resistance after ILP 17,18. Moreover, the safety of the procedure is such that 
in our opinion there should be no age limit. Especially in limb threatening disease, limb 
salvage is of prime importance and this treatment should not be withheld from the elderly as 
we have demonstrated in our extensive experience in patients over 75 years old 19. 
In conclusion, repeat TM-ILP is a valuable treatment option in patients with local progression 
after previous ILP treatment. In patients with bulky or numerous lesions that cannot be 
managed with surgery, repeat TM-ILP provides excellent disease control. Especially patients 
with recurrences after ILP for stage IIIA disease and patients with a long interval between 
initial and repeat ILP, who form a subcategory of melanoma patients with relatively favorable 
characteristics, profit from this treatment. Moreover patients with no response or rapid 
progression after a Melphalan-only ILP can still respond with a CR to a TM-ILP.  
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Summary 
 
Isolated limb perfusion (ILP) with TNF and Melphalan results in response rates greater than 
80% and limb salvage rates above 70% in limb threatening soft tissue sarcoma (STS). Also in 
the management of multiple and bulky in-transit melanoma metastases the use of TNF 
improves complete response rates. Because of fear for TNF associated toxicity, ILP with TNF 
is not offered to old patients in some cancer centers, whilst especially in older patients an 
amputation may end their independence and completely limit their mobility. Thus every 
attempt to avoid amputation must be considered in these patients. We evaluated our 
experience in patients older than 75 years treated by TNF-based  ILP. 
Out of a total of 306 TNF-based ILPs between 1991 and 2001, 50 ILPs were performed for 
limb salvage in 43 patients older than 75 years (range 75-91). In 27 patients for STS or other 
sarcomas, in 2 for large squamous cell carcinomas and in 14 patients for multiple or bulky in-
transit melanoma metastases.  
In the STS group an overall response rate of 76% and a limb salvage rate of 76% was 
achieved at a median follow-up of 18.0 months. In the melanoma patients a 100 % response 
rate and a 93% limb salvage rate was observed. Local toxicity was mild to moderate 
(Wieberdink grade I-III) in 96% of the perfusions. The 3 postoperative deaths that have been 
observed in the total series of 306 TNF-based ILPs in Rotterdam (< 1%) have all 3 occurred 
in patients > 75 years old, due to cardiovascular events in 2 high-risk patients and due to 
sepsis in 1 patient with an enormous infected necrotic ulcerating tumor. These deaths all 
occurred after leakage free ILP’s and were considered not to be associated to TNF. 
Old patients should not be withheld a TNF-based ILP for limb salvage as also in these 
patients the procedure is safe and highly effective.  
 
 
Introduction 
 
Isolated limb perfusion (ILP) is a technique of cancer treatment which delivers high doses of 
cytostatic drugs to a tumor-bearing extremity that is isolated from the systemic circulation and 
connected to a heart-lung machine (1). By ILP regional concentrations of chemotherapeutic 
agents 15-20 times higher than those reached after systemic administration can be achieved 
without systemic toxicity (2). In the management of locally advanced soft tissue sarcoma 
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(STS) limb salvage is a major challenge. In patients with multiple and or bulky in-transit 
melanoma metastases obtaining local control is a major challenge. In contrast to the inefficacy 
of ILP with Melphalan alone in the management of irresectable extremity STS, with response 
rates between 10 and 35% only (3,4), the introduction of tumor necrosis factor-alpha (TNF) in 
combination with Melphalan in ILP has been reported in a European multicenter trial to result 
in response rates greater than 80% and limb salvage rates above 70% in STS (5,6). These 
results led to the approval of TNF in Europe (7). Also in the management of in-transit 
metastases TNF seems to improve CR rates (8), especially in patients with bulky tumors and 
in patients that have failed a previous ILP with Melphalan alone, as has been demonstrated by 
the reports from the Surgery Branch of the NCI in the USA (9,10).  
The incidence of STS increases rapidly above the age of 50. About 18 % of the patient 
population is above the age of 70 (4). The incidence of malignant melanoma has more than 
doubled over the last 20 years (12). For both men and women rates increased relatively more 
in the older age groups. As a consequence of these epidemiological features we are confronted 
with a large group of elderly patients who might need a limb saving procedure such as ILP. 
Especially these patients will be severely limited in their mobility and loose independence 
when amputation of a limb has to be performed. Therefore especially in the elderly every 
attempt to avoid amputation must be considered and a TNF-based ILP must be considered in 
spite of the age of the patients. The perception that TNF-based ILP is a risky endeavor has 
been demonstrated to be false provided leakage is monitored and well controlled (13). But 
even in the event of significant leakage we have demonstrated that with correct fluid 
management and postoperative care patients do not develop major or life threatening 
complications (14). Therefore we do not think it is reasonable to consider age a limiting factor 
for patients to undergo a TNF-based ILP.  Here we present our single Rotterdam institution 
experience in a large series of patients aged above 75 years with irresectable STS or in-transit 
melanoma metastases of an extremity. These patients were all treated by ILP with high dose 
TNF and Melphalan.  
 
 
Patients and methods 
 
ILP methodology  
The procedure of the current TNF-based ILP has been described by us previously (1,2). In brief, 
isolation of the blood circuit of a limb is achieved by clamping and canulation of the major 
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artery and vein, connection to an oxygenated extracorporeal circuit, ligation of collateral vessels 
and application of a tourniquet. Once isolation is secured, drugs can be injected into the 
perfusion circuit. Drugs: Recombinant human Tumor Necrosis Factor-α (TNF, 4.9-5.8 x 107 
U/mg) was administered at doses of 2-4 mg in the perfusion circuit; recombinant human 
Interferon-gamma (IFN: 0.2 mg or 1.5 x 106 U/ampoule) was administered in the ILPs 
performed in period 1991-1993 on days –2 and –1 subcutaneously and on day 0 into the 
perfusion circuit. Both TNF and IFN-gamma were obtained from Boehringer Ingelheim GmbH, 
Ingelheim/Rhein, Germany. Melphalan (L-phenyl-alaninemustard = L-Pam, AlkeranR) was 
obtained as a sterile powder (100 mg) that was dissolved aseptically using solvent and diluent 
provided by Burroughs Wellcome (London, England). Because of its efficacy and low regional 
toxicity profile Melphalan is the standard drug, most commonly used a dose of 10 mg/L 
perfused tissue for a leg and at 13mg/L for an arm. The perfusate is heated to 39-40 0C  to 
achieve mild hyperthermia tissue temperatures in the limbs to be kept stable at 39 0C. 
Radiolabeled albumen is injected into the extra corporeal circuit so leakage into the systemic 
circulation can be detected with a precordial scintillation probe (8). Leakage monitoring is 
mandatory especially now that high doses of TNF are used in the treatment of soft tissue 
sarcomas and melanomas. After 1.5 hours of perfusion the limb is rinsed with an electrolyte 
solution, cannulas are removed, and the vessels are repaired. Classification of postoperative 
limb toxicity is done according to Wieberdink et al (9): (I) No reaction; (II) Slight erythema 
and/or edema; (III) Considerable erythema and/or edema with some blistering, slightly 
disturbed motility permissible; (IV) Extensive epidermolysis and/or obvious damage to the deep 
tissues, causing definite functional disturbances; threatening or manifest compartmental 
syndrome; (V) Reaction which may necessitate amputation. 
 
Patients 
At the Erasmus University Medical Center – Daniel den Hoed Cancer Center a total of 306 
TNF-based ILPs were performed in STS patients (224 ILPs) and melanoma patients (82 ILPs) 
between 1991 - 2001. In 43 patients (14 male and 29 female) older than 75 years 50 TNF-
based ILPs were done. Twelve patients also received 0.2 mg of IFN-gamma subcutaneously 
on the two days prior to the ILP as well as 0.2 mg IFN-gamma in the perfusion circuit during 
ILP. All ILP and follow up data in our institution are recorded prospectively in a database.  
Patient, ILP characteristics, treatment results, and follow-up data are listed in Table 1 for STS 
or other non-melanoma limb threatening tumors and in Table 2 for melanoma. The mean age 
of this selected group of patients was 79 (range 75-91) years. Twenty-nine patients with 
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irresectable STS or other limb threatening tumors of the leg (n=19) or arm (n=10) underwent 
34 ILP’s (Table 1). Nineteen were treated for primary tumors and ten for recurrences. In this 
group the median size of single tumors (n=20) was 10 cm (range 6-38) and for multifocal 
tumors (n=9) 5 cm (range 1-20). Two patients with Stuart Treves syndrome have undergone 3 
ILP’s each. One patient underwent two perfusions. Fourteen patients with in-transit 
melanoma metastases (all lower extremity) underwent 16 ILP’s (Table 2). Two patients 
underwent 2 ILP’s.  
 
 
Results 
 
Sarcomas and non-melanoma limb threatening tumors (Table 1) 
Response rates in the STS group: all patients but 2 (post operative deaths) were evaluated for 
response by MRI and histopathologic evaluation of tumor resection specimen of after response 
to the ILP: Complete responses were defined as clinical MRI-proven CRs, which were not 
operated on a second time and clinical MRI-proven PRs that after resection were demonstrated 
to be 100% necrotic and classified as histopathologic complete responses; Partial responses 
were defined as tumors that underwent shrinkage of greater than 50%, or in case of less than 
50% clinical shrinkage revealed a > 50% necrosis upon resection. The overall response rate 
(CR+PR) was 76%, consisting of 38% CR, 38% PR. No change (NC) was defined as < 50% 
tumor shrinkage and < 50% necrosis, was seen in 18% of the patients. None of the patients had 
PD of the tumor within 3 months of the ILP. 
In the soft tissue patient population 31 % of patients had multiple sarcomas and were not 
candidates for resections after ILP. In the patients with a single sarcoma resection was made 
possible by the induction treatment with ILP and performed in 16/20 patients at a median of 2.5 
months after ILP. ILP and surgical treatment resulted in limb salvage in 22/29 patients (76%) 
after a median follow-up of 18 months. Amputation was performed in 7/29 patients. In 3 
patients repeated ILP was performed after a median period of 20 months (range 13-24) after 
prior ILP.  
ILP in elderly people. 
 134 
 
 
 
Pat.  
No. 
Sex Age 
(yrs) 
Histology  Grd  
1-3 
Site No.  
Tum 
P/ R Type 
ILP 
Loc. 
Tox. 
1-5 
Clin. 
Resp 
Hist.  
Resp. 
(% necr) 
Final 
Out- 
come 
Limb 
Salv. 
Dead 
or 
Alive 
F-up  
(mo) 
1∗ V 78 Angiosarcoma 2 Lo Arm >100 R Brach 2 CR ND CR    
 V 80 Angiosarcoma 2 Lo Arm >100 RR Axil 2 CR ND CR    
 V 82 Angiosarcoma 2 Lo Arm >100 RR Axil 3 PR ND PR Y D 47 
2 V 75 Liposarcoma 1 Fo Arm 1 R Brach 3 CR ND CR Y A 85+ 
3 V 82 Leiomyosarc 2 Up Arm 1 P Brach 2 PR >70 PR Y D 57 
4 V 82 Mal Fibr Hist 3 Up Leg 1 P Iliac 3 NC ND NC Y D 6 
5 V 83 Liposarcoma 3 Up Leg 2 P Iliac 2 PR >90 PR Y A 55+ 
6∗ V 81 Mal Fibr Hist 2 Lo Leg 4 R Popl 2 NC ND NC    
 V 82 Mal Fibr Hist 2 Lo Leg 6 RR Fem 2 CR ND CR N D 22 
7 V 78 Pleiomorfsarc 3 Fos Popl 1 R Iliac 2 NC ND NC N D 14 
8† M 91 Liposarcoma 3 Fos Popl 1 P Iliac 2 ND ND ND Y D 0 
9 V 87 Leiomyosarc 2 Foot 1 R Popl 2 NC ND NC Y D 8 
10 M 76 Leiomyosarc 3 Fo Arm 1 P Brach 4 PR 90 PR Y A 43+ 
11 M 75 Clear cell tum 3 Up+Lo Leg 3 R Iliac 3 CR 100 CR Y D 9 
12 V 75 Mal Fibr Hist 2 Lo Foot 1 R Fem 3 NC >90 PR Y D 3 
13 M 83 Extraskel Osteo 3 Up Leg 1 P Iliac 3 NC 90 PR Y D 9 
14† M 76 Squamous cell NA Fo Arm 3 R Axil 4 ND ND ND Y D 0 
15 V 77 Leiomyosarc 3 Fos Popl 1 P Popl 2 PR 90 PR Y A 39+ 
16∗ V 77 Angiosarcoma 2 Fo Arm 30 P Brach 3 CR ND CR    
 V 78 Angiosarcoma 2 Up+Lo Arm 20 R Axil 2 CR ND CR    
 V 80 Angiosarcoma 2 Up+Lo Arm >10 RR Axil 1 CR ND CR Y A 46+ 
17 V 83 Mal Fibr Hist 3 Lo Leg 3 R Popl 2 PR <50 PR N D 26 
18 V 76 Angiosarcoma 1 Fo Arm 21 P Brach 3 CR 100 CR Y A 21+ 
19 M 83 Synoviosarc 2 Up Leg 1 R Iliac 2 CR ND CR N A 28+ 
20 V 76 Schwannoma 3 Up Leg 1 P Iliac - NC <50 NC Y A 26+ 
21 M 79 Schwannoma 3 Fo Arm 1 P Brach 2 PR <10 PR Y A 10+ 
22 V 77 Kaposisarcoma 1 Lo Leg 30 P Fem 1 CR 100 CR N A 18+ 
23 M 81 Mal Fibr Hist 3 Fo Arm 1 P Brach 1 NC <50 NC Y A 17+ 
24† M 76 Undif Carc 2 Up Leg 1 P Iliac 2 CR 100 CR N D 0 
25 M 75 Liposarcoma 3 Fos Popl 1 P Iliac 2 NC >50 PR N A 11+ 
26 M 81 Epitheloid sarc 3 Lo Leg 1 P Fem 1 PR >90 PR Y A 8+ 
27 V 78 Angiosarcoma 1 Tot Arm >20 P Axil 2 CR ND CR Y A 6+ 
28 M 80 Squamous cell NA Hand 1 P Brach 2 PR ND PR Y A 3+ 
29 M 86 Mal Fibr Hist 3 Lo leg  1 P Fem 2 PR ND PR Y A 3+ 
                
  79.5  mean           22/29  26.0 
  78 median             76%  18.0 
 
 
Table 1 Characteristics of 29 patients with irresectable STS or other limb threatening tumors at the time of ILP 
(n=34) with TNF and Melphalan. 
 
Abbreviations: Grd=Grade; Up Arm=upper arm; Lo Arm= lower arm; Up Leg= upper leg; Lo Leg= lower leg; 
Fos Popl= fossa poplitea; Iliac= Iliac ILP; Fem= femoral ILP; Popl= Popliteal ILP; Axil= Axilar ILP; Brach= 
brachial ILP; P= primary; R= recurrence; RR= re-recurrence; CR= complete response; PR= partial response; 
NC= no change; NA = not applicable; ND= not determined. Loc. Tox.=Local toxicity in Wieberdink grade; Clin. 
Resp= Clinical response; Limb Salv.=limb salvage; F-up=follow-up; mo=months. 
 
Notes: 
Overall Response rate is 76% (CR 38%, PR 38%).   
∗ These have undergone multiple perfusions.  
† Patients died postoperatively.  
 
Patients with multiple or bulky melanoma in transit metastases (Table 2) 
In the melanoma patients an overall response rate of 100% was achieved. Consisting of 75% 
CR and 25% PR. So all patients responded and no NCs or  PDs were observed.  This resulted in 
93% limb salvage at a median follow-up of 16 months. The single amputation in this group (#4, 
Table 2) was non tumor related but due to severe arteriosclerosis more than 14 months after the 
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last ILP. Two patients underwent a second perfusion 19 and 25 months after the first ILP 
respectively. Both resulted in a CR after the repeated ILP. In the melanoma patients no 
postoperative deaths occurred.  
 
 
Patient  
No. 
Sex Age 
(yrs) 
Site No.  
Tum 
Type 
ILP 
Local Tox. 
(Wieberdink) 
1-5 
Final 
Outcome 
Dead or 
Alive 
Follow-
up 
(months) 
1∗ V 78 Lo Leg >20 Fem 2 CR   
 V 80 Tot Leg >100 Iliac 2 CR A 132+ 
2 V 76 Tot Leg >100 Iliac 2 CR D 10 
3 V 75 Lo Leg >10 Popl 3 CR D 4 
4∗# V 82 Lo Leg >20 Popl 2 PR   
 V 83 Lo Leg >100 Iliac 3 CR D 44 
5 V 77 Lo Leg >10 Iliac 2 PR D 11 
6 V 76 Tot Leg >50 Iliac 2 CR D 45 
7 V 75 Lo Leg >50 Iliac 1 CR D 21 
8 V 76 Lo Leg <10 Popl 2 CR D 16 
9 V 80 Tot Leg >10 Iliac 2 CR A 46+ 
10 V 78 Lo Leg >10 Fem 2 CR A 40+ 
11 V 79 Foot >50 Fem 2 CR A 17+ 
12 V 82 Lo Leg >20 Fem 3 PR A 3+ 
13 M 77 Lo Leg >20 Iliac 3 PR A 3+ 
14 V 91 Lo Leg >100 Fem 2 CR A 3+ 
          
Mean  78.7     CR 75%  27.0 
Median  78     PR 25%  16 
 
Table 2 Characteristics of 14 patients with in-transit melanoma metastases at time of ILP (n=16) with TNF and 
Melphalan. 
 
Abbreviations: Up Leg= upper leg; Lo Leg= lower leg; Tot Leg =total leg; Iliac= Iliac ILP;  
Fem = femoral ILP; Popl = Popliteal ILP; CR= complete response; PR= partial response;  
NC= no change. 
 
Notes: 
Overall Response rate is 100% (CR 75%, PR 25%).  
∗ Patients that have undergone multiple perfusions (n=2). 
# This patient underwent an above knee amputation of the limb because of arteriosclerosis more 
than one year after the last perfusion. 
 
 
Local toxicity 
In 96% of the perfusions only mild to moderate (Wieberdink grade I-III) local toxicity was 
observed. In none of the patients an amputation had to be performed due to TNF-Melphalan 
related toxicity after ILP. Only in the patient with a large ulcerating undifferentiated 
carcinoma metastasis in the upper leg, that became completely necrotic after the ILP and 
subsequently got infected, a post-ILP amputation had to be undertaken as it was the source of 
(eventually fatal) sepsis. 
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Leakage Control and Systemic Toxicity 
Leakage Control. 
Median leakage rate was 0%  (range 0-20%) in the 50 ILPs described in this series.  
In the “sarcoma group” of 34 ILPs there were 26 ILPs with 0% leakage, 5 with < 7% leakage 
and 3 ILPs with significant leakage of 19, 20 and 20%   
In the ”melanoma group” of 16 ILPs there were 10 ILPs with 0% leakage and 3 with < 5% 
leakage. There were 3 ILPs with significant leakage of 10, 12 and 13 % . 
 None of these six patients with 10-20% leakage experienced grade 3-4 hypotension or any 
other form of grade 3-4 toxicity.   
Systemic toxicity. 
Most patients went through a slightly hyperdynamic postoperative period, that lasted usually 2-
6 hours, with slightly increased heart rates and elevated temperature as a reaction to the 
circulating TNF immediately after the ILP. No major toxicity was observed in the immediate 
postoperative phase in any of the 43 old patients.  
One patient with a history of multiple myocardial infarction and angina pectoris  (# 19, Table 1) 
developed a postoperative myocardial infarction. The ILP was associated with a leakage rate of 
3% and the postoperative course was associated with grade 2 hypotension. 
Except in the patient (# 8, Table1) who developed a thrombosis of the mesenteric artery 3 days 
after the ILP and in the patient (# 24 Table 1), who developed a septic shock, because of 
infection of the massive necrosis of an large ulcerated tumor mass, 10 days after the ILP, no 
grade 2, 3 or 4 toxicity was observed with respect to liver function, renal function or shock like 
symptoms. Temporary mild fever (WHO grade II-III) occurred after 32 of the 50 perfusions.  
 
Complications 
In the total series of 306 TNF-based ILPs performed between 1991 and 2001 in the Daniel den 
Hoed Cancer Center 3 patients have died from postoperative complications. All 3 patients are in 
the above 75 years old patient category. Two patients with a high risk cardiovascular status and 
prior history died because of cardiovascular complications: The 91 year old patient # 8 in 
Table1, developed a thrombosis of the mesenteric artery 3 days after the ILP with fatal 
outcome. The 76 year old patient # 14 of Table 1, with a history of prior cerebrovascular 
accidents died from a massive CVA on day 3 after an uneventful and leakage free ILP. A 
cardiovascular complication also occurred in 83-year-old patient # 19 of Table 1. This patient 
had a history of multiple myocardial infarctions and angina pectoris developed a postoperative 
myocardial infarction after yet another well-controlled ILP with a leakage rate of 3% and no 
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significant postoperative hypotension. The third patient who died in the postoperative phase (# 
24, Table 1) developed immediate and total necrosis of a very large ulcerating undifferentiated 
carcinomatosis metastasis in the upper leg. This necrotic mass got infected and the patient 
developed a septic shock. In spite of an amputation and optimal medical management the 
patient died of sepsis. 
 
Discussion 
 
In elderly people amputation of a limb has major impact on their independency and daily 
activities. However, exactly older patients with irresectable STS or recurrent melanoma of the 
extremities are often subjected to amputation, because the risk of an ILP is considered to be 
too high. Here we demonstrated that ILP is very efficient in achieving limb salvage and local 
tumor control in elderly patients, with acceptable morbidity and mortality. In the face of 
imminent amputation or unacceptable loss of control over locoregional tumor growth in 
melanoma patients we have not turned down any elderly patient above the age of 75 years for 
an TNF-based ILP. Thus we have accepted the considerable risk associated with this position. 
Here we report on the largest single institution experience on the efficacy and risks of TNF-
based ILP in elderly patients. Out of 306 TNF-based ILPs, 50 ILPs were performed in this 
patient population with the goal to avoid amputation, which more than in any other age group 
determines the quality and independence of how these patients can continue their lives.    
Until several years TNF was thought be inapplicable in a clinical setting because of its severe 
toxicity when administrated systemically. However, in an isolated perfusion setting it can be 
used in very safe way and is extremely efficient in inducing tumor responses when combined 
with cytostatic agents. We have demonstrated that this extremely potent synergy is based on the 
selective vasodestruction of the tumor associated vasculature (5,17) as well as on the greatly 
enhanced uptake of Melphalan or any other chemotherapeutic drug in the tumor when 
combined with TNF in the ILP setting (18,19)  
Safe administration of TNF is guaranteed since we use continuous leakage monitoring and 
adequate hydration of patients. These components are both essential in the management of 
possible TNF related toxic side effects (10). The median leakage during ILP was < 0% (range 
0-20). Even in cases with leakage this can be management very well. We described previously a 
series of patients with leakage from 12-65%. No fatal complications occurred and only a few 
shocks were observed which could be management without intubation and with little need for 
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vasopressor support (11). Also in case of leakage adequate hydration turned out to be the key in 
the treatment of TNF related toxicity.  
Also in this group of older patients ILP can be performed safely without severe toxicity and 
morbidity. In this patient group, with a mean age of 79 year, the overall perioperative mortality 
was low and the local toxicity was in the vast majority of patients Wieberdink grade II or III. 
Vrouenraets et al. recently reported on regional toxicity after ILP with TNF and demonstrated 
that increasing age was not correlated with more severe toxicity (12). The median hospital stay 
in this patient population of elderly patients, after ILP is about 2 weeks. In the postoperative 
period most patients were completely mobilized and left the hospital without severe functional 
impairment.  
The response rates and limb salvage percentage demonstrated in these is comparable to ILP 
studies reported in younger STS patients (1). In melanoma patients, especially the locally 
advanced bulky tumors may cause a lot of pain, hemorrhage or vascular compression that 
amputation of the affected limb sometimes has to be considered. ILP with TNF and 
Melphalan is an effective method to achieve local tumor control and thereby is of great anti-
morbidity value. It is regarded as the treatment of choice in bulky cases of melanoma or 
failures after ILP with Melphalan alone.  The 3 deaths reported in this series are the only 3 
postoperative deaths that we have encountered in the 306 patients, treated by TNF-based ILP in 
Rotterdam between 1991 – 2001 and reflects the risks that have been accepted in this patient 
population. Two patients had extensive cardiovascular disease. The third patient died from 
sepsis, due to the infection of a totally necrotic massive tumor in the upper leg after ILP, which 
was confirmed to be a histopathological CR. The fact that this rapid tumor had penetrated the 
skin and was ulcerating should have kept us from performing the perfusion, since there was no 
way that infection of this necrotic mass could have been prevented. The fact that the 
complications occurred after leakage free ILPs further underlines the point that the 
complications were due to patient-specific risks and not to uncontrolled elements of the ILP.  
This series of older patients with limb threatening sarcomas or multiple in-transit melanoma 
metastases demonstrates the safe and efficient use of TNF -based ILP. It results in high 
response rates and thereby high limb salvage rates and very good local tumor control rates in 
the melanoma patients. Old patients should be offered and not be withheld a TNF-based ILP 
for limb salvage. 
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Isolated Limb Perfusion (ILP) 
 
ILP methodology 
The technique of isolated limb perfusion was pioneered by Creech, Krementz and coworkers at 
Tulane University in New Orleans (1). Regional concentrations of chemotherapeutic agents 15-
25 times higher than those reached after systemic administration can be achieved by ILP in the 
tumor bearing extremity without systemic side effects (2). Isolation of the blood circuit of a 
limb is achieved by clamping and canulation of the major artery and vein, connection to an 
oxygenated extracorporeal circuit, ligation of collateral vessels and application of a tourniquet. 
Once isolation is secured, drugs can be injected into the perfusion circuit. Because of its 
efficacy and low regional toxicity profile Melphalan (L-phenyl-alaninemustard) is the standard 
drug, most commonly used a dose of 10 mg/L perfused tissue for a leg and at 13mg/L for and 
arm (3). Tissue temperatures in the limbs are monitored and radiolabeled albumen or 
erythrocytes is injected into the extracorporeal circuit so leakage into the systemic circulation 
can be detected with a precordial scintillation probe (4). Leakage monitoring is mandatory 
especially now that high doses of tumor necrosis factor-alpha (TNF) are used in the treatment of 
soft tissue sarcomas. After 1-1.5 hours of perfusion the limb is rinsed with an electrolyte 
solution, cannulas are removed, and the vessels are repaired. Classification of acute tissue 
reactions after perfusion is done according to Wieberdink et al (5): (I) No reaction; (II) Slight 
erythema and/or edema; (III) Considerable erythema and/or edema with some blistering, 
slightly disturbed motility permissible; (IV) Extensive epidermolysis and/or obvious damage to 
the deep tissues, causing definite functional disturbances; threatening or manifest 
compartmental syndrome; (V) Reaction which may necessitate amputation. 
 
 
ILP for in-transit melanoma metastases 
 
In-transit metastases occur in 5-8% of melanoma patients. Treatment options are primarily 
dictated by the number and size of in transit metastases, and the great variety in aggressiveness 
that this form of metastatic melanoma may exhibit. Thus it may vary from simple excision(s), to 
evaporation of the lesions by carbon-dioxide laser, to isolated limb perfusion (6). Various 
attempts, such as hyperthermia and the use of TNF, to improve the efficacy of ILP for in-transit 
melanoma metastases have been undertaken over the years. 
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Hyperthermia 
Prevention of vasoconstriction in cutis and subcutis by using a warm water mattress is 
advocated in the treatment of superficial in-transit melanoma metastases. In vivo drug uptake by 
in-transit metastases is two times higher at 39,50 C than at 370 C (7).  Moreover, tumor cells per 
se are sensitive to heat and hyperthermia also improves uptake of drug by the tumor cells, 
especially at temperatures > 410 C (8,9). The term hyperthermia in the setting of ILP should be 
specified along lines as defined hereunder.  
1. normothermia (37-380C). Normothermic ILP with Melphalan has been reported to result in 
a complete response (CR) rate of about 40% and a partial response (PR) rate of about 35%, 
and a median duration of local tumor control of about 6 months (10). Two perfusions at a 4 
week interval improves the the CR-response rate (77%) but does not improve duration of 
local control (11). 
2. "mild" hyperthermia (39-400C). Several reports have claimed improved response rates (12-
16) but a comparative study did not show a significant benefit for mild hyperthermia over 
normothermia (17).  
3. "borderline true" hyperthermia (40-410C); seems to be associated with higher CR-rates, but 
may also be associated with increased regional toxicity (18-20). 
4. "true" hyperthermia (41-430C), yields high CR rates (21,22), but is in some reports 
associated with unacceptable regional toxicity and even amputations (23).  
 
Isolated Limb Infusion (Percutaneous Hypoxic Isolated Limb Perfusion) 
Isolated limb infusions with application of a tourniquet, developed by Thompson and coworkers 
in 1993, is essentially a low-flow, normothermic, hypoxic isolated limb perfusion with 
Melphalan, but has been called isolated limb "infusion" (ILI) to differentiate it from ILP. The 
ILI procedure is technically much less complex than ILP, as small caliber catheters are inserted 
percutaneously into the vessels of the limb via the common femoral artery and vein in the 
contralateral groin. The patient is anaesthesized and a pneumatic tourniquet is applied and 
Melphalan (5-10 mg/L limb tissue) and Actinomycin-D (50-100µg/L limb tissue) in 300-400 ml 
heparinised normal saline at 400C is infused rapidly through the arterial catheter using a 
standard intravenous fluid pump set. Using a syringe and a three-way tap the infusate is 
continuously circulated by aspiration from the venous catheter and re-injection into the arterial 
catheter, via a standard blood-warming coil immersed in a hot water bath at 41-420C. After 30 
minutes the limb is flushed with saline, the tourniquet is deflated and the catheters are removed.  
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With a CR rate of 41% and PR in 44% in 207 cases the results of ILI seem similar to those 
obtained by classical ILP (24). This is doubtful as these results are obtained in patients without 
lesions all the way up to the groin. It should be realized that only lesions in the distal 2/3 of the 
legs are treated as an inflatable tourniquet is used positioned at about the 1/3-2/3 level of the 
upper leg.  ILP achieves higher CR rates for distal lesions are higher than for proximal lesions 
close to the groin, which may be due to suboptimal perfusion conditions high up in the leg on 
the one hand and to more extensive disease or more aggressive disease in patients who have 
extensive disease throughout the leg all the way up to the groin. Two ILI procedures at a 6 
weeks interval did not yield better results than a single perfusion (25). Yet ILI offers an 
effective, simple and cheep alternative to the technically (hart-lung machine) more complicated 
and more expensive isolated limb perfusion procedure. It is easily repeatable, requires litte 
operation theatre time, simple equipment, less personnel and is therefore more widely 
applicable than ILP. 
 
Tumor Necrosis Factor alpha (TNF) in melanoma 
The application of TNF in ILP was pioneered by Lejeune and Lienard in 1988 and has moved 
the field forward as it has resulted in very high response rates in all series reported thus far. TNF 
is a pleiotropic agent, with direct and indirect anti-tumor effects, and a mediator of septic shock 
(26).  Systemic administration of TNF in cancer patients has been ineffective as dose-limiting 
toxicity is encountered at concentrations 10-50 times lower than needed for anti-tumor effects in 
murine tumor models. (27). Such a difference can be overcome in the setting of isolated limb 
perfusion. The results of ILP with TNF + Melphalan with or without IFN-gamma have been 
published since 1992: Liénard et al (28); and Lejeune et al (29); Hill et al (30); Vaglini et al, 
(31); Eggermont et al, (32); Fraker et al. (33), and Lienard et al (34). Interferon-gamma (IFN) 
was added in the schedule in most studies because of synergistic anti-tumor activity of IFN plus 
TNF (35). Its role has been evaluated in a randomized phase II trial, which showed only a 
marginal improvement of outcome for the combination with IFN (34). The question whether 
TNF significantly improves outcome in melanoma patients over ILP with Melphalan alone is 
currently being addressed in a randomized trial in the USA. Fraker and collegues at the Surgery 
Branch of the National Cancer Institute observed a significantly better response (CR 64%) with 
TNF+Melphalan in bulky (“sarcoma-like”) melanoma in transit metastases than with Melphalan 
alone (CR 17%) (36). This is in line with our observations and the spectacular success of 
TNF+Melphalan in soft tissue sarcoma. Therefore we consider bulky “sarcoma-like” melanoma 
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metastases and failure to respond to or recurrences after an ILP with Melphalan alone, strong 
indications for the use of TNF in melanoma (37). 
 
Failure of Prophylactic ILP in High Risk Melanoma 
Retrospective studies suggested, as studies using historic control invariably seem to do, that a 
prophylactic ILP improved outcome in patients with high-risk primary melanoma (38). The only 
adequately sized trial addressing the question of the value of a prophylactic ILP with Melphalan 
in the management of high-risk primary melanoma of the extremity is the intergroup trial of the 
EORTC-WHO and NAPG (North American Perfusion Group) in 832 evaluable randomized 
patients. At a median follow up of > 6 years a definitive analysis showed that ILP had only a 
regional effect (reduction of in-transit metastasis from 6% to 3%). A reduction of regional lymph 
node metastases was noted without any effect on the appearance of distant metastases or 
survival. Prophylactic ILP should no longer be performed. It is a harmful procedure with 
significant morbidity and costs and without any impact on survival (39). 
In the symptomatic in-transit metastasis setting the benefit of an ILP after excision of metastases 
has not been demonstrated. Adjuvant isolated limb perfusion after excision of in transit 
metastases has not been demonstrated to have a significant impact on outcome of disease 
although improved disease free interval has been reported in a randomized phase III trial in 
this patient population (40). 
 
TNF- based ILP for extremity soft tissue sarcoma 
 
The Advent of TNF 
ILP with Melphalan, Doxorubicin and a variety of other drugs was tried in the seventies and 
eighties with poor results and was largely abandoned (41-44). This situation changed 
dramatically with the advent of TNF. TNF-based ILP has been established as a highly effective 
new method of induction biochemotherapy in extremity soft tissue sarcomas with a 20-30% 
complete remission (CR) rate and about a 50% Partial Remission (PR) rate (45-52). On the basis 
of results in a multicenter program in Europe TNF was approved and registered in Europe for the 
sarcoma-indication in 1998 (51). The European TNF/ILP assessment group evaluated 246 
patients with irresectable STS enrolled in 10 years in 4 studies. All cases were reviewed by an 
independent review committee and compared with conventionally treated patients (often by 
amputation) of a population based Scandinavian STS database. In short: there were 246 patient 
switch locally very advanced disease: Primary sarcomas in 55%, local recurrent sarcomas in 
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45%, multifocal primary or multiple local recurrences in 22 %. Overt concurrent metastatic 
disease in 15%. Tumors >10 cm in 46%. Grade III tumors in 66%. Previous radiotherapy 
(13%), chemotherapy (15%). Patients underwent 1 ILP (236pts) or 2 ILPs (12 pts) of 90 
minutes at 39-40 0 C with 2-4 mug TNF + Melphalan (10-13 mg/L limb volume). The first 62 
pts also received IFNγ. A delayed marginal resection of the tumor remnant was usually (75%) 
done 2-4 months after ILP. Major responses were seen in 56.5 to 82.6 % of the patients after 
which usually resection of the sarcoma became possible.  
 
Results 
 
Limb salvage was achieved in 74%-87% in these 4 studies and in 71 % of the 196 patients who 
had been classified by the independent review committees as cases that normally could only 
have been managed by amputation (87%) or by functionally debilitating resection + 
radiotherapy (13%). Comparison with the survival curves based on a matched control study 
with cases from the Scandinavian Soft Tissue Sarcoma Databank showed that TNF had no 
negative effect on survival (p=0.96). It was concluded that the application of TNF in 
combination with Melphalan in the setting of isolated limb perfusion represents a new and 
successful option in the management of irresectable locally advanced extremity soft tissue 
sarcomas (51). Smaller single center studies with TNF+Melphalan have been reported recently 
by Lejeune (53) reporting a 17% CR and 64% PR rate in 22 STS patients treated for limb 
threatening STS tumors, achieving limb salvage in 77% of the patients. From Rotterdam results 
in 2 special patient populations have been reported: one on the efficacy of the procedure in 
patients with Stewert Treves Lymphangiosarcomas. In 16 perfusions a CR rate of 56% and a PR 
rate of 31% were observed, achieving a limb salvage rate of 80% in this rare and otherwise non-
responsive condition (54). An important message is given by the report on the Rotterdam 
experience with 50 TNF-based ILPs in patients older than 75 years with limb threatening 
tumors. Results were very favorable in the 34 perfusions for limb threatening sarcomas, with a 
38% CR and a 38% PR rate, achieving limb salvage in 76% of the patients as well as in 16 
perfusions for bulky melanoma in-transit metastases resulting in a 75% CR and 25% PR rate. 
The procedure was proven safe in the elderly with the high reward of limb salvage which is of 
overriding importance in this age group as amputations lead to loss of independency in lives in 
the elderly (55)    
Italian perfusion groups have obtained very similar results with the drug doxorubicin in 
combination with TNF. Interestingly similar response and limb salvage rates are achieved while 
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using lower doses of only 1 mg TNF instead of the usual doses of 2-4 mg used in combination 
with Melphalan (52). The perfusions were performed at much higher temperatures (40-41 
degrees), which lead to higher locoregional toxicity. Grade IV locoregional toxicity was 
reported in 25% as opposed to only 5% in the large TNF+Melphalan series (46,49,51). We 
found that with Melphalan ILPs grade IV toxicity was clearly related to tissue temperatures of 
above 39 degrees when Melphalan was administered (56) Therefore we have only allowed for 
tissue temperatures to rise to 39 degrees after Melphalan has been added to the perfusion circuit 
the last 8 years and have hardly seen any cases with grade IV toxicity since, without a drop in 
response rates (49,53-55). Most likely therefore the higher regional toxicity in the Italian 
experience with doxorubicin is primarily related to the hyperthermia although doxorubicine 
may be responsible in part. 
Apart from activity in some 20 different histological types of soft tissue sarcoma and activity in 
melanoma, the efficacy of TNF + Melphalan ILP has also been demonstrated in various skin 
tumors (57), bony sarcomas (58) and limb desmoid tumors (59).  
 
Target is the Tumor Vasculature 
The target of TNF is the tumor-vasculature. This common denominator in all these tumors 
makes the use of TNF very attractive and explains its efficacy in combination with 
chemotherapy across all these different histology’s. The selective destructive effects of TNF-ILP 
on tumor-associated vessels have been illustrated in previous publications by means of pre- and 
post perfusion angiographies (46). Moreover in sarcoma patients magnetic resonance 
spectrometry studies we have clearly shown that the metabolic shut down of the tumor is 
virtually complete within 16 hours after the perfusion, confirming the likelihood of TNFα 
mediating its most important effects on the vasculature of the tumor (60). At the 
histopathological level we have also studies these intravascular effects such as thrombocyte 
aggregation, erythrostasis, endothelial and vascular destruction already in the early and late 
stages after ILP (61-62). 
 
Developments in the Laboratory 
 
To further insight in the mechanisms underlying the positive results obtained with ILP in humans 
we developed in rats extremity perfusion models using the BN175 non immunogenic 
fibrosarcoma in Brown Norways rats and the ROS-1 osteosarcoma in WAG rats. In both models 
we could demonstrate that the tumor cells were resistant to TNF in vitro and that ILP in vivo 
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with TNF alone had no major impact on tumor growth. In both models a strong synergistic anti-
tumor effect leading to CRs in some 60-70 % was observed after ILP with TNF+Melphalan 
(63,64). TNF alone only caused some central necrosis and no regression of the tumor was 
observed as has been reported for the clinical setting as well. Histopathologically hemorrhagic 
necrosis was most prominent after ILP with both drugs. Early endothelial damage and platelet 
aggregation in the tumor vessels are observed after ILP with TNF + Melphalan and this is 
believed to lead to ischemic (coagulative) necrosis, which is in line with observations in patients. 
Our observations confirm that TNFα has its major effect on larger tumors, with well-developed 
vasculature in contrast to small tumors (diameter < 3 mm) with lack of developed capillary bed. 
TNF may exert its effect mainly through the neovasculature of the tumor, which is more 
abundant in large tumors. Moreover there are distinct similarities between tumor stroma 
generation and wound healing and observations by us that sites other than the tumor (recent 
wounds or skin overlying tumors only when invaded by tumor), which undergo angiogenesis, 
also become necrotic after ILP with TNF+ Melphalan, but not after ILP with Melphalan alone. 
 
Prerequisites for an Effective ILP 
We have demonstrated a number of crucial elements in our rat tumor models identifying the 
mechanisms for the strong synergy between TNF and cytostatic drugs in ILP and have identified 
the prerequisites for an effective ILP. 
1)  Tumor vessel destruction:  
 The vasculotoxic effects of the combination of TNF + Melphalan leading to haemorrhagic 
and anoxic coagulative necrosis as described above. 
2)  Enhanced drug uptake by the tumor: 
 We have recently demonstrated that the addition of high dose TNF to the perfusate results in 
a 4-6 fold increased uptake by the tumor of the cytostatic drug. For Melphalan and for 
Doxorubicin is was demonstrated that this uptake was tumor specific and that no increased 
uptake was noted in the normal tissues, thus emphasizing the relatively selective action of 
TNF on the tumor-associated vasculature (65) This increase in concentration was also 
observed with doxorubicin (66). Whether the acute drop in interstitial pressure in the tumor 
after exposure to TNF, as reported by Kristensen and coworkers (67), plays an essential role, 
remains speculative. 
3) Role of Leukocytes: 
 We have shown that leukocytes play also an important role in the TNF-mediated antitumor 
effects. In rats that underwent total body irradiation and underwent an ILP at the time of 
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absolute leukopenia the antitumor effect of an ILP with TNF+Melphalan was very similar to 
the effects of a perfusion with Melphalan alone. In the leukopenic rat the TNF-effect was lost 
and the synergy between TNF and Melphalan was no longer observed (68) 
4) Dose range for TNF:  
 It was shown that 10 micrograms of TNF (a fivefold reduction of the “standard dose of 50 
microgram” was the threshold dose for activity of TNF in our rat tumor extremity perfusion 
model. At 2 microgram all TNF-effects were lost (69). This finding would suggest that also in 
the clinical setting dose reduction without loss of activity could be explored as been also 
suggested by the clinical results in the UK (30) and in Italy (52). 
5) Duration of ILP:  
 As the pharmacokinetics of Melphalan demonstrate that almost all Melphalan uptake occurs 
over 20-30 minutes the minimal duration for an effective ILP should be 30 minutes. Shorter 
perfusion times are associated with a drop in CR and PR rates whereas longer than 30 minutes 
ILPs do not seem to further improve the results (69) 
6) Mild Hyperthermia:  
 Temperatures of 38-39 degrees Centigrade were shown to be essential for obtaining a good 
anti-tumor response without damage to the normal tissues in the limb. True hyperthermia (42-
43degrees) resulted in an increase of CRs but was associated with very sever damage to the 
normal tissues. All anti-tumor efficacy was lost when perfusions were performed at room 
temperature.(69) 
7) Hypoxia: 
 It was shown that hypoxia can enhance the anti-tumor effects of an ILP with either TNF 
alone or Melphalan alone. Hypoxia did not further enhance the anti-tumor efficacy of an ILP 
with TNF+Melphalan as the synergy between these two agents “overrode” any minor 
enhancement mediated by hypoxia (69). 
8) Interferon-gamma: 
 In spite of many reports of the synergy between IFN-gamma and TNF both in vitro as well 
as in vivo in murine tumor models the role of IFN-gamma not very strong in our rat models. 
We demonstrated that about a 10% increase in CR rate and an increase of about 20% in 
overall response rate was observed in our animal models (70), which resembles the situation 
in the clinic (34) 
9) Idiosyncratic toxicity: 
 Interestingly unexpected interactions may lead to idiosyncratic reactions between TNF and 
certain cytostatic agents. Actinomycin D is commonly used in combination with Melphalan in 
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the clinical setting. When whether TNF would enhance the efficacy of Actinomycin D we 
discovered that it did in an idiosyncratic and nondiscriminative way. The combination was 
more effective against the tumor than TNF+Melphalan, but this advantage was annulled by 
the toxicity of TNF+Actinomycin D to the normal tissues, which was such that virtually all 
extremities in these animal models had to be amputated, bringing a strong warning to the 
clinic not to use TNF in combination with Actinomycin D (71) 
10) Vasoactive drugs:  
Various vasoactive drugs have been and are being studied in our laboratory models.  Nitric 
Oxide (NO) is an important molecule in the maintenance of both vascular tone and the 
integrity of the vascular wall and is highly produced in experimental and human tumors. We 
postulated that its inhibition could lead to hypoxia and an enhancement of TNF early 
vascular effects in the tumor. In our ILP BN175 rat model we performed a response study 
with TNF in combination with the Arginine analogues L-NAME and LNA, which inhibit 
NO synthase. In rats treated with TNF combined with L-NAME/LNA important and 
immediate anti-tumor effects were observed in all rats and necrosis of the skin at the tumor 
site. These effects are normally only observed when hypoxia or Melphalan are added to TNF 
as described above. Typical TNF tumor response was observed, when NO synthase was 
inhibited during ILP. (72). 
Another vasoactive drug is histamine that is currently being studied. Also in this case we see 
a clear synergy with Melphalan in our tumor models (manuscript under preparation) This 
finding shows the importance of agents that can change the (patho)physiology of 
tumorvasculature, and thereby can improve drug uptake in tumors. These findings underline 
the importance of investigating how to modulate tumor physiology and the potential that this 
approach has to improve efficacy of various standard agents. 
 
ILP and Gene Therapy 
Isolated limb perfusion is an interesting method for new treatment modalities such as 
adenoviral-vector mediated gene therapy. We have shown that ILP is the best and most 
selective method for effective homogeneous transvascular local gene-delivery by using 
adenoviral vectors. Experiments in our soft tissue sarcoma, osteosarcoma and 
rhabdomyosarcoma isolated limb perfusion models have clearly shown this by making use of 
luciferase-marker gene and LacZ gene methodology (73,74). Moreover we have shown that ILP 
with adenoviral-vector gene delivery of the cytokine IL-3 is the only method in these tumor 
models to achieve good tumor responses in contrast to the failure of other methods such as IV 
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administration, intra-arterial administration or intratumoral administration to do so (75). It 
demonstrates that ILP is a valuable method to treat advanced limb tumors and to develop new 
treatment modalities. 
 
Conclusions 
 
Isolated limb perfusion methodology provides us an excellent tool in the clinic to obtain local 
control and avoid amputations of limbs in patients with limb threatening tumors. This has 
been largely achieved by the success of the antivascular TNF-based biochemotherapy in this 
setting. TNF, for the first time, has brought us an effective treatment against large, bulky 
tumors. 
Moreover Isolated limb perfusion is a albeit somewhat exotic, but very interesting research 
model to develop and study agents that modify the pathophysiology of large tumors that 
blocks effective penetration of cytotoxic drugs into the tumor. 
We can now manipulate and study the tumor vascular bed in ways that will identify “new” 
drugs that can enhance the activity of “old” drugs. Moreover it has proven to be a model 
system that may also facilitate the development of vector-mediated gene therapy and other 
innovative approaches. 
Much of these developments have been initiated by the application of TNF in this setting. 
TNF-based isolated limb perfusion is a very successful treatment option to achieve limb 
salvage in the management of advanced, multiple or drug resistant extremity tumors. TNF-
based ILPs are now performed in thirty cancer centers in Europe with referral programs for 
limb salvage. TNF-based antivascular therapy of cancer is here to stay and its potential needs 
to be studied further (76). Other drugs will follow and we may well learn through this model 
how to use them systemically more effectively as well. 
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Summary 
 
Isolated hepatic perfusion (IHP) for irresectable metastases confined to the liver has reported 
response rates of 50-75%. Magnitude, costs and non-repeatability of the procedure are its major 
drawbacks. We developed a less invasive, less costly and potentially repeatable balloon-catheter 
mediated isolated hypoxic hepatic perfusion (IHHP).  
In this phase I-II study 18 consecutive patients with irresectable colorectal or ocular melanoma 
hepatic metastases were included. Two different perfusion methods were used, both with inflow 
via the hepatic artery, using Melphalan at a dose of 1 mg/kg. In the first eight patients the portal 
vein was occluded and outflow was via the hepatic veins into an intracaval double balloon 
catheter. This orthograde IHHP had on average a 56% leakage. In next 10 patients we performed 
a retrograde outflow-IHHP with a triple balloon blocking outflow into the caval vein and 
allowing outflow via the portal vein. The retrograde IHHP still had a 35% leakage on average.  
Although local drug concentrations were high with retrograde IHHP, systemic toxicity was still 
moderate to severe. Partial responses were seen in 12 % and stable disease in 81% of patients. 
Median time to local progression was 4.8 months. 
We have abandoned occlusion balloon methodology for IHHP as it failed to obtain leakage 
control. We are presently conducting a study utilizing a simplified surgical retrograde IHHP 
method, where leakage is fully controlled which translates into high response rates. 
 
 
Introduction 
 
Approximately 50-60 % of colorectal cancer patients will develop liver metastases during follow 
up. In nearly a quarter of these patients the liver is the only site of disease (1). If hepatic 
metastases of colorectal cancer are resectable, five-year survival rates are reported between 25-
45% depending on several prognostic factors (2). Patients with irresectable hepatic metastases 
have a 0-2% five year survival rate. Therefore, aggressive, selective treatment of the liver seems 
justified since control of hepatic metastases translates into improved overall survival. There is no 
standard treatment for unresectable hepatic metastases confined to the liver, so novel treatment 
modalities have to be developed. 
Although response rates with novel systemic chemotherapeutic agents such as oxaliplatin and 
irinotecan in combination with 5-FU are promising, overall survival remains poor (3-5). In 
order to improve responses and survival loco-regional chemotherapeutic regiments have been 
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developed such as hepatic artery infusion (HAI), chemoembolization and isolated hepatic 
perfusion (IHP). For most chemotherapeutic agents a steep dose response curve can be 
demonstrated and exposure of the liver metastases to higher drug concentrations by means of 
loco-regional treatment, might result in improved control of hepatic metastases. HAI exploits 
the first pass effect of the liver, resulting in high local, but low systemic drug exposure. 
Several repeated hepatic artery infusions regimens produced higher response rates, compared 
to systemic chemotherapy, with a 2 –year survival of 50-60% (6-11). 
In animal studies Marinelli et al demonstrated that significantly higher intrahepatic 
concentrations can be reached by IHP compared to HAI (12,13). In a leakage free perfusion 
setting IHP shields the systemic compartment to drug exposure and in combination with a 
washout procedure it protects against systemic toxicity. Classic surgical IHP (SIHP) with 
Melphalan or mitomycine C has been studied in animal models and resulted in high response 
rates (14-16). Clinical studies using Melphalan with or without tumor necrosis factor-alpha 
(TNF) have shown promising results (17-24). The phase II trial performed by the NCI of 
SIHP with Melphalan and TNF demonstrated an overall response rate of 75% (18). 
SIHP is a major, complex, expensive and time-consuming operation. These features in 
combination with potential toxicity are major drawbacks towards wide clinical application. 
Moreover, this procedure can only be performed once. In order to address these problems we 
developed a leakage free isolated hypoxic hepatic perfusion (IHHP) technique with balloon 
catheters in pigs (25).  Using Melphalan and TNF it was demonstrated that an isolated 
perfusion with balloon catheters was feasible and showed minimal systemic leakage. On the 
basis of these favourable pharmacokinetic results a phase I-II study with Melphalan was 
developed for patients with irresectable liver metastases. In this report we present the results 
of the first 18 patients who underwent an IHHP using balloon catheter techniques with 
orthograde or retrograde flow through the liver. 
 
Materials and methods 
 
Patient selection criteria: In all patients a radical resection of the primary tumor was performed 
prior to entering the study protocol. The liver metastases were considered irresectable, on the 
basis of multiple lesions in multiple segments of the liver or location near vascular structures. 
Tumor involvement had to be less than 50% of the total liver volume, to prevent massive 
necrosis in case of a response. Absence of extrahepatic tumor growth was evaluated by CT scan 
of thorax and abdomen. All patients had a Karnofsky performance score of at least 90, liver 
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enzymes (ALAT, ASAT and AF) not higher than 5 times the normal values and bilirubin not 
higher than 2 times the normal values. Exclusion criteria included: age younger than 18 or older 
than 75, portal hypertension, significant central nervous system disease, significant 
cardiovascular, pulmonary or renal disease, uncontrolled infections, presence of organ grafts, and 
chemotherapy or radiation therapy within 4 weeks prior to the IHHP. Routinely an angiography 
was performed to exclude aberrant hepatic arteries or to visualize other anatomic anomalies. 
Patients with severe arteriosclerosis of the aortic-iliac-femoral vessels which made placement of 
balloon catheters impossible were also excluded. All IHHP’s were performed at the Daniel den 
Hoed Cancer Center. The study protocol was approved by the Medical Ethical Committee of the 
Erasmus University Medical Centre and written informed consent was obtained from all patients. 
 
Perfusion circuit: Perfusion sets (PfM, GmbH, Cologne, Germany) consisted of  a double 
balloon catheter (12 F, balloon capacity 25 ml, distance between balloons 4-5 cm) for venous 
isolation of the liver. An aortic-occlusion balloon catheter (12 F, balloon capacity 25 ml) for 
compensating the decrease of cardiac preload during the procedure and  a tubing set with a 
volume of 220 ml, containing a bubble trap. All IHHP’s were performed with inflow via the 
hepatic artery. In the first 8 patients predominantly an open technique was used in order to 
cannulate the proper hepatic artery via the gastroduodenal artery with a 8F catheter (Figure 1). 
From patient 9 up to 18, we used a percutaneous 5F stopflow occlusion catheter (PfM, GmbH, 
Cologne, Germany)  introduced pre-operatively via the groin using the Seldinger technique 
(Table 1 and Figure 2). Except for patient no. 12 and patient  no. 15  who had a double hepatic 
artery. The balloon was positioned in the proper hepatic artery.  
The first 8 patients were perfused with a double balloon catheter in the caval vein with occlusion 
of the portal vein and outflow via the side holes in the caval vein catheter (Figure 1). To improve 
leakage control a triple balloon occlusion catheter was developed (PfM, GmbH, Cologne, 
Germany) and the outflow was diverted to the portal vein, creating a retrograde flow. This triple 
balloon was used from patient  9-18. It occludes the retrohepatic caval vein in a section of 18 cm 
vs. 12 cm with the double balloon catheter (Figure 2). In the perfusion circuit flow was 
maintained by a roller pump and pressure was measured via a side-line. 
 
Drugs: A dosage of 1 mg/kg Melphalan (L-Pam, Alkeran, Wellcome Ltd. London, UK) was 
used in all patients and infused through a side-line into the perfusion circuit. 
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Surgical procedure of the orthograde flow IHHP: A small right subcostal incision was 
performed, and cannulation of the gastroduodenal or hepatic artery was established.  A 
cholecystectomy was routinely performed in the first 5 patients only. When percutaneous 
techniques were used pre-operatively, palpation confirmed the position of the balloon in the 
proper hepatic artery. Surgical exposure of the femoral artery and vein in the groin and 
cannulation of the artery with an aorta-occlusion catheter positioned under radiographic control 
just above the celiac axis. Patients were subsequently heparinized with 2mg/kg heparin. 
Hereafter, cannulation of the femoral vein was performed with the caval double balloon catheter 
positioned under radiographic control. The proximal balloon at the level of the diaphragm and 
the distal balloon just below the liver, which was confirmed by palpation. In between the 2 caval 
balloons 20ml contrast solution is rapidly injected to visualize the hepatic veins at their 
confluence into the retrohepatic caval vein. After clamping of the portal vein, connecting the 
hepatic artery catheter and the caval balloon catheter to the perfusion circuit primed with 220 ml 
Haemaccel (Behring Pharma, Amsterdam, The Netherlands) the orthograde isolated perfusion 
was performed. (Figure 1, Table 1 patients 1-8). 
 
 
 
Fig. 1 Schematic representation of IHHP with a percutaneous catheter in the hepatic artery (inflow) and double 
balloon catheter in the caval vein (outflow). Orthograde flow method. 
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Surgical procedure of the retrograde flow IHHP: Prior to the operation the hepatic artery was 
cannulated via the groin as described above. Via the abdominal incision the portal vein was 
dissected. The femoral artery and vein were cannulated and the occlusion balloons were 
positioned both in the vena cava and the aorta. Hereafter, the portal vein was cannulated with 14 
F catheter for outflow (Table 1 patients no. 9-18). Patients are subsequently heparinized with 
2mg/kg heparin. Following connection to the perfusion circuit a retrograde perfusion was 
commenced through the portal veins. The  retrograde perfusion set-up is depicted in Figure 2.  
The perfusate was circulated by a constant flow (see Table 1). Stable perfusion was monitored by 
pressure measurement and the perfusate level in the bubble trap. Methylene blue was injected 
into the arterial catheter to check homogeneous distribution over both lobes of the liver. 
Hereafter, Melphalan was infused into the circuit and the perfusion was conducted for 20 
minutes. After 20 minutes a washout procedure was performed by 1 litre of Haemaccel 
collecting the venous effluent. Total liver ischemia time never exceeded 60 minutes.  
The isolation was terminated by deflating the caval balloon followed by the aortic balloon and 
releasing the ligature of the portal vein (orthograde IHHP) or decanulation and closing the 
venotomy of the portal vein (retrograde IHHP). 
 
 
 
Fig. 2 Schematic representation of IHHP with a percutaneous catheter in the hepatic artery (inflow), a triple 
balloon occlusion catheter in the caval vein and an outflow catheter in the portal vein. Retrograde flow method. 
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Pat 
Nr 
Sex Age 
(years) 
Tumor 
type 
Balloon
V.Cava 
Outflow
(site) 
Leakage
(%) 
Toxicity
Hematol 
 
Renal 
 
Hepatic 
 
GI 
Response
CEA pre 
 
CEA 6 w 
 
CT 
TTLPD 
(mo) 
1 M 67 Colorect Double Caval 50 3 0 3 0 236 56 SD 4 
2 M 70 Colorect Double Caval 60 4 0 2 0 74 10 SD 3 
3 F 67 Colorect Double Caval 20 4 0 3 0 211 171 SD 3 
4 F 58 Colorect Double Caval 100 3 0 3 0 9980 2260 SD 3 
5 M 69 Colorect Double Caval 50 3 0 2 0 13,7 5,9 SD 5 
6 M 66 Colorect Double Caval 33 1 0 1 0 29,7 30,2 SD 13 
7 M 68 Colorect Double Caval 40 4 0 3 0 45,9 27,6 PD 5 
8 M 39 Colorect Double Caval 100 4 0 2 0 12,0 20,7 SD 3 
9 F 68 Colorect Triple Portal 15 0 0 1 0 6,33 2,74 PR 5 
10 M 71 Colorect Triple Portal 30 4 0 2 0 15,73 21,5 SD 7 
11 F 64 Colorect Triple Portal 17 0 0 3 0 81,65 58,75 SD 3 
12 F 69 Ocul.mel Triple Portal 5 0 0 4 0 NA NA NA NA 
13 M 65 Colorect Triple Portal 35 3 0 3 0 480 87,74 SD 3 
14 M 51 Colorect Triple Portal 85 1 0 3 0 5,12 2.0 PR 5 
15 F 64 Colorect Triple Portal 55 0 0 3 0 2330 NA SD 4 
16 M 71 Colorect Triple Portal 65 3 1 3 0 54 NA abces NA 
17 F 52 Colorect Triple Portal 16 0 0 2 0 43,5 15,5 SD 4 
18 M 59 Colorect Triple Portal 50 3 0 3 0 14,27 NA SD 6 
      Gr 4     Mortality Response   
mean  63.2    Toxicity 5/18 0/18 1/18 0/18 1/18 SD 81% 4.8 
med  66.5    (%) 27% 0% 5% 0% 5% PR 12% 4.0 
 
Table 1 Characteristics of 18 patients with irresectable liver metastases treated by IHHP with Melphalan. 
 
Abbreviations: SD= stable disease, PD=progressive disease, PR=partial response, NA=not available, TTLPD= 
time till local progression of disease (at the liver); mo=months after IHHP; med=median. 
 
 
Leakage monitoring: During IHHP potential leakage of drugs was monitored using a 
radioactive tracer. A small calibration dose of human serum albumin radiolabelled with 131I was 
injected into the systemic circulation prior to the perfusion and 10-fold higher dose of the same 
isotope was injected into the isolated hepatic perfusion circuit. Continuous monitoring was 
performed with a precordial scintillation probe. Systemic leakage is expressed quantitatively as a 
percentage (100% leakage representing a homogeneous distribution of the isotope in the body 
(21). 
 
Blood sampling: Before, during and after the perfusion blood samples were taken and 
collected to study pharmacokinetics of Melphalan and haematological, renal, hepatic and 
gastro-intestinal toxic side effects. Toxicity is graded according to the standardized WHO 
common toxicity criteria (26). 
 
Measurement of Melphalan concentrations: Melphalan was measured in plasma by gas 
chromatography-mass spectrometry (GC-MS). P-[Bis(2-chloroethyl)amino]-phenylacetic acid 
methyl ester was used as an internal standard. Samples were extracted over trifunctional C18 
silica columns. After elution with methanol and evaporation, the compounds were derivatized 
with trifluoroacetic anhydride and diazomethane in ether. The stable derivates were separated 
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on a methyl phenyl siloxane GC capillary column and measured selectively by single ion 
monitoring GC-MS in the positive EI mode described earlier by Tjaden et al (27). 
 
Assessment of tumor response: This was done by comparing pre-perfusion CT and MRI 
scans of the liver with scans made at 6-8 weeks after IHHP. The tumor marker 
carcinoembryonic antigen (CEA) was monitored (when indicated) preoperatively and 6-8 
weeks post-perfusion, but was not used for response assessment. Clinical responses are 
assessed by standardized WHO criteria (26): Complete remissions (CR) of all measurable 
disease in the liver > 4 weeks; partial remissions (PR): regression of the tumor size by more 
than 50% for > 4 weeks; stable disease (SD): regression less than 50% of the tumor in the 
liver or progression less than 25% for > 4 weeks; progressive disease (PD) progression more 
than 25% 
 
 
Results 
 
Patient characteristics. In total 18 patients were included in the protocol. Seven women and 
eleven men with a mean age of 63.2 years (range 39-71). Seventeen patients with irresectable 
colorectal liver metastases, and one patient with ocular melanoma hepatic metastases.  
 
Leakage control. In the first 8 IHHP’s with a double balloon intracaval catheter a mean 
leakage of 56% (range 20-100) was measured. Repeated adaptations to the catheter design in 
terms of balloon size and interballoon distance were performed. This lead to a change of 
concept and the design of a triple balloon caval vein occlusion catheter with outflow via the 
portal cannula and a retrograde flow direction (patients 9-18). Now leakage decreased to an 
average of 35% (range 5-85).  
 
Toxicity study (Table 1). Regional toxicity consisted mainly of a transient rise of liver 
enzymes during the first week after IHHP, WHO grade II-III in 83 % of the patients. No 
coagulopathy was observed. In 1 patient we were confronted with severe hepatic toxicity 
(grade IV). Unfortunately this patient died within 30 days of the operation (discussed in detail 
in the Complications section).  
Because of the leakage of Melphalan during the perfusion most patients were treated with G-
CSF (Neupogen, Amgen B.V., Breda, The Netherlands) trying to prevent severe leucopenia. 
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Systemic toxicity consisted mainly of leucopenia, WHO grade I-III in 44% and severe grade 
IV leucopenia in 27%, during 10-20 days after perfusion. In most patients with relatively less 
leakage no or only mild leucopenia was observed. No renal or gastro-intestinal toxicity was 
observed. 
 
Melphalan pharmacokinetics. Figure 3 shows a drug-concentration vs. time curve in the 
isolated circuit and in the systemic circulation. It shows Melphalan concentrations during a 
retrograde IHHP (patient no. 9). Very high regional and negligibly low systemic Melphalan 
concentrations were observed. Post-operatively this patient only had mild hepatic toxicity and 
no signs of systemic toxicity. Area under the concentrations versus time curve (AUC) 
calculation showed a regional concentration advantage with AUC ratio regional/systemic of 
28.2.  
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Fig. 3 Pharmacokinetics of Melphalan during IHHP.  
IHHP no. 9 with 15% leakage during perfusion. Area under the concentration vs. time curve (AUC) calculated 
between t=5 and t=20 minutes. Regional 335500 (ng x min/ml) vs. systemic 11870. The AUC ratio 
regional/systemic is 28.2.  
 
 
Complications. Patient no. 3 developed a paralysis of both legs a few days after the 
procedure. During the clinical observation period the symptoms decreased and after about 3 
months the paralysis had disappeared completely. This temporary neurological feature was 
probably caused by peroperative ischemia of spinal marrow by occlusion of the Adamkiewicz 
artery. This arteria radicularis magna supplies part of the spinal marrow and was probably 
occluded by the aortic balloon catheter. 
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One patient developed liver abscesses 2 weeks after IHHP (no.20). He underwent the 
perfusion with 65% leakage and developed grade III haematological and hepatic toxicity. 
Then a period with fever occurred and CT scan demonstrated multiple abscesses in the liver. 
These abscesses were located at the former sites of the colorectal metastases. Moreover, an 
abscess was apparent at the blind end of the rectum as a result of the Hartmann procedure 
performed for his primary tumor several months before. This was the possible focus for the 
bacteraemia causing the infected necrotic masses in the liver. After a period of 2 months with 
multiple percutaneous draining periods of the liver abscesses and antibiotic treatment he 
finally developed a aspiration pneumonia and died because of respiratory failure.  
One patient died within 30 days of the operation, resulting in a mortality during this phase I-II 
study of 5%. This patient (no 12.) presented with ocular melanoma metastases and had an 
uneventful IHHP with only 5% leakage. Post-operatively she developed severe dyspnoea and 
grade IV hepatic toxicity.  Mechanical ventilation was indicated because of respiratory 
failure. Hepatic dysfunction increased rapidly and 8 days post-operatively the patient died. 
Autopsy showed pneumonia. There were no signs of pulmonary (thrombus or tumor) 
embolism. An ischemic liver was found with almost total necrosis of the melanoma 
metastases. Surprisingly almost 70% of liver was replaced by tumor. Although a CT-scan 4 
weeks prior to perfusion showed an estimated tumor involvement of < 40%. We assume that 
the metastases must have grown very rapidly the last weeks before IHHP and the remnant of 
normal liver tissue was not enough to survive the hepatic toxicity due to the IHHP.  
 
Tumor response and patient survival. Stable disease was demonstrated in 81% of evaluable 
patients (13 out of 16) after 6-8 weeks (Table 1). Patients no. 12 and 16 were not evaluable 
with respect to tumor response. In 12 % of patients a PR was seen (2/16). Two patients 
developed progressive disease after IHPP (12%). In both patients who had a PR, CEA levels 
decreased to normal (<5 µg/ml) levels. CEA levels decreased in at least 8 of the SD patients 
but none had reached normal levels. Progressive disease at the liver occurred with mean 
interval after IHHP of 4.8 months (range 3-13). Seven patients developed systemic 
metastases. Five of them developed pulmonary metastases in range from 3 to 7 months after 
IHHP. One patient had metastatic lesions in the sacral bone at the same time of liver 
metastases progresion at 4 four months after perfusion. In one patient peritoneal 
carcinomatosis was detected 5 months after IHHP. In one patient a local recurrence at the 
rectum was detected. Median patient survival was 11.1 months (range 0-32).  
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Discussion 
 
In the last decade isolated liver perfusions are performed by a few centres world-wide and the 
anti-tumor effect showed promising response rates up to 75% and a potentially prolonged 
mean survival of 16-24 months (17,20). The major drawbacks of the technique are the 
magnitude, the costs and the non-repeatability of the surgical procedure. In the open 
procedure the whole liver has to be mobilised and all lumbar veins have to be ligated to 
guarantee a leakage free perfusion. Classical SIHP also uses a veno-venous bypass and a 
heart-lung machine which is a time-consuming procedure necessitating a specialized 
perfusion team. The mean SIHP operation time is 8.6 hours with a mean number of packed 
RBC’s transfusion of 5.7 units. The main goal of our study was to develop a less invasive, 
less costly and potentially repeatable percutaneous technique, allowing safe perfusion in a 
much shorter time, which can be repeated and performed without a heartlung machine or 
veno-venous bypass. Moreover, IHHP makes use of hypoxia which renders tumor cells more 
sensitive to cytostatic agents in general and which enhances in particular the anti-tumor 
effects of drugs such as Melphalan (28,29). In pigs we previously demonstrated a leakage free 
IHHP technique with an open double balloon catheter in the caval vein (25). The same 
technique in patients resulted in major leakage in this study. This despite positioning the two 
balloons directly above and below the orifices of the hepatic veins and trying to occlude the 
lumbar veins. By replacing the open double balloon catheter by a triple balloon occlusion 
catheter, which should occlude the adrenal vein and all lumbar veins, but also the hepatic 
veins, more successful hepatic perfusion could be performed with inflow via the hepatic 
artery and outflow via the portal vein. The mean operating room time was reduced to 3 hours 
and mean transfusion is 1 RBC unit compared to SIHP.  
The mean leakage decreased from 56% in the orthograde IHHP to 35% in the retrograde 
setting. We anticipated on a decrease in leakage along the learning curve, however unless 
increasing experience and technical modifications IHHP it is still not possible to perform it a 
leakage free in this current setting. We assume that diaphragmatic, lumbar, and adrenal veins 
are the main cause for the type of leakage we observed. Veins around the common bile duct in 
the hepatic ligament could also be a potential cause, but temporary ligation of the ligament 
during perfusion was performed routinely since we started with the retrograde perfusion and 
leakage remained. Leakage started directly after start of the perfusion and remained at a 
constant level during the procedure. Due to this persisting leakage problem and subsequent 
dose limiting systemic toxicity we were not able to escalate to higher Melphalan dosages. 
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Higher local Melphalan concentrations seem to be a prerequisite for improving tumor 
responses. Vahrmeijer et al. reported a correlation between high dose Melphalan SIHP (3 
mg/kg) for colorectal liver metastases and patient survival (20).   
Leakage free perfusion is of major importance for the potential application of tumor necrosis 
factor-alpha (TNF), a cytokine with significant anti-tumor effects at high concentrations. The 
adequate concentration for TNF to induce its synergistic anti-tumor effect is to high to 
administer it intravenously. The use of TNF has led to excellent clinical responses observed 
after isolated limb perfusion (ILP) with Melphalan and TNF for irresectable soft tissue 
sarcomas and melanomas (30,31).  In ILP TNF proved to be very effective and safe since 
these perfusions are performed with minimal systemic leakage of 0-10% (30,31). Whether 
TNF contributes to therapeutic efficacy in IHP remains unclear. We recently demonstrated in 
a pre-clinical rat liver metastases model that increased intratumoral Melphalan uptake is 
strongly correlated with the microvessel density of the tumor (32). Only hypervascularized 
tumors showed improved Melphalan uptake in tumor tissue and synergistic anti-tumor effects 
after IHP with Melphalan and TNF. Since colon carcinoma metastases are hypovascular, IHP 
with Melphalan alone might be probable just as effective as combined with TNF. This was 
demonstrated in our colorectal liver metastases model, which showed no increased 
intratumoral Melphalan concentrations and lack of therapeutic efficacy compared to IHP with 
Melphalan alone. Results from the NCI showed same duration of response after SIHP for 
colorectal metastases with or without TNF (18,33,34). But in patients with highly 
vascularized ocular melanoma metastases addition of TNF in SIHP yielded to prolonged 
duration of response compared to SIHP with Melphalan alone: 14 months vs. 6 months (35). 
These clinical results seem to confirm the hypothesis about the indication for the utility of 
TNF in IHP. Since the minimal invasive IHHP methodology we report here is not without 
leakage the addition of TNF in this setting seems impossible.  
Savier et al. recently reported a phase I study with 4 patients repeatedly treated by ten courses 
of Melphalan based SIHP and percutaneous IHP (36). At percutaneous IHP the hepatic artery 
was used for inflow of the perfusate and an open double caval balloon catheter was used for 
outflow. The portal vein was occluded by a percutaneous balloon catheter to complete 
isolation. This group was also confronted with major leakage starting as soon as the perfusion 
commenced. This was postoperatively measured by systemic Melphalan levels. Severe (grade 
III-IV) systemic toxicity (haematological) was observed postperfusion in this study. Due to 
lower Melphalan doses varying from 15 to 45 mg used no severe hepatic toxicity was 
observed. Others have used percutaneous IHP techniques combined with extracorporal 
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chorcoal hemoperfusion filters for the venous effluent, predomininantly in patients with 
hepatocellular carcinoma (37-39). This technique is completely different compared to the 
balloon catheter technique described in our study, but results look promising although toxicity 
is also significant. Systemic toxicity might not only be related to the surgical technique or 
catheter, but influenced by the used drug as well. Our study with eighteen consecutive 
patients in this phase I-II study showed advantages compared to SIHP regarding magnitude 
and operating time, although morbidity and mortality are still significant. Despite technical 
modifications and increasing experience leakage is still observed and regional and systemic 
toxicity remained.  
With respect to regional toxicity we emphasise that at least 50 % of functional liver tissue 
should be present. Especially in fast growing melanoma metastases liver imaging should be 
performed shortly prior to the operation as well as laboratory investigation. The only fatal 
complication occurred after a technically uncomplicated IHHP with less leakage, but was due 
to hepatic failure based on massive liver replacement by fast growing metastases   
Systemic toxicity is directly correlated with leakage of cytostatic agents during perfusion and 
an effective washout procedure. Vahrmeijer et al. could escalate up to 3 mg/kg Melphalan 
safely provided leakage was minimal (20). In our series leakage less than 20% prevented 
leucopenia almost completely. In a leakage free perfusion setting hepatic toxicity will be the 
dose limiting factor.  
In conclusion balloon catheter mediated IHHP has failed since no good leakage control was 
achieved by neither the orthograde nor the retrograde method. We therefore have abandoned 
this program. Instead we have used the experience to develop a surgically much simplified 
method to perform a retrograde IHHP with fully controlled leakage and thus improved local 
drug concentrations, improved washout at the end of the perfusion, and much improved 
toxicity and response rates. Lastly we want to emphasize that systemic or locoregional 
maintenance therapy after IHHP also has to be considered in order to control the liver 
metastases. Continuing locoregional treatment by HAI after an IHP procedure is technically 
feasible and appears to prolong the duration of the response and survival (18).  
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Introduction 
 
The optimal treatment for patients with primary or metastatic malignancies confined to the 
liver is surgical resection with curative intent. Isolated liver metastases occur frequently in 
colorectal and neuroendocrine tumors, but other malignancies such as gastrointestinal cancers, 
sarcomas, ocular melanoma and even breast cancer, occasionally develop isolated liver 
metastases as well (1). The liver is the only site of initial colorectal cancer recurrence in as 
many as 30 % of patients (2,3). If left untreated, the mean survival rate in these patients is 
poor and will rarely surpass one year. In contrast, 5-year survival rates of up to 40 % have 
been reported for patients who underwent a radical resection, the standard treatment for 
isolated liver metastases (1,3). Similar results with long-term survivors have been reported for 
endocrine and non-colorectal, non-endocrine liver metastases (1,3). 
Many patients with tumors confined to the liver are not amenable for surgical resections 
because of tumor size, number of tumors, tumor location, involvement of vascular structures 
and/or significantly compromised liver function. Several treatment options are available in 
this situation, systemic chemotherapy being the most widely used. In case of colorectal liver 
metastases, standard treatment with the combination of 5-FU and leucovorin provides a 
median survival of 10-14 months (1,4).  Recently developed drugs such as oxaliplatin or 
irinotecan seem to improve survival rates up to 20 months or more in multiple sequential 
combinations of these agents (5). 
Most patients eventually die due to intrahepatic progression and/or development and 
progression of extrahepatic disease. In order to achieve a better control of intrahepatic disease 
and to reduce systemic toxicity of the applied therapy, locoregional therapies have been 
developed. These therapies include hepatic arterial embolization (6), intratumoral injections 
of ethanol (7), acetic acid, biological agents (8,9), stereotactic or intraarterial radiotherapy, 
intralesional laser therapy, cryotherapy, radiofrequency ablation (10) and regional infusion or 
perfusion of chemotherapeutic drugs (11). The best approach for regional infusion of 
chemotherapeutics in the liver is unknown (12). Hepatic artery infusion (HAI), hepatic artery 
ligation with hepatic artery and portal vein infusion, or portal vein infusion, have all been 
attempted (4,13). Of these modalities, HAI is the most widely applied form. A number of 
studies have been conducted comparing systemic chemotherapy with HAI and a modest but 
significant improvement of survival was demonstrated by HAI in a meta-analysis (4). Isolated 
hepatic perfusion with chemotherapeutic drugs is another locoregional therapeutic option, 
which allows maximal locoregional drug concentrations, and at the same time protects the 
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patient from systemic toxicity. 
 
Isolated Hepatic Perfusion 
Isolated hepatic perfusion (IHP) was first performed more than 40 years ago by Ausman (14), 
but experience with the technique has been limited to a few centers worldwide. The main 
principle for an IHP is to achieve high local drug concentrations and thus high exposure of 
tumor tissue to these agents. Local hepatic toxicity will be the dose-limiting factor using this 
treatment modality, but systemic toxicity will be minimal provided leakage from drugs to the 
systemic circulation is prevented. Since for most chemotherapeutics steep dose-response 
curves have been demonstrated, this should theoretically result in greater tumor responses. 
Other theoretical advantages of IHP are the possibility to use perfusion drugs that do not have 
a high first pass hepatic extraction rate. Perfusion drugs with high systemic toxicity such as 
tumor necrosis factor (TNF) might be used because the liver can be washed out after a 
perfusion and thus prevents systemic toxicity. Hyperthermic and/or hypoxic conditions can be 
achieved during IHP, which might induce synergistic effects in combination with 
chemotherapeutic drugs (15).  
Different ways of performing an IHP are developed using experimental animal models and in 
several institutions IHP is currently used in controlled trials for patients with inoperable 
primary or metastatic liver disease. 
 
Animal studies 
Large Animals. 
The first experimental IHP studies have been performed in the 60’s in large animal models 
such as pigs and dogs, since the liver anatomy and vasculature in these animals resemble 
those in humans (14,16). When the technique proved to be feasible, hyperthermia was 
introduced by Skibba in a dog IHP model and demonstrated to be possible with preservation 
of good hepatic function (17). A few years later, IHP studies performed in pigs with 
increasing doses of 5-FU with or without hyperthermia demonstrated temporary hepatic 
enzyme disturbances, but without systemic toxicity in all animals. Levels of 5-FU tolerated by 
the liver were significantly higher than maximum levels achieved by routine systemic, intra-
arterial or intraperitoneal administration (18). In another reliable and technically feasible IHP 
model in pigs developed by Van de Velde et al. increasing doses of 5-FU were used and 
demonstrated that at least four times the conventional dose of this drug can be safely 
administered (19).  
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As a result of the dramatic responses observed after the use of tumor necrosis factor (TNF) in 
the isolated limb perfusion setting in melanoma (20) and in large soft tissue sarcomas in 
combination with or without IFN-gamma (21,22,23) the utility of this cytokine was studied 
also in the IHP setting. 
We investigated in pigs the possibility to utilize the highly toxic cytokine tumor necrosis 
factor (TNF) in the classic surgical IHP procedure (24). For an agent like TNF to be used 
successfully a leakage free IHP is a prerequisite and therefore leakage monitoring is essential. 
We demonstrated that IHP with Melphalan with or without TNF in pigs resulted in very high 
and stable concentrations of Melphalan and TNF in the perfusate, without measurable 
systemic TNF concentrations during the perfusion, which proofs a leakage free system (24). 
Hepatotoxicity was observed in all control animals after IHP, but the transient rise in hepatic 
enzymes was normalized within one week. Histological sections of the liver demonstrated 
mild septal edema with polymorph nuclear cell infiltration, without apparent hepatocellular 
damage or parenchyma necrosis. The addition of high dose TNF and Melphalan did not seem 
to cause additional hepatotoxic side effects, so most of the changes observed, were interpreted 
as the result of the IHP procedure itself. Similar results have been reported by others who also 
showed that washout of the liver with a protein solution reduces systemic TNF levels as well 
(25).  
From other experiments in large animals it became clear that IHP with hyperthermia is 
technically feasible and safe. Since transplantable tumor cell lines do not exist in large 
animals, evaluation of anti tumor effects of IHP is studied in tumor bearing IHP models in 
rodents, but the obvious technical difficulty of performing hepatic perfusions in these animals 
has limited the number of available data. 
Rodent models. 
De Brauw et al developed the first IHP model in hepatic tumor bearing rats (26). They 
demonstrated that a 200-400 % higher dose of mitomycin C (MMC) or Melphalan could be 
safely administered during IHP and resulted in a 4-5 times higher tumor tissue concentration 
compared with HAI (27-30). A well-tolerated dose of mitomycin C could induce complete 
tumor remissions in IHPs, which could not be achieved in tumor bearing rats using HAI (31). 
Others demonstrated a significantly decreased tumor growth using 5-FU in IHP, but there was 
also some decreased tumor growth in the control group suggesting an anti tumor effect of the 
hyperthermic IHP alone (32). In a rabbit hepatic metastases model, hyperthermia 
preferentially increased vascular permeability in tumors compared with liver tissue in a dose-
dependent fashion, thus providing a mechanism for inducing anti tumor effects using IHP 
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(33). 
IHP studies performed in our institution in hepatic sarcoma bearing rats with TNF and 
Melphalan demonstrated a dramatic increase in regional concentrations of perfused agents 
(34). IHP with carrier solution only resulted in a significantly decreased growth rate of liver 
tumors compared to the growth rate of tumors in non-perfused rats. Perfusion with Melphalan 
alone resulted in minimal antitumor effects and perfusion with TNF only had no effect on 
tumor growth. When TNF was used in combination with Melphalan, a dramatic anti-tumor 
effect was observed similar as has been demonstrated in isolated limb perfusions (35-37). 
These results could not be extrapolated to a colon carcinoma hepatic metastases model in the 
rat. The difference in response rates between the two tumor models seem to correlate with the 
hyper – and hypovascular properties of the tumors (38).  
Nakamoto et al demonstrated in a similar model that anti-tumor activity of a less toxic TNF 
mutant (TNF-SAM2) was similar to standard TNF (39). In a recently published study TNF 
was combined with 5-FU and no additive or synergistic effect was demonstrated with the 
combination of these drugs (40). 
New perfusion methods to improve IHP were recently studied by Rothbarth et al (41). They 
analyzed Melphalan concentrations in a retrograde perfusion system with occlusion of the 
hepatic veins and performing hepatic inflow via the hepatic artery and outflow via the portal 
vein. It was demonstrated that retrograde IHP with continuous infusion of Melphalan in the 
hepatic artery provides high Melphalan concentrations in the tumor with reduced Melphalan 
concentration in the liver tissue compared with an orthograde hepatic perfusion. (41) 
Gene therapy is another treatment modality that has recently been evaluated in IHP models. In 
the development of gene therapy protocols it has often been shown that data from in vitro 
experiments do not predict anti-tumor effects in vivo. To expose viral vectors mainly to the 
organ of interest and minimize systemic exposure, the IHP setting seems an elegant 
administration option. A transendothelial route is important in targeting unresectable liver 
metastases because there is often a wide spread disease trough out the whole liver. Other 
groups and we already demonstrated effective administration of adenoviral and herpes 
simplex vectors in regional limb perfusion models (42,43). However, we recently were not 
able to demonstrated significant transfection or tumor responses after IHP, HAI, intratumoral 
or systemic treatment (44). Repeated HAI could induce transfection and responses in this 
study using an adenoviral vector. Thus gene therapy might be a promising option, but needs 
further experimental studies to establish the optimal route of administration for further clinical 
trials. 
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IHP in rodents has confirmed the theoretical advantages of IHP in terms of achieving higher 
tumor tissue concentrations of the used drugs with subsequent significant better response rates 
as compared to HAI. With the combination of TNF and Melphalan in IHP, similar synergistic 
response rates have been demonstrated in highly vascularized tumors as in the isolated limb 
perfusion setting. 
 
IHP Technique 
IHP is an extensive surgical procedure in which the liver and its vasculature are completely 
isolated from the systemic circulation. The technique involves briefly a bilateral subcostal 
incision and the liver is mobilized from its retroperitoneal and diaphragmatic attachments and 
a prophylactic cholecystectomy is performed. Tributaries to the vena cava such as the adrenal, 
lumbar and diaphragmatic veins are dissected and ligated.  The vena cava is isolated and 
clamped above and below the liver to prevent venous leakage and the isolated segment of the 
inferior vena cava is cannulated to collect the hepatic venous outflow. A veno-venous bypass 
is established to maintain venous return from the subhepatic inferior vena cava and the portal 
venous system. Cannulas are introduced in the saphenous vein and the superior mesenteric 
vein and connected to a pump that returns blood to the systemic circulation via the axillary 
vein. The portal vein, proper hepatic artery and gastroduodenal artery are dissected and the 
hepatic artery and portal vein are cannulated for inflow of the perfusate usually via the 
gastroduodenal artery and a venotomy of the portal vein. Temperature probes are placed in the 
liver to measure adequate tissue hyperthermia. Leakage can be monitored using different 
radioactive labeled agents that are introduced in the perfusion circuit. The perfusate is 
circulated for 60 minutes using an oxygenator and a roller pump. After the isolated perfusion 
a washout procedure is performed with crystalloid or colloid solutions. When the cannulas are 
removed, the liver vascularization is restored.   
The best mode of perfusion is not known, but determination of the most optimal route of 
infusion involves issues of vascular variations, technical aspects of cannulation, as well as 
tumor blood supply. Normal hepatic parenchyma receives most of its blood supply from 
branches of the portal vein, but hepatic metastases rely almost entirely on the hepatic artery 
for its blood supply (45,46). Regardless the route of administration, drugs are delivered to the 
sinusoid where it is extracted by the hepatocyte and the route of regional administration might 
not be important for hepatic uptake of drugs. Although most perfusion centers started 
performing IHP with a dual infusion system, inflow of chemotherapeutic drugs is now mainly 
via the hepatic artery only, which makes the procedure less invasive.   
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 Clinical experience 
A limited number of studies has described IHP inpatients using chemotherapeutics and/or 
hyperthermia only (Table 1). Hyperthermia enhances cytotoxic effect of several 
chemotherapeutic drugs, by increasing cell membrane permeability and altering drug 
transport and cell metabolism (15). Skibba et al. used hyperthermia as the only antitumor 
modality in a 4 hour IHP and demonstrated a high response rate, but with significant mortality 
(47). Several chemotherapeutic agents have been used in IHP, of which 5-FU, cisplatinum, 
MMC are the most widely used (48,49). Chemotherapy-related hepatotoxicity turned out to be 
significant and the finding of severe veno-occlusive disease was observed when high doses of 
MMC were applied in clinical phase I/II studies (50-52). In IHP experiments in rats was 
demonstrated that Melphalan was not only more effective than MMC, but also resulted in 
lower hepatotoxic side effects. This resulted in the use of Melphalan in phase I/II dose-
findings studies (51). Results after several Melphalan based IHP studies indicate that median 
survival after one IHP treatment is at least comparable to the results obtained from the most 
effective (multiple treatments) HAI schedules (15,53).  
The dramatic increase in response rate reported after addition of TNF in combination with 
Melphalan to the isolated circuit in ILP (20-23) has stimulated to investigate the possible 
application of TNF in IHP in patients. TNF acts mainly by damaging the tumor-associated 
neovasculature and as a result increased intratumoral drug concentrations have been reported 
in both ILP and IHP animal models (34-36). TNF as a single agent does not appear to have 
any significant anti-tumor activity when administered in IHP (54). In patients with 
unresectable hepatic metastases of ocular melanoma the combination of Melphalan and TNF 
yielded a 62% response rate, which was similar to IHP with Melphalan only. But more 
interesting, overall median duration of response was significantly longer in those treated with 
the combination of Melphalan and TNF (14 vs. 6 months, respectively) (55).  
IHP with TNF and Melphalan in patients with unresectable hepatic metastases of different 
origin resulted in a similar overall response rate in a study from our institution and from 
various reports of the group of the National Cancer Institute (56-60). However, Alexander et 
al demonstrated that TNF did not improve intratumoral uptake of Melphalan in colorectal 
metastases (59). We have demonstrated in animal models that TNF significantly enhances 
drug uptake in highly vascularized tumors, both in the isolated limb perfusion models (35.36), 
as well as in the IHP models for liver metastases (38). Our observations would correspond 
quite well with the lack of improvement of drug uptake in colorectal metastases in patients as 
these metastases are notoriously hypovascular. Together these results suggest strongly that 
Isolated Hepatic Perfusion. 
 182 
indeed also in the clinic the effect of TNF and chemotherapeutics is dependent on the 
vascularity of the tumor, which is recently confirmed in animals. For well vascularized 
tumors the addition of TNF seem to improve responses or duration of response, but in 
hypovascularized tumors such as colorectal metastases this effect remains to be defined. In a 
Swedish study group using both Melphalan and TNF in IHP similar results were seen with 
only partial responses in patients with hepatic metastases from melanoma or leiomyosarcoma. 
Patients with liver metastases from colorectal origin showed no response (61). In order to 
prolong duration of response after IHP, Bartlett et al reported the results of IHP with TNF and 
Melphalan followed by HAI with FUDR and leucovorin in patients with unresectable 
colorectal hepatic metastases. Response rates were similar, but median duration of response 
and survival was improved using the maintenance therapy. This combined strategy could be a 
manner to improve the present results of IHP (62).  
 
Toxicity 
Morbidity is significant after IHP and varies between centers and used perfusion agents. A 
transient rise of liver enzymes and bilirubin is normal, subsides usually after one week and 
seems to be mainly related to the surgical procedure itself. Surgical complications and 
systemic side effects have been described such as postoperative symptoms such as malaise 
and nausea or symptoms that reflect high leakage during the procedure such as 
myelodepression and hair loss. Mortality is reported between 0-33% and was due to veno-
occlusive disease, TNF-related coagulation disorders and hepatic failure (63). Lans et al 
showed that the production of secondary mediators in the liver after IHP with TNF and 
Melphalan might result in subsequent transient hemodynamic alterations not observed with 
Melphalan alone (64). Most of these side effects can be minimized by a complete isolation 
and a thorough washout in order to keep systemic levels of perfusion agents during and after 
IHP as low as possible.  
 
Percutaneous IHP 
A new method to improve the current IHP technique is the development of a percutaneous 
balloon catheter technique, which makes the surgical procedure must easier and faster and in 
theory would allow for repeated perfusions. Several groups have developed different 
modifications (65-67) but the technique usually involves an inflow catheter inserted into the 
proper hepatic artery advanced from the groin. Balloon catheters inserted at the site of the 
femoral artery or vein and positioned at the upper side just above the hepatic vein and at the 
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lower side just above the renal vein. A roller pump circulates venous outflow from the liver 
into the hepatic artery. The portal vein is clamp to avoid leakage. A balloon catheter in the 
aorta is positioned above the diaphragm to compensate for the blocked venous return. The 
balloons are inflated and the bloodstream is blocked and perfusion commenced under hypoxic 
conditions to create an Isolated Hypoxic Hepatic Perfusion (IHHP).  We performed IHHP 
with TNF, Melphalan and MMC in pigs and demonstrated that a leakage free isolated IHHP 
can be performed with a small surgical procedure and is well tolerated in pigs. Regional drug 
levels were 20 to 40 times higher than after systemic drug injection (68). After these 
promising results in pigs, our group started a phase I-II study on IHHP with Melphalan in 
patients with unresectable hepatic metastases of colorectal origin (66). In our first patients we 
have had no serious adverse events, but responses were marginal presumably due to 
substantial leakage, which was present and exceeded 30% in most patients. In these patients a 
double balloon catheter, which had been shown to allow for a leakage-free IHHP in pigs, was 
used. This experience in patients lead to a modification of the perfusion concept by using a 
triple balloon catheter that would completely block the inferior caval vene over a trajectory 
that spanned the immediate suprahepatic, the whole retrohepatic and the immediate infra-
hepatic part of the inferior caval vein. In this setting also the hepatic veins are blocked and 
thus Inflow was via the hepatic artery but outflow of the perfusate was retrograde via the 
portal vein. Using this modifications we assumed that venous leakage though tributaries from 
the inferior vena cava would be stopped and leakage minimal. In 10 patients perfused with 
this modified technique we demonstrated that the technique of retrograde venous outflow via 
the portal vein was feasible, but again systemic leakage was a dose-limiting problem. We 
concluded that with the current balloon catheter techniques no complete isolation of the liver 
could be established which makes the use of agents such as TNF impossible. Using hypoxia 
and Melphalan we could not demonstrate responses as were reported with oxygenated 
leakage-free IIHP (66). Using a percutaneous IHP in its current form must be combined with 
other treatment modalities such as systemic or HAI to become clinically significant. Another 
means of using the percutaneous technique is to repeat it during several courses. This has 
recently been reported by Savier et al., who used a complete percutaneous technique, which 
they performed repetitively in 4 patients (65). Our disappointing experience with the various 
forms of occlusion catheters has brought us now to perform a smaller surgical procedure 
maintaining the method of retrograde outflow through the portal vein: the surgical IHHP. This 
procedure takes 2-2.5 hours, includes a 30 minutes isolated hypoxic perfusion period and an 
overall hypoxia of the liver of maximally 1 hour. The procedure is leakage-free and is 
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consistently associated with clinical responses, including CRs. After 7 patients it is too early 
to express this in percentages. 
 
 
Study Year N Drugs Art/ 
Dual 
Mortality Responses Median 
survival 
        
Ausman 1961 5 Nitr Mus ? ? ? 2 LT surv 
        
Aigner 1984 32 5-FU Dual 20%  ? 8 months 
        
Skibba 1986 8 None ? 25%  RR 83% - 
        
Schwemmle 1987 32 5-FU Dual ? CR 22 %,  14 months 
  14 MMC   PR 68%  
  4 Cisplatin     
        
Hafstrom 1994 29 Melph/Cispl Dual 14% PR 20% 7 months 
        
Marinelli 1996 9 MMC Dual 11% CR11% , PR 11%  17 months 
        
De Vries 1998 8 Melph + TNF Dual 33% PR  83% 10 months 
  1 TNF     
        
Alexander 1998 34 Melph + TNF Art 3%  CR 3%, PR 77%  11 months 
        
Oldhafer 1998 6 Melph + TNF Art 0% CR 17%, PR 33% 9 months 
  6  MMC   CR 0%, PR 33%  
        
Hafstrom 1998 11 Melph + TNF Dual 18% PR 27% 16 months 
        
Vahrmeijer 2000 24 Melphalan Dual 4% RR 29% 19 months 
        
Alexander 2000 11 Melph + TNF Art 3%  CR 18%, PR 36%  11 months 
  11 Melphalan Art 0% CR 0%, PR 64%  11 months 
        
Bartlett 2001 19 Melph +  
HAI-FUDR 
Art 0% RR 74% 27 months 
  32 Melph + TNF Art 3% RR 77% 11 months 
 
 
Table 1 Overview of literature concerning clinical IHP.  
 
Abbreviations: N, number of patients included in the study; art, arterial inflow site of IHP; dual, arterial and 
portal inflow site of IHP; Nitr Mus, nitrogen mustard; 5-FU, 5-fluorouracil; MMC, mitomycine-C; Melph, 
Melphalan; TNF, tumor necrosis factor-alpha; HAI-FUDR, hepatic artery infusion with FUDR; RR, response 
rate, CR, complete response; PR, partial response; LT surv, long-term survivors. 
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Future directions 
 
Clinical experience with IHP is limited and is still in its developmental stage. It’s efficacy 
needs to be established in a large phase II experience and only when a response rate of over 
70% is achieve I(H)HP would need to be evaluated in a randomized trial to establish its role 
as compared to systemic chemotherapy and/or HAI. Improvement can be expected using 
more effective or less toxic drugs. The combination of IHP with maintenance HAI or 
systemic chemotherapy is tested and looks promising. Results from preclinical research of the 
past have demonstrated that tumor growth requires an adequate blood supply. In order to 
obtain a sufficient vasculature, tumor cells stimulate the formation of new vessels 
(angiogenesis). Subsequently, this dependency of tumors on angiogenesis provides the 
possibility to limit tumor outgrowth by specific inhibition of new vessel formation (69,70). It 
is conceivable to combine IHP with adjuvant anti-angiogenic treatment strategies, in order to 
reduce the recurrence rate, which is the major determinant of the survival rate after IHP. Other 
modalities such as gene therapy might be used in the IHP setting to increase viral vector 
uptake to the organ of interest and to minimize exposure systemically. This would minimize 
the costs and reducing systemic toxicity, herewith morbidity and even mortality of gene 
therapy. Further simplification and refinement of the technique using percutaneous balloon 
catheters is expected and may make the technique more applicable. However our own 
experience has been quite negative with these occlusion catheters since substantial leakage 
was the common denominator during this period of trials. New endovascular techniques, the 
growing experience and instrumental improvements in laparoscopic surgery could make a 
minimal invasive approach feasible. The main problem of percutaneous IHP at this moment is 
to obtain a leakage free system. The major advantage of the percutaneous technique (if 
demonstrated effective) would, in contrast to the "open" surgical IHP, a repeatable procedure. 
  
Conclusions 
 
Many patients with tumors confined to the liver are not amenable for surgical resection and an 
increasing number of these patients are treated by local ablation methods. Isolated hepatic 
perfusion is another treatment option especially suitable for patients with multiple or bulky 
primary or metastatic tumors and can mediate clinical regression of advanced liver 
metastases. Experience with IHP is still limited to a few centers in the world because of the 
technical difficulties, surgery-related morbidity and unproven efficacy. IHP remains an 
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experimental modality restricted to specialized units dedicated to treat this difficult group of 
patients. Experimental animal IHP models have lead to explore new ways of improving 
efficacy, reducing technical difficulties and minimizing regional and systemic toxicity. Future 
research should be directed to the identification of suitable biological or chemotherapeutic 
agents, defining clinical indications, and development of technical modifications to make it 
more generally applicable. 
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Summary 
 
In Chapter 1 an introduction to the several studies is given. The aims of the thesis are 
described here. 
Chapter 2 addresses the efficacy of TNF in isolated hepatic perfusion (IHP). In an isolated 
limb perfusion (ILP) model in rats we previously observed synergistic anti-tumor effects of 
tumor necrosis factor-alpha (TNF) and Melphalan on BN-175 soft tissue sarcoma extremity 
tumors. The aim of the present study was to investigate if similar synergy in anti-tumor effect 
could be achieved by treating experimental BN-175 soft tissue sarcoma liver tumors by IHP 
with these agents. We demonstrated in our IHP model with TNF and Melphalan a dramatic 
increase in regional concentrations of perfused agents with virtually no concomittant systemic 
leakage. IHP with only carrier solution resulted in a diminished growth rate of BN-175 liver 
tumors compared to the growth rate of tumors in non-perfused rats. Perfusing with Melphalan 
alone resulted in minimal anti-tumor effects. When TNF was added to Melphalan a dramatic 
anti-tumor effect was observed. Thus, TNF induced synergy with Melphalan is tumor-site 
independent. Strikingly, potentiation of tumor response in IHP occurred at relatively low 
concentrations of TNF compared to concentrations eliciting synergy with Melphalan in ILP. 
The study performed in Chapter 3 is based on the favourable results of the a forementioned 
study of Chapter 2. Previous studies led to the hypothesis that the use of TNF in isolated limb 
perfusion causes specific destruction of tumor endothelial cells and thereby induces an 
increased permeability of tumor vasculature. However, whether TNF contributes to the 
therapeutic efficacy in IHP still remains unclear. In a rat liver metastases model we studied 
three different tumors: colon carcinoma CC531, ROS-1 osteosarcoma and BN-175 soft tissue 
sarcoma which exhibit different degrees of vascularization. IHP was performed with 
Melphalan with or without addition of TNF. IHP with Melphalan alone resulted in all tumor 
types in a decreased growth rate. In the BN-175 tumor addition of TNF again resulted in a 
strong synergistic effect. In the majority of the BN-175 tumor bearing rats a complete 
response was achieved. Secondly,  the response rate in BN-175 tumor bearing rats when TNF 
was co-administrated with Melphalan, was strongly correlated with drug accumulation in 
tumor tissue, as only in these rats a 5-fold increased Melphalan concentration was observed. 
Thirdly, immunohistochemical analysis of microvascular density of the tumor showed a 
significantly higher MVD for BN-175 tumor compared to CC531 and ROS-1. These results 
indicate a direct relationship between vascularity of the tumor and TNF-mediated effects. 
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Assessment of the tumor vasculature of liver metastases would be a way of establishing an 
indication for the utility of TNF in this setting. 
In Chapter 4 gene therapeutic strategies are investigated in our experimental colon carcinoma 
liver metastases model. In order to target the ras-oncogene we studied the transduction 
efficacy and anti-tumor activity of an adenoviral vector expressing a intracellular, neutralizing 
single chain antibody to p21-ras (Y28). Different routes of administration were evaluated to 
determine which regimen resulted in the best transfection levels and tumor responses: 
intravenous injection (IV), intratumoral injection (IT), isolated liver perfusion (IHP), or 
hepatic artery infusion (HAI). Intravenous injection did not result in any measurable 
transfection. Intratumoral injection resulted only in the transfection of tumor cells along the 
needle track. IHP as well as single HAI achieved low transfection levels of tumor tissue. 
Expression of Y28 was demonstrated in tumors after IT injection, HAI and IHP. Whereas, 
repeated HAI’s clearly achieved expression in and around tumor associated vessels. Only five 
times repeated HAI’s with Y28 resulted in significant tumor responses.  
Immunological effects of adenoviral gene therapy in IHP are studied in Chapter 5. IHP is a 
methodology that offers possibilities to deliver high concentrations of viral vectors locally 
without systemic exposure and washout possibilities for non-bound viruses. By means of IHP 
a very high transduction efficacy is achieved in vivo without significant toxicity using 
adenoviral vector in fully immunocompetent rats. Moreover a remarkable decreased immune 
response to the adenoviral vector after IHP was observed. Significantly impaired neutralizing 
antibody formation and decreased leukocytes proliferation was demonstrated.  These findings 
are a strong argument for further development of gene therapy in pre-clinical isolated 
perfusion settings. 
The study described in Chapter 6 explores the anti-tumor activity of the previously 
mentioned adenoviral construct encoding an intracellular single-chain antibody (scFv) against 
p21ras (Y28).  In order to determine the influence of the ras status on the efficacy of the scFv 
we used a wild type rat rhabdomyosarcoma and its ras–oncogene transfectant, for in vitro 
studies. In vivo we used the ILP delivery method to study anti-tumor activity on established 
limb tumors. In vitro studies demonstrated an inhibition of growth caused by the Y28 
construct. No significant difference between transfected and wild type cell lines could be 
demonstrated. Upon ILP homogeneous transduction in the tumor with on estimate 5 % 
transduction of tumor cells was observed. Perfusion with the Y28 construct however, did not 
result in any additional anti-tumor activity compared to controls. 
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Chapter 7 reviews the current literature on gene therapy in in vivo isolated perfusion models. 
Locoregional administration of the genetic construct by means of isolated perfusion (IP) of 
the target organ or extremity is a method that may increase in vivo efficacy. Vascular 
isolation and perfusion minimizes systemic exposure and thereby reduces unwanted side 
effects. Several models of IP like hepatic perfusion and limb perfusion, but also isolated 
kidney, lung and spleen perfusion are discussed. IP delivers vectors highly selectively, with a 
long exposure time and high concentrations at the target side. This results in higher 
transduction rates and thereby may improve therapeutic effects. 
A clinical ILP study was performed in patients with recurrent melanoma of the limb in 
Chapter 8.  Many treatment options are possible, mainly depending on tumor site, the size 
and the number of the lesions. Repeat biochemotherapeutic ILP with Melphalan and TNF 
(TM-ILP) is a valuable treatment option in patients with local progression after previous ILP 
treatment. Of the 25 repeat ILPs performed in our institution, 19 (76%) had a complete 
response (CR). With an additional 5 ILPs with a PR, total response rate was 96%. Compared 
to our total database of TM-ILP for melanoma, consisting of 100 ILPs, CR rate of repeat 
perfusions did not differ from the CR rate of patients undergoing only one ILP. In patients 
with bulky or numerous lesions that cannot be managed with surgery, and in patients without 
evidence of systemic disease, repeat ILP provides excellent disease control. 
We described our experience in patients older than 75 years treated by TNF-based  ILP in 
Chapter 9. The incidence of soft tissue sarcoma (STS) increases rapidly above the age of 50. 
About 18 % of the patient population is above the age of 70. Also in melanoma the incidence 
increases in older age groups.  Because of fear for TNF associated toxicity, ILP with TNF is 
not offered to old patients in some cancer centers, whilst especially in older patients an 
amputation may end their independence and completely limit their mobility. Thus every 
attempt to avoid amputation must be considered in these patients. In elderly STS patients ILP 
and surgical treatment resulted in limb salvage in 22/29 patients (76%). In the elderly melanoma 
patients (n=14) an overall response rate of 100% was achieved. This resulted in a 93% limb 
salvage. We demonstrated that ILP is very efficient in achieving limb salvage and local tumor 
control in elderly patients, with acceptable morbidity and mortality. The fact that the 3 fatal 
complications occurred after leakage free ILPs further underlines the point that the 
complications were due to patient-specific risks and not to uncontrolled elements of the ILP.  
Chapter 10 is review of the results ILP methodology performed in the clinical and 
experimental setting in different cancer centers worldwide. Several perfusions strategies are 
discussed such as the isolated limb infusion, the impact of hyperthermia, and the addition of 
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TNF. The role of prophylactic ILP is evaluated, as well as the importance of targeting the tumor 
vasculature. Laboratory studies performed to get better insight in the mechanism of TNF based 
ILP are described. Future directions based on current experimental ILP developments like gene 
therapy and new vaso-active drugs are discussed.  
The results of a clinical isolated hepatic perfusion (IHP) study are described in Chapter 11. IHP 
for irresectable metastases confined to the liver has reported response rates of 50-75%. 
Magnitude, costs and non-repeatability of the procedure are its major drawbacks. We developed 
a less invasive, less costly and potentially repeatable balloon-catheter mediated isolated hypoxic 
hepatic perfusion (IHHP). In a phase I-II study 18 consecutive patients with irresectable 
colorectal or ocular melanoma hepatic metastases were included. Two different perfusion 
methods were used: IHHP with orthograde or retrograde flow, both with inflow via the hepatic 
artery and using Melphalan at a dose of 1 mg/kg. IHHP using balloon catheters resulted in high 
local drug concentrations but failed to obtain leakage control by neither an orthograde nor a 
retrograde flow method. Due to this persisting leakage problem and subsequent dose limiting 
systemic toxicity we were not able to escalate to higher Melphalan dosages. 
In Chapter 12 an overview is given on the worldwide experience of isolated liver perfusion in 
the treatment liver tumors. Animal studies, IHP techniques, clinical results, toxicity and new 
developments like percutaneous techniques are reviewed. 
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Conclusions 
 
Based on the studies performed in this thesis the following conclusions can be drawn: 
 
• Addition of TNF to Melphalan in an isolated hepatic perfusion may induce synergestic  anti-
tumor effects compared to Melphalan alone. 
• Intra-tumoral Melphalan uptake can be enhanced by TNF and is correlated with the 
microvessel density of the tumor. 
• A high intra-tumoral Melphalan concentration improves tumor regression. 
• Isolated hepatic perfusion in patients using balloon catheter techniques is less invasive than 
classical IHP but a leakage free perfusion can not be achieved. 
• Colorectal liver metastases are difficult to transduce transvascularly by recombinant 
adenoviruses. Repeated locoregional administration seems to be essential in achieving a 
tumor response in vivo. 
• IHP with recombinant adenoviruses results in an impaired neutralizing antibody formation 
compared to systemic treatment. 
• Adenoviral gene therapy mediated anti-tumor activity in vitro does not always predict in vivo 
activity.  
• ILP with recombinant adenoviruses in a rat sarcoma model results in transduction of tumor 
cells especially at the viable rim and around tumor associated vessels. 
• Amputation of limb should be avoided especially in elderly patients: TNF based ILP is safe 
and effective in elderly people with limb threatening sarcoma and melanoma. 
• In patients with recurrent melanoma repeated TNF based ILPs remain highly effective after 
failure of previous ILP. 
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Samenvatting 
 
In Hoofdstuk 1 wordt er een introductie aangaande de diverse studies gegeven. Het doel van het 
proefschrift  wordt eveneens beschreven. 
Hoofdstuk 2 onderzoekt de bruikbaarheid en effectiviteit van TNF in de geïsoleerde lever 
perfusie (IHP). In een geïsoleerd ledemaat perfusie (ILP) model in ratten hebben we reeds eerder 
een synergistisch anti-tumor effect van TNF en Melphalan op BN-175 weke delen tumor gezien. 
Het doel van de huidige studie was om te onderzoeken of dit synergistisch anti-tumor effect ook 
kon worden behaald bij BN-175 lever tumor in een IHP model met deze agentia. In ons IHP 
model met TNF en Melphalan een zeer sterke stijging van regionale concentraties zonder 
evidente gelijktijdige systemische lekkage. IHP met alleen perfusie vloeistof resulteerde in een 
licht vertraagde groeisnelheid vergeleken met onbehandelde tumoren. Perfusie met Melphalan 
alleen resulteerde eveneens in een minimaal anti-tumor effect. Wanneer TNF werd toegevoegd 
aan Melphalan resulteerde dit in een sterke tumor respons. Dus TNF gemedieerde synergie met 
Melphalan is onafhankelijke van de plaats van de tumor. Bovendien trad dit effect op bij relatief 
lage dosering TNF gezien in vergelijking met de benodigde dosis in de ILP. 
De studie uitgevoerd in Hoofdstuk 3 is gebaseerd op de veelbelovende resultaten uit het 
hierboven beschreven Hoofdstuk 2. Eerdere studies hebben geleid tot de hypothese dat het 
gebruik van TNF in de ILP specifieke destructie veroorzaakt van tumor endotheel cellen en 
daarbij een toegenomen vaatpermeabiliteit induceert. Echter of  TNF ook van therapeutisch 
waarde is in de IHP is nog steeds niet geheel duidelijk. In een rat lever metastases model hebben 
we drie verschillende tumoren onderzocht: colon carcinoom CC531, ROS-1 osteosarcoma en 
BN-175 weke delen sarcoom. Elk van deze drie tumoren heeft een andere vascularisatiegraad. 
IHP werd uitgevoerd met Melphalan met of zonder TNF. IHP met Melphalan alleen resulteerde 
in alle genoemde tumor types in een afname van de groeisnelheid. Toevoeging van TNF 
resulteerde bij de BN-175 tumor opnieuw in een sterk synergistisch effect. In de meeste van de 
BN-175 tumoren werd een complete respons bereikt. Ten tweede was de tumor respons zoals 
gezien in de BN-175 tumoren sterk gecorreleerd aan de Melphalan opname in het tumor weefsel. 
Slechts in deze tumoren werd een 5-voudige verhoogde Melphalan concentratie in de tumor 
gemeten. Ten derde toonde bij immuno-histochemische analyse van de microvaatdichtheid 
(MVD) een significant hogere MVD van de BN-175 tumor vergeleken met de CC531 en de 
ROS-1. Deze resultaten wijzen op een directe relatie tussen tumor vascularisatie en TNF 
gemedieerde effecten. Pre-operatief vaststellen van de tumor vascularisatie graad van lever 
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metastasen zou een methode zijn om de indicatie voor het gebruik van TNF in de IHP wel of niet 
te stellen. 
In Hoofdstuk 4 worden gentherapie strategieën in ons experimenteel colon carcinoom lever 
metastasen model onderzocht. In deze studie hebben we gebruik gemaakt van een adenovirus 
vector welke een intracellulair antilichaam (Y28) tegen p21-ras herbergt. Dit ras-oncogen is vaak 
gemuteerd in colon carcinomen. Transfectie (infectie van een cel met dit virus) efficientie en 
anti-tumor werking werden bestudeerd. Verschillende toedieningswegen zijn geëvalueerd om te 
bepalen welke het beste transfectie resultaat behaalde evenals een mogelijke tumor respons: 
intraveneuze injectie (IV), intra-tumorale injectie (IT), geïsoleerde lever perfusie (IHP) en arteria 
hepatica infusie (HAI). Intraveneuze injectie gaf geen meetbare transfectie van de tumor.  IT 
toonde slechts transfectie langs het traject van de naald. Zowel IHP als HAI gaven meer 
homogene, doch lage transfectie percentages in tumor weefsel. Y28 expressie kon worden 
aangetoond in tumoren na IT, HAI en IHP. HAI biedt de mogelijkheid voor herhaalde 
locoregionale toedieningen. Slechts een 5 x herhaalde HAI met Y28 virus resulteerde in een 
tumor respons: in alle onderzochte ratten werd een tumor groei remming gezien, en in 3 van de 8 
was er een complete tumor respons. 
Immunologische effecten van adenovirus gentherapie door middel van IHP werden bestudeerd in 
Hoofdstuk 5. IHP is een methode welke de mogelijkheid biedt tot het bereiken van hoge virale 
vector concentraties lokaal in het doelgebied zonder systemische blootstelling en met de 
mogelijkheid van een spoel procedure om aan het eind van de perfusie niet gebonden virussen uit 
te spoelen. Door middel van IHP met een adenovirale vector werd een hoge transductie 
efficiëntie van het leverweefsel bereikt zonder significante toxiciteit. Bovendien bleek er een 
sterk verminderde antilichaam formatie tegen de virussen en was er ook een verminderde 
leucocyten aanmaak. Deze bevindingen zijn een sterk argument om door te gaan met het 
ontwikkelen van gentherapie protocollen in pre-klinische geïsoleerde perfusie modellen. 
De studie beschreven in Hoofdstuk 6 verkent opnieuw de anti-tumor effect van het reeds 
genoemde adenovirus construct tegen p21-ras oncogen (Y28). Dit maal hebben we gebruik 
gemaakt van een ratten rhabdomyosarcoma welke het ras-oncogen in verschillende sterkte tot 
expressie brengt: een “wild-type” rhabdomyoasrcoma en een voor ras-oncogen genetisch 
gemanipuleerde vorm. Deze verschillende tumor cel lijnen werden in vitro getest op hun 
gevoeligheid voor het Y28 virus. Er werd een duidelijke groei remming van door Y28 gezien in 
vitro, maar was geen significant verschil tussen de tumor cel lijnen. In vivo werd het anti-tumor 
effect bestudeerd in het ILP model met een solide tumor ter plaatse van de achterpoot van de rat. 
De transfectie efficiëntie studie toonde ongeveer 5% getransfecteerde tumor cellen. Echter dit 
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resulteerde bij Y28 ILP niet in een additionele tumor response ten opzichte van de controle 
groepen. 
Hoofdstuk 7 geeft een overzicht van de huidige aanwezige literatuur over gentherapie in in vivo 
geïsoleerde perfusie (IP) modellen. Locoregionale toediening van het genetisch construct door 
middel van IP van het doel orgaan of extremiteit is een methode welke de efficiëntie kan doen 
toenemen. Vasculaire isolatie en perfusie minimaliseert de systemische blootstelling en 
vermindert daardoor ongewenste neveneffecten. Verschillende IP modellen passeren de revue 
van lever en ledemaat perfusie tot milt, long en nier perfusie. Door de sterk selectieve toediening, 
een lange blootstelling en hoge concentraties resulteert dit in hogere transductie graad en 
daardoor mogelijk ook tot een verbetering van therapeutische effecten. 
Een klinische ILP studie uitgevoerd in patiënten met recidief melanomen van een extremiteit is 
beschreven in Hoofdstuk 8. Voor recidief melanomen zijn meerdere behandelopties 
voorhanden, voornamelijk afhankelijk van plaats van de tumor, de grootte en het aantal laesies. 
Herhaalde biochemotherapeutische ILP met Melphalan en TNF (TM-ILP) zou een waardevolle 
optie kunnen zijn voor patiënten met lokale progressie na eerdere ILP behandeling. In de Daniel 
den Hoed Kliniek hebben we 25 herhaalde ILP uitgevoerd met daarbij in 76% (19/25) een 
complete respons (CR). In 5 ILPs werd een partiele respons bereikt, een totale respons van dus 
96%. Vergeleken met onze complete database TM-ILPs voor melanomen (100 ILPs) was het CR 
percentage hetzelfde als voor patiënten met slechts een ILP. Voor patiënten met grote of talrijke 
laesies die niet middels chirurgie behandeld kunnen worden, waarbij er geen systemische ziekte 
is waarvoor systemische chemotherapie beter is, biedt  herhaalde ILP zeer goede locale controle 
van de ziekte. 
Onze ervaringen opgedaan in patiënten met weke delen tumoren (WDT) en melanomen ouder 
dan 75 jaar welke een TM-ILP hebben ondergaan zijn beschreven in Hoofdstuk 9. De incidentie 
van WDT neemt snel toe in patiënten ouder dan 50. Ongeveer 18% van patiënten populatie is 
ouder dan 70 jaar. Ook in melanomen stijgt de incidentie in de oudere patiënten groepen. Als 
gevolg van angst voor TNF geassocieerde bijwerkingen worden in sommige ziekenhuizen TNF 
ILPs niet aan de oudere patiënten aangeboden. Terwijl juist in oudere patiënten een amputatie 
van een ledemaat een einde kan betekenen van hun onafhankelijkheid en mobiliteit. Dus juist 
alles moet worden ondernomen om een amputatie te voorkomen. In oudere WDT patiënten 
behandeld met TM-ILP en aanvullende chirurgie kon in 76% (22/29) het ledemaat gespaard 
worden. In de oudere melanoompatiënten (n=14) een totaal respons percentage van 100% werd 
behaald. Dit resulteerde in ledemaat sparing in 93%. Hierbij hebben we dus aangetoond dat ILP 
is zeer efficiënt in oudere patiënten, met daarbij acceptabele morbiditeit en mortaliteit. Het feit 
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dat in het geval van de 3 besproken fatale complicaties er een lekvrije perfusie aan vooraf was 
gegaan onderstreept het feit dat de complicaties het gevolg waren van patiënt specifieke risico’s 
en niet als gevolg van ongecontroleerde elementen van de TNF-ILP. 
Hoofdstuk 10 is een overzichtsartikel dat de resultaten bespreekt van de ILP methode zoals 
uitgevoerd in zowel de klinisch als de pre-klinische experimentele setting. Verschillende perfusie 
condities worden besproken zoals de geïsoleerde ledemaat infusie, het effect van hyperthermie 
en de toevoeging van TNF. De rol van een profylactische ILP wordt geëvalueerd, evenals het 
belang van het doelgericht behandelen van het tumorvaatbed. Verder worden laboratorium 
studies beschreven welke zijn uitgevoerd om de werking  van TNF in de ILP beter te begrijpen. 
Toekomstige ontwikkelingen gebaseerd op recente experimentele ontwikkelingen zoals 
gentherapie en nieuwe vaso-actieve stoffen worden besproken. 
De resultaten beschreven in Hoofdstuk 11 betreffen in klinische geïsoleerde lever perfusie (IHP) 
studie. IHP voor irresectabele lever metastasen heeft gerapporteerde respons percentages van 50-
75%. Een aantal nadelen aan de procedure zijn de grootte en kosten van de ingreep en tevens het 
feit dat behandeling niet herhaald kan worden. We hebben een minder ingrijpende, goedkopere 
en potentieel herhaalbare balloncatheter gemedieerde geïsoleerde hypoxische lever perfusie 
(IHHP) ontwikkeld. In een fase I-II studie werden 18 opeenvolgende patiënten met irresectabele 
colorectale of melanoom lever metastasen geïncludeerd. Twee  verschillende perfusie methoden 
werden gebruikt: IHHP met orthograde of retrograde stroomrichting door de lever, beide met de 
instroom via de arteria hepatica en gebruikmakend van Melphalan (dosis 1 mg/kg). IHHP met 
behulp van balloncatheters resulteerde in hoge locale Melphalan concentraties. Het lukte helaas 
niet om de perfusie lekkage vrij te krijgen, zowel bij de orthograde als retrograde stroomrichting 
methode. Als gevolg van dit persisterend lekkage probleem en de daarbij optredende toxiciteit 
konden we niet doorgaan met hogere Melphalan doseringen. 
In Hoofdstuk 12 wordt een uitgebreid overzicht gegeven over de wereldwijde ervaringen van de 
IHP in de behandeling van lever tumoren. Pre-klinische diermodellen, diverse IHP technieken, 
klinische resultaten, toxiciteit en nieuwe ontwikkelingen zoals percutane methoden worden 
geëvalueerd. 
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Conclusies 
 
Gebaseerd op de studies zoals uitgevoerd in dit proefschrift kunnen de volgende conclusies 
worden getrokken: 
 
• Toevoeging van TNF aan Melphalan in een geïsoleerde lever perfusie kan een synergistisch 
anti-tumor effect induceren in vergelijking tot perfusie met Melphalan alleen. 
• Intra-tumorale Melphalan opname kan versterkt worden door TNF en is gecorreleerd aan de 
microvaatdichtheid van de tumor. 
• Een hoge intra-tumorale Melphalan concentratie bevordert tumor regressie. 
• Geïsoleerde lever perfusie in patiënten met behulp van balloncatheter technieken is minder 
invasief dan de klassieke IHP, maar een lekkage vrije perfusie kan niet worden bereikt. 
• Colorectale levermetastasen zijn moeilijk te transfecteren door adenovirussen. Een herhaalde 
locoregionale toediening lijkt essentieel om een tumor respons te bereiken. 
• IHP met recombinante adenovirussen resulteert in een verminderde antilichaam productie in 
vergelijking tot systemische behandeling. 
• Gentherapie met adenovirussen resulteren in anti-tumor activiteit in vitro, voorspelt niet altijd 
een tumor respons in vivo.  
• ILP met adenovirussen in een sarcoom model in de rat resulteert in transductie van tumor 
cellen met name in de vitale rand van de tumor en rond tumor geassocieerde bloedvaten. 
• Juist in oudere patiënten dient een amputatie te worden voorkomen: TNF gebaseerde ILP is 
veilig en effectief in oudere patiënten met ledemaat bedreigende sarcomen en melanomen. 
• In patiënten met recidief melanomen blijven herhaalde TNF gebaseerde extremiteit perfusies 
zeer effectief, zelfs na eerdere ILP behandeling. 
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Color figures 
Chapter 4 (page 65) 
Fig. 2 Y28 fluorescence immunohistochemistry on cryosections of tumours collected 24 hours after treatment in 
vivo with AV.1.0CMV.Y28 (Y28). A: tumour after IT, transfection around the needle track. B: foci of Y28 
expression in tumour after IHP. C: expression in tumour after HAI.  
Original magnification: A, B and C: 16 x, insert 40 x. No staining was found in case of treatment with 
AV1.0CMV.
Fig. 3 Two examples of X-gal stained and RECA stained cryosections of tumours of different animals after HAI 
treatment with AV.1.0CMV.LacZ  (left and right). Tumour vessel (brown) and perivascular orientation of 
transfected cells (dark blue) are clearly visible. Original magnification: 40 x.  No staining was found in case of 
treatment with AV1.0CMV. 
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Chapter 5 (page 77) 
Fig. 1
X-gal staining of liver tissue after treatment with AV1.0CMV.LacZ.  
A After IHP, estimated transduction of 80-90 % B After IV injection, estimated transduction of about 5 %. 
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Chapter 6 (page 92) 
Fig. 3 Light microscopy of X-gal stained cryosections of tumor and liver 24 hours after in vivo treatment by ILP 
with 2.5 x 1011 vp AV1.0.CMV.LacZ. Showing: A R2T24 tumor, viable rim area B R2T24 tumor, central area, 
C: R2T24 tumor, detail: perivascular transduction , D: liver. Original magnification: A, B and C: 160 x, D: 400x.
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Dankwoord 
 
Afgelopen jaren heb ik met zeer veel plezier gewerkt aan het promotieonderzoek en de 
totstandkoming van dit proefschrift. Vooral de combinatie van preklinisch basaal 
wetenschappelijk onderzoek in het laboratorium en de link naar klinische, patiënt gebonden 
onderzoeken vond ik erg inspirerend en motiverend. Ondanks opstart perikelen, frustrerende 
experimenten en eindeloze weekend sessies in het lab is het uiteindelijk toch dit boekje tot 
stand gekomen. Vele mensen hebben hier direct of indirect aan bijgedragen en aantal wil ik 
hier met name voor bedanken. 
 
Allereerst mijn promotor prof.dr. A.M.M. Eggermont, beste Lex, al vroeg tijdens mijn Agnio-
periode in de Daniël den Hoed Kliniek wist je mijn interesse te wekken voor het basale 
wetenschappelijk onderzoek. Je was van plan om gentherapie toe te passen in de geïsoleerde 
perfusie modellen welke op jou lab inmiddels waren opgezet. Deze nieuwste ontwikkeling in 
het kankeronderzoek was op dat moment een veelbelovende ontwikkeling en je overtuigde 
mij in de keuken van afdeling A1 om de stap te wagen een aantal jaar het onderzoek in te 
gaan. Of zoals jij het noemde: “You have to ride the wave!” Deze “wave” ging vrij lang door, 
en bracht uiteindelijk de reeds besproken resultaten naar voren. In deze onderzoeksperiode 
was jij degene die altijd vertrouwen had in de goede afloop en jou motiverende sessies 
maakten van elk resultaat altijd iets positiefs. Zo inspireerde je mij om door te blijven gaan.  
Bedankt hiervoor! Ik zie er naar uit om tijdens mijn opleiding weer een periode in de Daniël 
te kunnen werken! 
 
Dan uiteraard mijn copromotor Dr. T.L.M. ten Hagen, beste Timo, onder jou leiding heb ik 
het lab zien uitgroeien tot zijn huidige omvang. Wat een ontwikkeling, niet alleen in 
kwantiteit, maar meer nog in kwaliteit. Gelukkig heb je nog steeds oog voor de chirurgische 
basis van het lab. Al die jaren gaf je mijn onderzoek gedegen en gestructureerd begeleiding, 
wat een “wit jas” in een lab ook nodig heeft! Jouw brede onderzoekservaring bleek een must 
voor het sturen van dit soort onderzoek, en regelmatig gaf jij zeer waardevol advies of wist je 
wel iemand die een bepaald proefje of techniek kende. Verder hebben we ook buiten het lab 
gezellige tijden beleefd  tijdens de verschillende buitenlandse congressen die we hebben 
bezocht. Dank voor je hulp! 
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Verder wil ik de gehele promotiecommissie bedanken: 
Prof.dr. I.H.M. Borel Rinkes, beste Inne, dank voor het lezen van het manuscript, jammer dat 
je er bij de verdediging niet bij kan zijn. We drinken er vast nog een keer een (nachtelijke) 
borrel op! 
Prof.dr. H.W. Tilanus, dank voor het door werken van het proefschrift en de bijkomende 
secretariële activiteiten.  
Prof.dr. T. Wiggers, beste Theo, jij was degene die mij binnenhaalde als Agnio op de afdeling 
Chirurgische Oncologie in de Daniël, nadat ik daar als keuze-co-assistent had gewerkt. Voor 
dit vertrouwen ben ik je nog steeds erg dankbaar, en vind dan ook erg mooi dat je in mijn 
promotie commissie zit! 
Prof.dr. G. Stoter, prof.dr. C.J.H. van de Velde en prof.dr. C.H. Bangma, dank voor het 
beoordelen van het proefschrift en uw bereidheid voor het plaatsnemen in de promotie 
commissie.  
 
Roland Klein Nagelvoort en Marc van IJken, mijn paranimfen.  
Roland, we zijn al vrienden vanaf het eerste jaar van onze studie. We hebben veel samen 
meegemaakt, o.a. onze reis naar Australië waar we onze eerste klinische stappen waagden 
tussen de Aboriginals, ons afstudeeronderzoek gedurende een halfjaar op 4 m2  op de CCU 
van het Thoraxcentrum, en de gezellige assistententijd in Delft, waar we samen hebben 
geopereerd. Op 30 en 31  januari 2004 stonden we zij aan zij. Nu opnieuw, echter nu in rok in 
plaats van jacquet! Ook Stephanie bedankt voor je hulp en adviezen! 
Marc, vriend en mede leverperfusionist. Jij leerde mij de techniek van de ratteleverperfusie en 
het bedienen van de hart-long machine voor de klinische leverperfusies. Gedurende je 
opleiding in het Dijkzigt hebben we nog intensief samengewerkt aan de HAP en HPP-studies 
die je uiteindelijk nu ook in je eigen boekje gaat verwerken. Succes met de laatste loodjes! 
Marieke en Marc bedankt voor jullie hulp afgelopen periode. 
 
Het Laboratorium voor Experimentele Chirurgische Oncologie.  
Sandra, Ann, Gisela, Titia, Mark  de Vries, Cindy, Remco, Joost, Saske, Flavia, Lucy, Debby 
en stagieres. Een gezellige en gemotiveerde club om mee te werken!  
Sandra en Gisela, ontelbare uren in het D2 lab boven de dampende ether en pruttelende 
melphalan, hebben geleid in dit resultaat. Zeer veel dank voor jullie geduld en inzet. Ann, jij 
ook veel dank voor je hulp met het kweken, meten en statistische berekeningen. Succes met 
het afronden van je boekje!  Remco en Saske, jullie gaven als niet-medische AIO’s een totaal 
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andere visie op het onderzoek, wat vernieuwende vruchten heeft afgeworpen. Naast boeiende 
discussies en het luisteren naar Remco’s band was de vrijdagmiddagborrel met de frituurpan 
op de kamer elke weer een hoogtepunt! Joost en Cindy, bedankt voor jullie hulp als ik weer 
eens binnen kwam lopen en de meest lastige vragen kwam stellen of achter jullie PC wilde 
zitten. Titia, je hebt je promotie inmiddels al achter de rug. Bewonderenswaardig wat een 
vaart jij er achter hebt gezet! Bedankt voor je gezelligheid, hulp en adviezen. Mark, bedankt 
voor de gezellige uren klussen met onze “witte vrienden”, en nodige avondjes eten of 
bioscoop tijdens jouw lab-tijd. Nu is natuurlijk erg mooi om weer samen te werken in het 
Delftse! 
 
De medewerkers en dierverzorgers van het EDC. Pim van Schalkwijk en Ton Boijmans voor 
het analyseren van de bloed en urine monsters.  
 
De (ex)-chirurgen en assistenten van de Daniël den Hoed Kliniek.  
Dr. A.N. van Geel, beste Bert, mede door jou zijn er nog een aantal klinische ILP studies 
opgezet en uitgevoerd die aan dit proefschrift hebben bijgedragen. Dank hier voor.   
Dr. J.H.W. de Wilt, beste Hans, jou hulp met het uitwerken van de klinische studies was zeer 
waardevol. Dank voor je snelle en kritische analyses. 
Dr. J.R.M. van der Sijp, beste Joost, met jou heb ik mijn eerste DDHK onderzoek opgezet. 
Dit was weer eens een bewijs dat de volhouder wint! Bedankt voor je hulp en geduld. 
Dr. A.W.K.S. Marinelli, beste Andreas, jou rustige benadering gaf een goed evenwicht 
gedurende de soms hectische besprekingen met Lex en Hans. Dank voor je hulp met de 
analyses van de IHHP studie. 
Drs. C. Verhoef, beste Kees, dank voor de gezellige samenwerking met de leverperfusies. 
Dirk Grünhagen, dank voor het afschrijven van het repeated ILP artikel, veel succes met het 
afronden van jou proefschrift. 
 
Het secretariaat van de Chirurgische Oncologie. Dames, dank het zoeken van de stapels 
statussen en alle andere vervelende klusjes. Marja, bedankt voor je hulp met het plannen van 
afspraken met Lex, wat een vak apart is, en je hulp met de administratieve afronding rondom 
deze promotie.  
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“The Belgian connection” met de Universiteit Leuven. Prof.dr. Ernst de Bruijn, Dr. Gert de 
Boeck en Dr. Gunther Guetens. Dank voor alle honderden melphalan bepalingen die jullie 
hebben uitgevoerd! 
 
Tot slot vrienden en familie. 
Vrienden, iedereen heeft jarenlang mijn onderzoeks-ups en -downs moet aanhoren, toch 
waren jullie altijd geïnteresseerd en stimulerend om door te gaan! 
Willem van Etten, erg leuk om zo’n gezellige en geïnteresseerde oom in Rotterdam te hebben. 
Ik hoop nog vaak etentjes met je te hebben, bedankt voor je hulp! 
Joep, “broertje”, en Carola, bedankt voor jullie hulp in de afrondende fase van dit proefschrift. 
Bedankt voor het ontwerpen van de fraaie omslag! 
Lieve pap en mam, jullie hebben mij altijd gestimuleerd om deze weg in te slaan. Nu wordt 
deze fase afgesloten, maar er liggen nog voldoende uitdagingen in het vooruitschiet. Bedankt 
voor het vertrouwen en geduld wat jullie alle jaren hebben gehad, en het feit dat jullie altijd 
voor me klaar staan! 
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